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Abstract 
 
Background: ĐĐŽƌĚŝŶŐƚŽt,KƌĞƉŽƌƚƐ͕ůŽǁƋƵĂůŝƚǇŵĞĚŝĐŝŶĞƐƌĞƉƌĞƐĞŶƚĂďŽƵƚϭϬйŽĨƚŚĞ
global pharmaceutical market of ǁŚŝĐŚĂďŽƵƚϰϬйǁĞƌĞƐƵďƐƚĂŶĚĂƌĚ medicines. Most of the 
studies of quality of medicines recommend development of additional innovative techniques 
to control the existence of substandard medicines in the market. In Sudan, the system 
applied to detect substandard and/or counterfeit medicines is not effective enough. A round 
ϵйŽĨƉŚĂƌŵĂĐĞƵƟĐĂůƉƌŽĚƵĐƚƐĂƌĞƌĞƉŽƌƚĞĚƚŽďĞƐƵďƐƚĂŶĚĂƌĚŵĞĚŝĐŝŶĞƐ͘ƐƚƌŽŶŐƉŽƐƚ
marketing surveillance system would be a more powerful tool for detecting substandard 
and/or counterfeit medicines and showing a true picture of the situation in Sudan. 
Strengthening the system by applying risk-based model for supporting the decisions is 
proven to be useful and possible approach. Setting: This study was conducted in Khartoum 
city, Sudan. Objectives: this research aimed at developing risk-based quality monitoring 
scheme or model for pharmaceutical products. The model should help medicines regulatory 
authorities in resource limited settings to improve surveillance systems. The research will 
provide a practical model for the expanding the existing surveillance system for quality check 
of pharmaceuticals currently adopted in Sudan. Methods: different methods were used to 
build this model. These include health professionals’ survey targeting the pharmacists and 
physicians and chemical ĂŶĂůǇƐŝƐŽĨϯϬŵĞĚŝĐŝŶĞƐ͘ĂƐĞĚŽŶƚŚĞŽƵƚĐŽŵĞƐŽĨƚŚĞƐĞƐƵď-
studies, further experiments were conducted that include bioequivalence study of 
Glibenclamide products, microbiological sensitivity test on Amoxicillin; biological assay of 
three Ceftriaxone products and modeling process of data generated. Results: A model has 
been successfully formulated and adopted to improve the surveillance system. This model is 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  PageͳͶ 
unique and it was the first time to develop such tool globally to help in indicating critical 
information about the quality of medicines and associated hazard factors to its quality. The 
model was designed as large and complex computerized system using Microsoft excel 
program. A sample from the outcomes of the model was printed and attached in annex 
ŶƵŵďĞƌϵĨŽƌƌĞĨĞƌĞŶĐĞ͘dŚĞŵŽĚĞůǁĂƐƚĞƐƚĞĚĨŽƌŝƚƐƵƐĞĨƵůŶĞƐƐĂŶĚĞīĞĐƟǀĞŶĞƐƐĂŶĚƚŚĞ
results obtained showed potential applications of the system in improving the system. This 
would include its use in the selection technique of products for inclusion in post-marketing 
quality monitoring. It can also be applied to increase the detection rate of low quality 
products. Using the developed model, the chance to detect substandard and/or counterfeit 
productƐǁŝůďĞŝŶĐƌĞĂƐĞĚďǇĂďŽƵƚϯϬй͘Conclusion: the outcome of this proposed 
approach will enable the authorities to expand the input measures of its surveillance system 
beyond quality to consider also the efficacy of medicines. 
  
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ͳ: Introduction and Literature review 
 
Background 
 
The harmful and ethical implications of allowing low quality medicines to be available in the 
market for human use are a non-debatable issue ;dĞŶ,Ăŵ͕ϭϵϵϮͿ. While in last decade there 
was a great revolution in producing medicines; it is still valid that significant percentage of 
medicines circulated in the global markets was of low quality either substandard or 
counterfeit. Nevertheless, these low quality medicines could be considered as not available 
for the effective and safe human use ;t,K͕ϮϬϬϳͿ. 
According to WHO: “Substandard drugs are genuine drug products which do not meet quality 
specifications set for them” ;t,K͕ϭϵϵϳͿ. The term substandard used to describe the quality 
status of genuine drugs produced by legitimate manufacturers. Normally, for each drug 
product the manufacturer produce it based on a set of quality standards or specifications. 
Such specifications are also published in official pharmacopoeias such as the United States 
Pharmacopoeia, the European Pharmacopoeia, and the WHO International Pharmacopoeia. 
If a drug, upon laboratory testing is with accordance to the specifications so it claimed to be 
complied and if fails to meet these specifications, then it is classified as a substandard drug 
;>ĂǇůŽī͕ϭϵϵϳͿ. 
Although WHO exert hard work and strategies to contain the problem of low quality 
medicines still there is obvious confusion between the nature of substandard and 
counterfeit products ;WŝŶĐŽĐŬ͕ϮϬϬϯͿ ;zƵƐƵĨǌĂŝ͕ϮϬϬϮͿ. Both types are critical and very 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  PageͲʹ 
important issue to pay focused attention on it; still the control of counterfeit medicines is a 
very complicated process. It includes multi-sectors collaboration and it entails direct criminal 
control interventions so usually it needs special and complex management plans (Kopp, 
ϮϬϬϯͿ. On the other hand, the nature of substandard medicines is clear forward issue, its 
control involves fewer parties and it is usually under the direct responsibility of Medicines 
Regularity Authorities “MRAs” in each country. It is usually a controllable problem and this 
depends on the capacity and strength of MRAs in the country and how well prepared to 
carry out this function. In fact many interventions could contribute directly to resolve this 
problem, unlike the problem of counterfeiting which is illegal commerce that is very difficult 
to be compact ;ƌǇĂ͕ϭϵϵϱͿ. The control of substandard medicines is generally stressed by 
many factors; for example, these medicines are usually authorized products and are legal to 
be sold for the public within the retail facilities. This is important fact as patients and even 
pharmacy personnel can handle it as “safe and effective medicines” unless the authorities 
state other notification. This in fact adds more responsibility and pressure on MRAs to detect 
these medicines before it reaches the patients. 
All of this raises many concerns about the strategies currently used on the ground to face 
this problem ;dŚŽŵĂƐΘŽƚŚĞƌƐ͕ϮϬϬϯͿ. This may include, but not only limited to, the 
following: 
- Development of more effective quality monitoring system; 
- Improving the detection rate of substandard medicines; 
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- Increasing the availability and sharing of information about the existence of 
substandard medicines; 
- The advance analysis of the detected cases (its nature, possibilities to be compact, 
crosscutting factors lead to the incident and other data). 
- Application of continuous improvement process of the system (through research and 
development). 
When we look into the current systems used to control substandard medicines in Sudan we 
can realize the problems associated with considering these factors to improve the system. 
The availability of data from previous activities is essential part of any proposed actions for 
any problem solving scheme, as building any decision based on evidence become essential. 
It is important also to evaluate the cause-effect relationships in these kinds of problems. This 
could help the authorities to build effective strategies that are based on evidence of 
interrelationships and how each part contribute to the problem and how that could be 
managed and solved effectively. 
The capacity of the regulatory authority in any country is the determinant factor that affects 
the ability of the government to control the problem. In fact, the capacity of the “Quality 
Control Laboratory, as one of the major components of the regularity authority, is 
determinant key ;t,K͕ϮϬϬϲͿ. This issue has been raised several times in the previous 
period in Sudan. Many concerns were voiced out about the effectiveness and efficacy of the 
laboratories to meet the services expected from it and also in comparison to the nature of 
pharmaceuticals market in Sudan. 
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Chemical analysis is usually one of the main and essential quality control tests that should be 
conducted in order to assure the quality of different types of medicines ;>ĂǇůŽī͕ϭϵϵϳͿ, 
;t,K͕ϭϵϵϭͿ. In many countries, the chemical analysis department in the medicines 
regulatory laboratories is essential part of the system and usually countries consider its 
capacity development seriously as a part of the national priorities. The results of chemical 
analysis and other analysis data should be combined and interpreted carefully; so as to 
obtain authentic facts about the extent of any quality related problem ;,ĂƌƌŝƐ͕ϮϬϬϯͿ. 
Chemical analysis by its own is usually not sufficient indicator about the quality of medicines. 
The data generated in this combined manner could point out some knowledge about what 
are the factors leads to suspected results from the analysis. By considering this, the results 
of the analysis will become supporting means to verify the quality suspected cases or could 
be used to support regular and routine checks of medicines. 
ĐĐŽƌĚŝŶŐƚŽt,KƌĞƉŽƌƚƐ͕ůŽǁƋƵĂůŝƚǇŵĞĚŝĐŝŶĞƐƌĞƉƌĞƐĞŶƚƐĂďŽƵƚϭϬйŽĨƚŚĞŐůŽďĂů
ƉŚĂƌŵĂĐĞƵƟĐĂůŵĂƌŬĞƚŝŶǁŚŝĐŚĂďŽƵƚϰϬйǁĞƌĞƐƵďƐƚĂŶĚĂƌĚ͘tŚĞŶƚŚŝƐĨĂĐƚŝƐĐŽŵďŝŶĞĚ
with the picture about the size of pharmaceuticals market it became obvious how this 
problem is triggering. Additional innovative techniques need to be developed to control the 
existence of substandard medicines in the market (WHO, Counterfeit Medicines," fact sheet, 
ϮϬϬϲͿ. The statistics in developing countries showed even more critical situation regarding 
the existence of these medicines ;ZĂǀŝŶĞƩŽ͕ϮϬϬϮͿ. The degree to which these substandard 
medicines exist in Sudan is very difficult to be concluded in one figure or in simple report. 
This is due to the complicated detection mechanisms and not mentioning the concerns 
about the quality of the data. The available reports may provide indicative information if it 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  Pageʹ͵ 
becomes more systemized, arranged and gathered. It will help the decision-makers to obtain 
the true picture about cause-effect relationships that directly outline the situation in Sudan 
regarding the problem of substandard medicines. Once more the capacity of the system is 
major factor; because the information management in regulatory bodies in Sudan could be 
considered as a weak point of the system ;t,K͕ϮϬϭϬͿ. 
Establishing Post Marketing Surveillance (PMS) System in many countries in collaboration 
with WHO help these countries for better improvement of its regularity functions (WHO, 
ϭϵϵϳͿ. PMS system considered as one of the important tools and methods to monitor the 
quality of medicines and as strategy of choice to improve the quality of medicines (FDA, 
ϮϬϬϳͿ. Usually two parts of the system, (Quality Assurance/Control “QA/QC” and Adverse 
Drug Reactions “ADRs” monitoring) are implemented together for better results (WHO, 
ϮϬϬϮͿ. But this usually depends on the capacity of each country in terms of human resources 
and knowledge as well. In Sudan till this study there is no systemic widely established ADRs 
monitoring at national or at sub-national levels. When we consider PMS system, the main 
scope of the system is the observation and control of the authorized products “substandard” 
in the direct way and non authorized low quality products “counterfeit” indirectly 
;&ŽŶƚĂŶĂƌŽƐĂW͕ϮϬϬϰͿ. 
In this system, the quality of any product could be surveyed by analyzing samples taken from 
manufacturers and from the distribution chain either randomly or on purpose (based on 
incidents reporting for suspected medicines). Quality tests in this system were performed to 
ensure conformance to pharmacopoeial requirements (e.g., British Pharmacopoeia, U.S. 
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Pharmacopeia, International Pharmacopoeia, etc.) or to the manufacturer’s specifications 
where necessary or applicable ;t,K͕ϮϬϬϳͿ. 
Most of the studies that has been conducted in this area affirmed that the problem of 
substandard medicines usually existed due to one of the major causes or all of them. In most 
of the cases the problem was due to inadequate quality control/assurance measures during 
the production and/or stability problem due to instable nature of the API and/or 
inconvenient storage conditions of the final product ;EŝĐŚŽůƐŽŶ͕ϮϬϬϱͿ, ;h^W͕ϮϬϬϱͿ. 
The chemical contents of each medicine usually play important role in medicines 
ineffectiveness problems. Because it indicates that the desired quantity of the medicine is 
available or not as patient need it; and any interruption in this relationship could lead to 
failure of therapeutic process ;tĂƚƐŽŶ͕ϮϬϬϱͿ. This is important because all treatment 
hypnosis’s were based on producing certain and specific amount of the medication per unit 
dosage form; which will be used for certain patient with specific needs; so any disturbance in 
this balance could lead to failure of treatment.  
The partnership models in detecting, analyzing and resolving the problem of substandard 
medicines become fundamental ;t,K͕ϭϵϵϳͿ, ;h^W͕ϮϬϬϰͿ. The extent to which the key 
players; including communities, professionals and policy-makers from different sectors; are 
involved in implementation of PMS system, this make it easier to get support and 
collaboration in managing and compacting the existence of substandard medicines in the 
country ;t,K͕ϮϬϬϯͿ. In country like Sudan this concept is required; as there are several 
contributing and limiting factors that affect the situation. For example; the vast area of 
Sudan, differences in climatic conditions, economic situation and the great differences and 
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diversities in cultures and believes among publics and even health workers; all of these limit 
the ability of the authorities to respond alone for this problem. With no doubt, health care 
professionals (pharmacists, doctors and others) are the major partners with potential 
importance and roles in improving the detection of substandard medicines. Since this 
category is well oriented and educated about this problem, they should be essential part of 
any solution. This will add additional value for appreciating the detection of these medicines 
before it reaches the patients. But at the same time any possible incorporation of these 
professionals should consider their knowledge, attitude and practice towards the issue of 
substandard medicines. This is important because how doctors and pharmacists act towards, 
and deal with, substandard medicines, is the corn-stone in any solution could help in 
improving the situation. 
This research aimed to examine the potential solutions and practical models to expand 
quality & efficacy monitoring of pharmaceutical products beyond chemical analysis. Through 
assessing the existence of substandard medicines and its detection tools, this could provide 
scientific approach for solving this problem ;dĂǇůŽƌ͕^ŚĂŬŽŽƌ͕ΘĞŚƌĞŶƐ͕ϭϵϵϳͿ. The study 
focused mainly on selecting medicines that circulated in the market and there are major 
complaints about its quality and effectiveness. In this regard it is important to note that the 
number of reported occurrences from health professionals about particular medications 
may indicate not only the prevalence of the problem about it, but it may also reflects the 
reporters' perceptions of the its importance, law enforcement issues surrounding the 
medications, product's length of time in the market, and/or widespread use of the product. 
The study used this concept in identifying the possible problems behind reported cases of 
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suspected medicines. This approach was adopted as in many cases the results obtained from 
chemical analysis tests weren’t somewhat enough to answer all of the complaints received 
from the health professionals about the quality issues. This emphasizes the fact that 
combining the interpretation of quality control results with other data about clinical or 
therapeutic outcomes for any medicines could be of potential importance. It helps to include 
or exclude any potential factors that contribute to treatment failure whether the product is 
anti-infective, chronic disorder treatment or over the counter product. The study team 
considered and adopts WHO definition of substandard as basic definition and the study 
concepts was built on that. The study concentrates mainly on medicines available legally as 
authorized products that obtained marketing authorization from the National Medicines and 
Poisons Board “NMPB” (national regularity authority). The study doesn’t include the 
counterfeit medicines that are not authorized to be marketed in Sudan. 
 
Currently used quality monitoring systems 
 
Officials in areas related to pharmaceutical services are focusing most of their efforts on 
assuring the safety, efficacy and quality of pharmaceutical products. By reviewing the global 
ƉŽůŝĐǇĚŝƌĞĐƟŽŶƐŝŶŵŽƐƚŽĨƚŚĞŝŶŝƟĂƟǀĞƐĞƐƚĂďůŝƐŚĞĚĚƵƌŝŶŐƚŚĞůĂƐƚϮĚĞĐĂĚĞƐ͕ǁŚĞƚŚĞƌďǇ
international agencies (like WHO) or by the relevant authorities within the countries, we 
noticed the obvious focus on safety and efficacy as dimensions of importance as safety 
always become first ;WŚĂŶŽƵǀŽŶŐ͕ϮϬϬϯͿ, ;t,K͕ϮϬϬϲͿ. The quality dimension gets the less 
attention among the three areas not because of its less significance but most likely this was 
related to its management system. This system relied greatly on the national authorities 
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from one side and more the manufacturers on the other side. As part of quality monitoring 
system, post-marketing surveillance (PMS) was not an exception of this observation. The 
system gets less consideration among drug monitoring information systems. Unlike the 
monitoring of Adverse Drug Reactions (ADRs) and other drugs associated harms which were 
improved noticeably during ƚŚĞůĂƐƚϭϬǇĞĂƌƐ͖WD ^ǁĂƐŶŽƚĂƐƵďũĞĐƚŽĨŵĂũŽƌĐŚĂŶŐĞƐ
towards more improvements in its process or outcomes during the same period. This is 
principally true in Sudan as case under study in this review. However, there are some 
individual and exceptional initiatives in some countries that aimed to improve the PMS and 
to develop new approaches in the system. The justification for establishing post-marketing 
quality surveillance in most countries was influenced by the fact that; the authorities have 
mild influence on premarketing quality management which relies on the compliance of the 
industry with quality assurance schemes. The need for strong post-marketing surveillance 
was the driven force for all of these projects. 
Systematic review of these projects will be explored below to compare different approaches 
attempted in this area. The review mainly focused on what is currently implemented in key 
members in the International Conference of Harmonization (ICH). This help, to great extend, 
to inform the way in which this study was designed and the recommendations were 
formulated to expand the system in Sudan and globally as well. 
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European Union (EU) 
 
It is known that EU Member States adopted the application of Mutual Recognition 
Procedure for the provision of Marketing Authorization (MA) of pharmaceutical products 
ƐŝŶĐĞϮϬϬϱ͘This is usually coordinated by the European Medicines Agency “EMA” but the 
authorities in each member state should issue the MA separately. Besides that, the 
monitoring of the quality of any registered product is rests with the individual Member 
States ;D͕ϮϬϭϭͿ. But since the products should be registered using the same dossier, this 
open important area for cooperation between the member states (OMCL, Co-operation in 
Post-Marketing Surveillance of MRP/DCP-WƌŽĚƵĐƚƐ͕ϮϬϬϲͿ. The authorities created voluntary 
surveillance scheme at the EU level in the field of independent official control of registered 
products ;KD>͕ϮϬϬϳͿ. The main principles of this scheme: 
· Creation of optimal and cost-effective scheme through sharing the work i.e. by 
reducing the duplication of tests and by testing shared products (different batches 
from different states); 
· The voluntary surveillance could help the member states to share the test results, 
which give the participants in this scheme broader and in-depth overview about the 
quality of targeted products and give them the opportunity to get more focused 
national surveillance activities 
The design of the surveillance scheme under this initiative is risk based model ;D͕ϮϬϭϭͿ. 
It uses risk evaluation approaches for targeting medicinal products for surveillance testing 
;D͕ϮϬϬϴͿ͘dŚĞĂĐƚƵĂůďĞŐŝŶŶŝŶŐŽĨƚŚŝƐƐĐŚĞŵĞǁĂƐŝŶϮϬϬϳŝŶĂƉŝůŽƚƉŚĂƐĞ͘dŚĞŵŽƐƚ
remarkable outcome of implementing this risk-based approach is its use in the 
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establishment of more “informed testing plans” ;D͕ϮϬϬϴͿ. The new system enabled the 
member states moving from the focus on generics towards more focusing on certain trades 
with sufficient available evidences to justify these targeting decisions. By doing this, the 
member states could avoid unnecessary tests and decrease the load on the individual 
responsible laboratories. Moreover, the EU is now moving towards community based 
feedback system and started to focus more on the community concerns about quality 
aspects ;D͕ϮϬϭϭͿ. 
United States of America (USA) ;&͕ϮϬϬϲͿ: 
Food and Drug Administration (FDA) used what is currently known as Drug Quality Reporting 
System (DQRS). In this system there are voluntary as well as mandatory reporting schemes 
that enrich the data to contribute in what is called Quality Risk Management (QRM). This 
basically used in premarketing phase of products’ lifecycle and then it was extended later to 
involve the post-marketing phase as well. Based on the experience of FDA; it was clear that 
in order to build a risk assessment model this may need many considerations to be included 
in the assumptions to support this model. The decisions taken based on this model are 
similar to other model known as “Problem Tree Model” in which different decision nodes 
could be identified based on the anticipated risk(s) at each stage. 
The principles of quality risk management include: 
· Evaluating the risk to quality that was based on scientific knowledge; 
· Proportional responses from the authorities (effort, formality, and documentation of 
the quality risk management process) with the level of risk 
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FDA currently include the QRM as part of its regulatory operations especially inspection and 
assessment activities. This was considered for many reasons as this system assist in 
allocating the resources and in prioritization of the activities. In addition to that it becomes 
more uncomplicated to evaluate the significance of, for example, quality defects, potential 
recalls, and inspectional findings. Many methods could be used under QRM, FDA relaying 
more on Hazard Analysis and Critical Control Point (HACCP) methodology. The method 
increasingly used in food industry and other industries (car, chemicals and aviation), now 
extended to be applied in pharmaceutical industries. Specialists from different disciplines are 
part of the implementation of this method and training of staff from the authorities and the 
industry was considered before starting the system. 
Japan ;:WD͕ϮϬϭϭͿ: 
Japan, as one of founding members of ICH, re-established its modified monitoring system in 
ϭϵϵϲ͕ŬŶŽǁŶĂƐYƵĂůŝƚǇZĞ-evaluation System (QRS), earlier than any other country in ICH. It 
was based on the idea that post-marketing surveillance should be able to gather and obtain 
data required for re-evaluation applications. These applications usually came out from 
different sources, including drug use-results surveys, specified drug-use surveys, and post-
marketing clinical trials. The system, which is similar to great extent to EU system, responds 
to concerns about the quality from different sources. The system emphasizes more on the 
role of the marketer in assuring the quality of their products during all of its lifecycle. 
Focusing on formative case report formats, the system enables the authorities to build its re-
evaluation decisions based on evidence. The “accumulated knowledge” about the products 
through this reporting mechanism becomes routine part of quality management system. 
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Based on this policy, the dissolution test was proposed as a routine verification method and 
ƐŝŶĐĞϭϵϵϳŝƚŝŵƉƌŽǀĞƐƚŽŐƌĞĂƚĞǆƚĞŶƚƚŚĞŬŶŽǁůĞĚŐĞĂŶĚĚĞĐŝƐŝŽŶƐĂďŽƵƚƚŚĞƋƵĂůŝƚǇŽĨ
products marketed in Japan. This step was done to assure the quality of generic drugs by 
confirming their equivalence to the original products ;ĚĞůŵĂŶΘEŽƌƌŝƐ͕ϮϬϬϮͿ. 
World Health Organization (WHO) 
World Health Organization established many projects to strengthen the harmonization of 
medicines registration and quality control; e.g. in Southern African Development Community 
it established strong scheme in this area ;t,K͕ϭϵϵϵͿ, ;t,K͕ϮϬϬϬͿ . Other similar project is 
the development of Good Manufacturing Practices (GMP) and the training programs on 
these guidelines. Strengthening the official medicines control laboratories in member states 
was additional major element of quality assurance projects in which the organization has 
clear inputs ;t,K͕ϮϬϬϮͿ. In this regard it provided considerable amounts of international 
chemical reference materials to selected laboratories in order to enhance their capacity to 
carry the official tests ;<ĞŶǇŽŶ͕<ĞŶǇŽŶ͕Θ^ŝďŝǇĂ͕ϭϵϵϰͿ͘/ŶϮϬϬϭt,Kwith collaboration 
with USP introduced the use of “Mini-Labs” in analyzing certain antimalarials used in Africa 
;KŶĚĂƌŝ͕ϮϬϬϯͿ. The project respond to growing concerns about the quality of antimalarials 
circulated in the market ;WŚĂŶŽƵǀŽŶŐ͕ϮϬϬϰͿ, ;KĚŝůŝΘŽƚŚĞƌƐ͕ϮϬϬϲͿ. This initiative drew the 
attention back to the potential uses of basic tests of pharmaceutical products at different 
sites in improving the capacity of regularity bodies. There was significant argument behind 
the utilization of this approach to expand currently used quality surveillance and to the 
practical way to involve health facilities in this scheme. On the other hand there are many 
reservations about the drawbacks of using this technique in resource limited settings and in 
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countries with huge health system especially at the primary care level (Sudan is clear 
example).  
Africa 
/ŶϮϬϭϬt,KƉƵďůŝƐŚĞĚĂŶŽǀĞƌǀŝĞǁŽĨĮŶĚŝŶŐƐĨƌŽŵϮϲĂƐƐĞƐƐŵĞŶƚ reports of medicines 
regulatory systems in sub-Saharan African countries (including Sudan). One of the 
weaknesses identified by this review is the weak implementation of post-marketing 
surveillance which was very poor ;t,K͕ϮϬϭϬͿ. 
The report stated: “Quality monitoring was not prioritized based on risk, but was generally 
performed in case of complaints if at all” 
In addition to that the report stated: “&ŽƵƌƚĞĞŶŽĨϮϲEDZƐ;ϱϰйͿůĂĐŬĞĚĂƋƵĂůŝƚǇ
ŵŽŶŝƚŽƌŝŶŐƉƌŽŐƌĂŵŵĞĂůƚŽŐĞƚŚĞƌ͖ϳƚĞƐƚĞĚƐĂŵƉůĞƐŝŶĐĂƐĞŽĨcomplaints or in the 
ĨƌĂŵĞǁŽƌŬŽĨƐƉĞĐŝĮĐƉƌŽŐƌĂŵŵĞƐ͕ĂŶĚŽŶůǇϱ;ϭϵйͿŚĂĚĂƐǇƐƚĞŵĂƟĐĂƉƉƌŽĂĐŚ”. These 
findings are very important and remarkable. 
The report recommends the following: 
“A risk-based system of inspections and sampling should be in place to monitor the quality of 
pharmaceutical products on the market. Manufacturers should be obliged to report 
complaints and quality problems to the NMRA. An effective recall procedure should be in 
place to remove defective products from the market”. 
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 Studies done about the detection of substandard medicines 
 
Adequate review of the available documents and searching through the internet was 
completed to find if any other similar studies were conducted within the same scope or 
fieldwork of this study (expansion of post-marketing surveillance system). No similar study 
found to be served as guidance for this study. Still there are other categories of studies that 
are connected to the area of medicines quality assessment which were summarized below: 
Study Title Review of Drug Quality in Asia with Focus on Anti-/ŶĨĞĐƟǀĞƐϮϬϬϰ ;h^W͕ϮϬϬϰͿ 
Objectives 
· ZĞǀŝĞǁƐƚŚĞĚƌƵŐƋƵĂůŝƚǇďĂƐĞĚŽŶƚŚĞĂǀĂŝůĂďůĞŝŶĨŽƌŵĂƟŽŶŝŶϭϭƐŝĂŶ
countries with focus on anti-infective drugs in order to more fully understand 
the extent of the problem of poor drug quality 
· To identify gaps in quality assurance regionally and within countries and to 
point the way toward addressing the issues. 
Results 
· dŚĞƌĞƉŽƌƚĞĚƉĞƌĐĞŶƚĂŐĞŽĨƐƵďƐƚĂŶĚĂƌĚͬĐŽƵŶƚĞƌĨĞŝƚĚƌƵŐƐƌĂŶŐĞƐĨƌŽŵϮй
ƚŽŐƌĞĂƚĞƌƚŚĂŶϲϬй͘ 
· On avĞƌĂŐĞƚŚĞĂǀĂŝůĂďŝůŝƚǇŽĨƐƵďƐƚĂŶĚĂƌĚŵĞĚŝĐŝŶĞƐƌĂŶŐĞĚĨƌŽŵϴйŝŶ
sŝĞƚŶĂŵƵƉƚŽϮϳйŝŶĂŶŐůĂĚĞƐŚ͘ 
 
Study Title 
In vitro evaluation of the quality of essential drugs on the Tanzanian market 
ϮϬϬϮ ;WĞƚĞƌΘKƚŚĞƌƐ͕ϮϬϬϮͿ 
Objectives 
· The study aims to evaluate the essential drug formulations in Tanzanian 
market that met potency requirements and yet had unsatisfactory in vitro 
availability as they were not robust enough to withstand storage under 
simulated tropical conditions. 
Results 
· All formulations passed the pharmacopoeia requirements for the drug 
content. 
· Ğ^ǀĞŶĨŽƌŵƵůĂƟŽŶƐĨĂŝůĞĚƚŽŵĞĞƚƚŚĞh^WϮϰƚŽůĞƌĂŶĐĞůŝŵŝƚƐĨŽƌ
dissolution. 
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Study Title 
Pharmacopoeial quality of drugs supplied by Nigerian pharmacies (Taylor & 
KƚŚĞƌƐ͕ϮϬϬϭͿ 
Objectives 
· To investigate the quality of different drugs obtained from retail 
pharmacies in two urban areas of Nigeria, and, in instances of poor quality, 
to ascertain the reason why. 
Results 
· Ϯϳϵ;ϰϴйͿƐĂŵƉůĞƐĚŝĚŶŽƚĐŽŵƉůǇǁŝƚŚƐĞƚWŚĂƌŵĂĐŽƉŽĞŝĂůůŝŵŝƚƐ͕ĂŶĚƚŚŝƐ
proportion was uniform for the various types of drugs tested. 
· Some preparations contained no active ingredient, most had amounts just 
outside the Pharmacopoeial limits. 
 
Study Title 
Assessment of the incidence of substandard drugs in developing countries 
(Taylor ΘŽƚŚĞƌƐ͕ϭϵϵϳͿ 
Objectives 
· Evaluation of drugs quality in Nigeria & Thailand in control and 
methodological manner  
Results 
· dŚĞƌĞƐƵůƚƐŝŶĚŝĐĂƚĞƚŚĂƚϯϲ͘ϱйŽĨƚŚĞƐĂŵƉůĞƐǁĞƌĞƐƵďƐƚĂŶĚĂƌĚǁŝƚŚ
respect to Pharmacopoeial limits. 
· Decomposition was the cause of poor quality in a number of the samples 
but overall, poor manufacturing appeared to be prevalent. 
· The analyses generated little evidence to indicate fraudulent 
manufacturing. 
· Treatment failure and drug-resistance are possible consequences of the 
use of substandard drugs. 
 
No similar study has been conducted in Sudan and no available documents or data found 
states that similar study done in the previous period in Sudan. In conclusion after this 
review, building a post-marketing surveillance system for monitoring the quality of 
pharmaceutical products is not new. Developed countries succeed to establish different 
approaches and still they are in continuous research for more innovative models. The system 
formulation varies depends on the objectives behind its establishment, but they all share the 
same vision about the aim of the system. The review emphasizes the potential role of 
partnerships in expanding the system and how it is used as possible sources for information. 
Strengthening the system with analytical models (mainly risk-based model) for supporting 
the decisions is useful and possible approach.  
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ʹ: Research methodologies & materials 
 
Study purpose & objectives 
General: 
· The main aim of this study is to develop risk-based quality monitoring scheme of 
pharmaceutical products. The scheme intended to be part of Post-marketing Surveillance 
System used by the Federal Board of Medicines & Poisons in Sudan. 
Specific objectives: 
ϭ. To understand the cause & effect relationships around substandard medicines in 
Khartoum city and to illustrate the influence of this problem on the practice of health 
professionals; 
Ϯ. To analyze the knowledge, attitude and practice of pharmacists and doctors when they 
are facing quality related problems, and how they deal usually with that; 
ϯ. To serve as random check to detect the existence of substandard medicines in Khartoum 
city according to the feedback and surveillance of complaints emanated from health 
professionals; and  
ϰ. To investigate factors affecting the quality of clinical outcomes of three generics in 
Khartoum using different investigation methodologies 
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Study design and methodologies 
 
In this chapter an overview about the studies and experiments done under this research 
will be described, this includes the materials used in each part. Since there are many parts 
of this research done in linked manner, the illustration of the materials and method 
under each part will be described separately. This includes: 
ϭ. Health professionals  survey; 
Ϯ. Collection of samples for chemical analysis; 
ϯ. Chemical analysis of selected medicines; 
ϰ. ŝŽĞƋƵŝǀĂůĞŶĐĞƐƚƵĚǇŽĨϮƉƌŽĚƵĐƚƐŽĨ'ůŝďĞŶĐůĂŵŝĚĞƚĂďϱŵŐ; 
ϱ. Microbiological sensitivity test of Amoxicillin; 
ϲ. ŝŽůŽŐŝĐĂůĂƐƐĂǇŽĨϯƉƌŽĚƵĐƚƐŽĨĞŌƌŝĂǆŽŶĞƉŽǁĚĞƌĨŽƌŝŶũĞĐƟŽŶϭŐ; and  
ϳ. Qualitative evaluation of reconstitution practice of Ceftriaxone powder for 
injection ŝŶ<ŚĂƌƚŽƵŵϮϬϭϬ 
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Health professionals’ survey 
 
The study methodology of this survey was formulated in order to get benefit from the 
experience of health professionals who work in the field and have a good occurrence in 
dealing with medicines (prescribing, dispensing and evaluating its effectiveness). The 
study investigators decided to evaluate the quality of medicines which were circulated in 
the pharmaceutical market in Khartoum. Due to many reasons it was not easy, and 
complicated, to select the targeted medicines on which the study would focus. This 
methodology principally relied on the feedback from doctors and pharmacists. With 
special focus on their observations, their concerns and their comments on medicines they 
have concerned about its quality and/or effectiveness. Later, and based on the results 
obtained from the analysis of the feedback from health professionals, the investigators 
decided which medicines should be subjected to pharmaceutical analysis and testing for 
quality check. 
ϭ͘ϭSelection of information providers 
ϭ. Pharmacists: 
The list of private retail pharmacies located in Khartoum state has been requested from 
“Khartoum State Directorate of Pharmacy” and the sample determined according to this 
list (please refer to sampling technique in the sampling protocol below). 
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Ϯ. Doctors: 
The list of doctors licensed to practice into private clinics in Khartoum state that issued by 
“Khartoum State Ministry of Health” has been used to determine the sample of doctors 
clinics in Khartoum city (please refer to sampling technique in the sampling protocol 
below).  
ϭ͘ϮQuestionnaires design 
The opinions of doctors and pharmacists were collected using two different types of 
questionnaires in the study: 
ϭ. Non-self administrative questionnaire designed for pharmacists. It was consisted ŽĨϮϯ
questions that aimed to evaluate the knowledge, attitude and practice of pharmacists 
towards low quality medicines. Beside that it was designed to collect their opinions about 
the quality of certain medicines (ƉůĞĂƐĞƐĞĞĂŶŶĞǆϭͿ͘ 
Ϯ. Self administrative questionnaire designed for doctors. It was consisted ŽĨϮϬƋƵĞƐƟŽŶƐ 
that aimed to evaluate the knowledge, attitude and practice of pharmacists towards low 
quality medicines. Beside that it was designed to collect their opinions about the quality 
of certain medicines (please ƐĞĞĂŶŶĞǆϮͿ͘ 
These two questionnaires have been discussed in organized group discussion to evaluate 
its structure and to critically assess the questions included. According to the comments 
and feedback from the participants some changes have been made and adopted by the 
study supervisors. Then the questionnaires were tested in the field using random sample 
ŽĨƚŚĞƚĂƌŐĞƚŐƌŽƵƉƐ;ϭϬƉŚĂƌŵĂĐŝƐƚƐ ĂŶĚϭϬĚŽĐƚŽƌƐͿ͘dhe data obtained from this pilot 
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was analyzed and some amendments made in the questionnaires based the 
recommendations of another group discussion conducted for this purpose. 
E͗dŚĞƌĞƐƵůƚƐŽĨƚŚĞƉŝůŽƚƐƚƵĚǇƐĞĞĂŶŶĞǆϯ͘ 
ϭ͘ϯMedicines selection criteria 
The information providers were asked to provide their comments on certain medicines. 
dŚĞƐĞǁĞƌĞϮϬŐĞŶĞƌŝĐƐƐĞůĞĐƚĞĚďĂƐĞĚŽŶĐĞƌƚĂŝŶĐƌŝƚĞƌŝĂ͘dŚĞŝĚĞĂǁĂƐƚŽŝůƵƐƚƌĂƚĞŵŽƌĞ
about how the health professionals evaluate the quality of medicines they use. 
The selection criteria for choosing the surveyed medicines include: 
ϭ. Highly consumed medicines –was ďĂƐĞĚŽŶƐƚĂƟƐƟĐĂůƌĞƉŽƌƚϮϬϬϳ (FMOH, 
ϮϬϬϴͿ; 
Ϯ. Quality problems experienced in other countries; based on the literature review 
including studies and reports from the authorities (Kopp, Counterfeiting: An 
overview Counterfeiting: An overview of problems and of problems and 
ĚĂŶŐĞƌƐ͕ϮϬϬϯͿ ; 
ϯ. All medicines selected were classified as essential medicines in Sudan based on 
the Essential Medicines LŝƐƚϮϬϬϱ ;&DK,͕ϮϬϬϲͿ; 
ϰ. Therapeutically different medicines were selected among different 
pharmacological groups and dosage forms; and  
ϱ. Considerations regarding health system indicators in Sudan; priority diseases 
ďĂƐĞĚŽŶƚŚĞƐƚĂƟƐƟĐĂůƌĞƉŽƌƚϮϬϬϳĨƌŽŵDOH ;&DK,͕ϮϬϬϴͿ;  
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ϭ. Consumption: 
According to the statistical reports; ƚŽƉϱŵŽƐƚĐŽŶƐƵŵĞĚŐĞŶĞƌŝĐƐŝŶϮϬϬϳ were: 
ϭ.   Amoxicillin; 
Ϯ.    Metronidazole; 
ϯ.    Paracetamol; 
ϰ.   Ampicillin + Cloxacillin; 
ϱ.    Glibenclamide; 
Ϯ. Experience in other countries: 
Studies from other countries were reviewed and the following generics were reported in 
many studies as involving quality problems: 
ϭ. Chloramphenicol inj; 
Ϯ. Chloramphenicol cap/tab; 
ϯ. Gentamycin inj; 
ϰ. ĞĨƵƌŽǆŝŵĞƐŽĚŝƵŵϳϱϬŵŐsŝĂů͖ 
ϱ. Ciprofloxacin; 
ϲ. Methylergometrin; 
ϳ. Streptokinase; 
ϯ. Pharmacological Diversity: 
ǇƚŚĞĞŶĚŽĨƚŚĞƐĞůĞĐƟŽŶƉƌŽĐĞƐƐϮϬŝƚĞŵƐŚĂƐďĞĞŶƐĞůĞĐƚĞĚĨƌŽŵĚŝīĞƌĞŶƚϳ
pharmacological groups in order to be surveyed using the questionnaire. This includes: 
Anti-infectives, NSAIDs, Cardiovascular system, Endocrine system, Antihistamines and 
Steroids. 
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Final selection of medicines to be surveyed 
Based on all of these factors, the following medicines were included in the 
questionnaires: 
Generics 
1.  Amoxicillin susp/cap 2.  Co- trimoxazole 
3.  Ampiclox 4.  Digoxin inj/tab 
5.  Artesunate 6.  Ethinylestradiol/levonorgestrel 
7.  Aspirin 8.  Furosemide 
9.  Atenolol tab 10.  Glibenclamide tab 
11.  Carbimazole tab 12.  Hydrocortisone 
13.  Cefuroxime sodium inj 14.  Mefenamic Acid 
15.  Chloramphenicol cap/tab 16.  Metronidazole susp/tab 
17.  Chlorphenarmine 18.  Nifedipine 
19.  Ciprofloxacin tab 20.  Paracetamol 
 
ϭ͘ϰStudy geographical area 
Sudan is one of the largest countries in the region and this vast area usually represents 
enormous challenge for medicines regularity authority. The authority is mandated to 
ensure that all populations in the country receive/use safe and effective pharmaceutical 
products and of good quality. This is not in Sudan only but also in all over the world. 
<ŚĂƌƚŽƵŵŝƐƚŚĞĐĂƉŝƚĂůĂŶĚƚŚĞŵĂŝŶĐŝƚǇŝŶƚŚĞĐŽƵŶƚƌǇ͘/ƚĐŽŵƉƌŝƐĞƐĂďŽƵƚϭϯ͘ϱйŽĨƚŚĞ
total populations in Sudan. Khartoum, Omdurman, Khartoum Bahri are the main cities 
within the state; among which Khartoum include more than ϯϱ% of the population in the 
state (CBS- Ƶ^ĚĂŶ͕ϮϬϬϳͿ. Studies indicated that the major health services for citizens in 
Khartoum state and other country sites actually provided in Khartoum city (large number 
of public and private health facilities). The patients’ frequency in Khartoum cities is the 
highest among all cities in the country ;&DK,͕ϮϬϬϴͿ. Khartoum city also host the core 
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pharmaceutical activities in Sudan, as the headquarters of main organizations in 
pharmacy sector are based in Khartoum city. This includes the National Medicines and 
Poisons Board “medicines regularity authority”, Central Medical Supplies Corporation, 
National Medicines Quality Control Laboratory, Federal Ministry of Health, some of local 
pharmaceutical plantƐ͕ϵϱйŽĨŵĞĚŝĐŝŶĞƐǁŚŽůĞƐĂůĞƌƐ. Due to all these facts, Khartoum 
was selected as study site for this research. 
Indicator Khartoum city Rest of Sudan 
Total number of the population ϯ͘ϰŵŝůŝŽŶ ϯϲ͘ϳŵŝůŝŽŶ 
% of the total population Ϭϴ͘ϲй ϵϭ͘ϰй 
Total patients frequency ϭϵ͘ϯй ϴϬ͘ϳй 
Number of hospitals Ϭϵ͘ϭй ϵϬ͘ϵй 
Number of retail pharmacies Ϯϯ͘ϵй ϳϲ͘ϭй 
Number of private doctors clinics Ϯϱ͘ϰй ϳϰ͘ϲй 
Table ϭϭ͗ƐƐĞŶƟĂůŚĞĂůƚŚŝŶĚŝĐĂƚŽƌƐ- Sudan 
Source: FMOH AnnuĂů,ĞĂůƚŚ^ƚĂƟƐƟĐƐZĞƉŽƌƚϮϬϬϳ 
 
ϭ͘ϱStudy population 
There are many players in Sudan Health System and they represent the main health 
services/care providers in the system. They include: 
ϭ. The public sector: 
- Primary health care facilities 
- Health centers 
- Hospitals 
Ϯ. The private sector: 
- Private clinics 
- Private retail pharmacies 
- Private hospitals 
ϯ. Non Governmental Organizations Sector. 
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Statistically the private sector represents the major targeted sector for the provision of 
health services (in Sudan as general and in Khartoum state in specific). As studies showed 
this is due to inefficiency of the health services in the public sector as well as NGOs sector 
;^ŚĂƌŝī͕ϮϬϬϰͿ. 
For that reason the study focused on the private sector in Khartoum city and it consider 
the representation of the following categories: 
ϭ. Private clinics: 
These clinics are usually under the authority of Khartoum State Ministry of Health 
(Department of Private Curative Establishments). Each clinic should be licensed 
for certain medical practitioner to be allowed for practicing.  
This includes: 
v  Specialists; 
v  Registrars; and 
v  General practitioners 
 
Ϯ. Private retail pharmacies: 
These pharmacies are also under the regulation of Pharmacy Directorate in 
Khartoum State (Department of Pharmaceuticals Establishments). Similarly, each 
pharmacy should be licensed for certain pharmacist to be allowed for practice. This 
includes all registered pharmacists except those practicing less than ϭǇĞĂƌĂŌĞƌ
graduation. 
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ϭ͘ϲSampling protocol 
ϭ. Information provider:- 
A. The purpose of sampling the information providers: 
To get representative data regarding the opinions of health care professionals about the 
problem of low quality medicines in Khartoum, how they evaluate the situation and how 
they deal with it. 
Sampling of the targeted groups: 
First: Pharmacies 
The list of private retail pharmacies located in Khartoum state (as per end of January 
ϮϬϬϳͿŚĂƐďĞĞŶƌĞƋƵĞƐƚĞĚĨƌŽŵWŚĂƌŵĂĐǇŝƌĞĐƚŽƌĂƚĞŝŶ<Śartoum State and the sample 
was determined and located according to this list. This list consisted ŽĨϳϴϵƌĞƚĂŝů
ƉŚĂƌŵĂĐŝĞƐŝŶ<ŚĂƌƚŽƵŵƐƚĂƚĞŝŶǁŚŝĐŚϯϮϴǁĞƌĞďĂƐĞĚŝŶ<ŚĂƌƚŽƵŵĐŝƚǇ͘ĐĐŽƌĚŝŶŐƚŽ
statistical sampling tables the sample size was estimated to include ϳϱƐĂŵƉůŝŶŐƵŶŝƚ 
(pharmacy). The sampling interval was calculated according to these figures to determine 
the details of the sample. Then the first item in the list was selected as starting point and 
the remaining units were determined based on the interval until the details of the sample 
were completed. 
Second: Clinics 
The list of doctors licensed to practice in private clinics in Khartoum state (as per end of 
:ĂŶƵĂƌǇϮϬϬϳͿƚŚĂƚŝƐƐƵĞĚďǇ<ŚĂƌƚŽƵŵ^ƚĂƚĞDŝŶŝƐƚƌǇŽĨ,ĞĂůƚŚwas used to determine 
the sample of clinics. This list consisted ŽĨϭϬϭϱƉƌŝǀĂƚĞĐůŝŶŝĐƐŝŶ<ŚĂƌƚŽƵŵƐƚĂƚĞŝŶǁŚŝĐŚ
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ϰϮϬǁĞƌĞďĂƐĞĚŝŶ<ŚĂƌƚŽƵŵĐŝƚǇĂŶĚĂĐĐŽƌĚŝŶŐƚŽƐƚĂƟƐƟĐĂůƐĂŵƉůŝŶŐƚĂďůĞƐŝŶƚŚŝƐƌĂŶŐĞ
of population the sample size was estimated to include ϵϱƐĂŵƉůŝŶŐƵŶŝƚ (clinic). The 
sampling interval was calculated according to these figures to determine the details of 
the sample. Then the first item in the list was selected as starting point and the remaining 
units were determined based on the interval until the details of the sample were 
completed. 
ϭ͘ϳData Management and Analysis Plan 
Data analysis process was done using mixed analysis methods according to the type of 
data and the tool of data collection, but in general it was done using the following: 
· Manual analysis; 
· Computer programs e.g. SPSS and MS Excel 
 
Collection of samples for chemical analysis 
A. The purpose of samples: 
The selection of medicines for this study was based on the feedback from the field 
(pharmacists and doctors) as described above. The collection technique of medicines 
sample considered the sampling methodology adopted to survey the health 
professionals. The samples have been collected and then it was subjected to 
pharmacopoeias quality control tests including physical and chemical tests. 
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B. Sampling considerations: 
This sampling methodology was used in order to verify the quality of medicines reported 
in the feedback from the health professionals with concerns about its quality. 
Accordingly, the sampling technique took into the considerations the following factors: 
ϭ. The sampling sites should be only within Khartoum city as study area; 
Ϯ. The samples collected only from the retail private pharmacies within the 
determined area; 
ϯ. The sampling technique took into consideration the differences between the 
geographical areas within Khartoum; 
· The sampling method considered also the classification of pharmacies located in 
household areas and that located near clinics and hospitals in the central areas of 
Khartoum; and 
ϰ. The sampling method was based on collection process using the trade products 
available in the market 
 
C. Determination of sampling sites: 
The availability of selected medicines was essential factor in this sampling methodology. 
Accordingly, it was important to found the targeted trade product itself rather than to 
focus on certain batch(s) of that trade product. Still whenever it was possible, the 
ĐŽůĞĐƟŽŶĐŽŶĐĞŶƚƌĂƚĞĚŽŶŵĂǆŝŵƵŵŽĨϮďĂƚĐŚĞƐŽĨĞĂĐŚƚƌĂĚĞƉƌŽĚƵĐƚƚĂƌŐĞƚĞĚ͘ The 
selection of the sites wasn’t based on the fixed number of pharmacies but the target was 
to collect the required quantities with special consideration to the geographical areas and 
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pharmacies classification as illustrated above (With conditional aspect regarding the total 
number of collection sites which should not exceeded five sites in worst scenario). 
D. Sample size: 
The size of sample collected was determined according to the requirements of reference 
pharmacopeia for the official tests. This done under the following guidelines: 
· For each solid dosage form products (tablets and capsuůĞƐͿŵŝŶŝŵƵŵŽĨϭϬϬƵŶŝƚƐ
were collected from different sites; 
· &ŽƌĞĂĐŚŝŶũĞĐƚĂďůĞƉƌŽĚƵĐƚƐŵŝŶŝŵƵŵŽĨϭϬƵŶŝƚƐwere collected from different 
sites; and 
· &ŽƌĞĂĐŚůŝƋƵŝĚĚŽƐĂŐĞĨŽƌŵƉƌŽĚƵĐƚƐ;ƐƵƐƉĞŶƐŝŽŶĂŶĚƐǇƌƵƉƐͿŵŝŶŝŵƵŵŽĨϭϬƵŶŝƚƐ
were collected from different sites 
 
E. Storage of the samples: 
After the collection process was completed, the samples were treated considering the 
following points: 
ϭ. Each sample was stored with its prefilled “Sampling form-͟ ͖;ĂŶŶĞǆEŽϰͿ͖ 
Ϯ. The sample was labeled using small stickers containing the sample code; 
ϯ. Each sample was kept in storage conditions specified by the manufacturers; 
ϰ. The samples were stored in their original containers until the start of the next 
procedure 
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F. Coding system: 
Due to the confidential nature of this part of the study, it was necessary to develop well 
structured coding system that ensured the confidential identity of all entities under the 
study. This coding system enabled only the study investigators to identify the trade 
names or the manufacturers and even the analysts were not able to expose the identity 
of any drug. This system based on the following: 
ϭ. Pharmacies & private clinics: 
The codes consisted of serial numbering that used for each pharmacy or 
clinic included in the sample. Any facility in the list has identity number that 
pre-recorded in the questionnaire and the information provider wasn’t asked 
to write or provide his/her name or his/her premises name or any other 
identification data. 
 
Ϯ. Generic name: 
All generic names were ordered alphabetically and the coded according to its 
order; for example: 
;'ϬϲͿ 
G for GĞŶĞƌŝĐĂƐĮǆĞĚůĞƩĞƌĂŶĚϬϲĨŽƌŝƚƐŽƌĚĞƌ 
ϯ. Companies’ Code: 
All companies (that own any product under testing) were ordered 
alphabetically and coded according to its order; as example: 
(CϯϯͿ 
C for CŽŵƉĂŶǇĂƐĮǆĞĚůĞƩĞƌĂŶĚϯϯĨŽƌŝƚƐŽƌĚĞƌ 
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ϰ. Trade Products Code: 
The code of each trade name contains its company code, generic name code 
and in addition to that trades was ordered alphabetically and coded 
according to its order; as example: 
(GϬϲͬϯϯͬdϭϰͿ 
T for TƌĂĚĞŶĂŵĞĂŶĚϭϰĨŽƌŝƚƐŽƌĚĞƌǁŝƚŚŝŶĂůƚƌĂĚĞŶĂŵĞƐ 
ϱ. Sample Code: 
Each sample code contains all of the above codes in addition to its unique 
number based on its order in collection process; as example: 
;'Ϭϲͬϯϯͬdϭϰͬ Ϭ^ϱͿ 
S for Sample and ϬϱĨŽƌŝƚƐŽƌĚĞƌŝŶƚŚĞĐŽůĞĐƟŽŶƉƌŽĐĞƐƐ 
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Chemical analysis of selected medicines 
 
Ϯ͘ϭQuality control tests 
After the completion of medicines selection process and samples collection, the samples 
were subjected to general physiochemical analysis regarding its compliance with quality 
requirements and specifications in the reference pharmacopeia. The process done in 
collaborative approach between the study team, Faculty of Pharmacy – University of 
Khartoum and National Quality Control Laboratory - Federal Board of Medicines and 
Poisons. This collaboration remarkably has driven this study in effective way to address 
the important issues and to concentrate on vital policy issues. Also this study benefit from 
such collaboration, because there is different capacities in each laboratory (the University 
& National labs) and this gave the opportunity to conduct different quality control tests in 
both laboratories. This was reflected on the quality of the data obtained and the coverage 
of all selected medicines included in the study. 
Ϯ͘Ϯͳ- Visual/physical inspection 
The following indicate how this inspection process was done for the samples: 
· Physical quality check was completed for each batch/sample collected from the field 
using standardized check list (for details see annex ϴ); 
· The integrity of packs, appearance of tablets, or other physical characteristics of the 
dosage forms were visually being inspected and reported for each sample; 
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· Determination of remaining shelf-life, compliance with approved labeling, packaging, and 
shipping instructions were all checked and verified by data obtained from “NMPB”; 
· The physical appearance of the dosage form (including its shape, size and color) were all 
compared based on random selection process to ensure similarity of the samples 
collected for each product; 
· Visual inspection was done to ensure that no breakdown, fragmentation, or cracks in the 
collected dosage forms for all products collected; 
· The conditions of the primary and secondary packages for each sample were also 
examined to ensure that there are no defects exist, beside that to make sure if there are 
incomplete, damaged, or missed labels; 
· Random selection of samples among each trade product has been selected to compare 
the outer package identity in terms of color, size and other physical factors. 
Ϯ͘ϯʹ– Chemical Analysis 
· This level usually combined many types of testing methods to be under taken. But due 
to the limited scope of this part of the research; only chemical assay of each product 
under testing was conducted; 
· All of the collected samples were subjected to this level of assessment; 
· Analytical tests were performed according to the quality specifications in the 
monographs of reference pharmacopeia with respect to each sample examined; 
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· The results of each sample were compared with the limits of contents in the reference 
pharmacopeia to determine whether or not it complies with the standard 
specifications; 
· Samples that failed to comply with the reference limits of content were subjected to 
fƵƌƚŚĞƌĂƐƐĂǇƚĞƐƚƐƵƉƚŽϯƟŵĞƐƚŽĞŶƐƵƌĞƚŚĞǀĂůŝĚŝƚǇŽĨƚŚĞresults; 
· Accordingly the study team decided to develop the analysis plan based on the capacity 
of each laboratory and this result in the following: 
Generics Dosage Form Assay Laboratory 
Ciprofloxacin Tablet LC National Lab 
Glibenclamide Tablet LC National Lab 
Amoxicillin Capsule LC National Lab 
Diclofenac Tablet LC National Lab 
Ceftriaxone Injection UV University Lab 
Paracetamol Tablet UV University Lab 
Chlorphenarmine  Tablet UV University Lab 
Mefenamic Acid Tablet Titration University Lab 
Aspirin Tablet Titration University Lab 
Metronidazole Tablet Titration University Lab 
Table Ϯ: generic medicines selected for chemical analysis 
Ϯ͘ϰSamples retesting 
This has been regarded as specific considerations for medicines that didn’t comply with 
the requirements during the first round of analysis. Its purpose was to verify the failure 
results for further assurance. After the determination of the medicines that fail the tests 
the plan was developed, then: 
- Additional samples (the same batch) were collected from the retail pharmacies 
using the same method used before and this sample tested in the same way; 
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- The results from each round of analysis compared with each other. The 
comparisons were made to determine the type of problems that are possibly 
affecting the results. 
The forms used to collect these data (physical and chemical) were filled using the coding 
system described before and it will be kept confidential as stated before 
 
Ϯ͘ϱThe materials used in chemical analysis 
Absolute ethanol , acetone, acetonitrile HPLC, anhydrous acetic acid, ether, methanol HPLC, 
potassium dihydrogen orthophosphate, orthophosphoric acid, sodium dihydrogen 
orthophosphate, triethylamine. 
 
 
 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  PageͷͶ 
Ϯ͘ϲMethods of analysis 
Serial Number ϭ 
Generic Name Acetylsalicylic Acid 
Dosage Form Tablet 
Concentration ϯϬϬŵŐ 
Reference Pharmacopeia BP 
Limits for Contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
Chemical Analysis: 
ϭ. Procedures: 
· ϮϬƚĂďůĞƚƐǁĞƌĞǁeighed and powdered. To a quantity of the powder containing 
Ϭ͘ϱŐŽĨĐĞƚǇůƐĂůŝĐǇůŝĐĐŝĚϯϬŵůŽĨϬ͘ϱDƐŽĚŝƵŵŚǇĚƌŽǆŝĚĞǁĂƐĂĚĚĞĚ͘dŚĞ
ƐŽůƵƟŽŶǁĂƐďŽŝůĞĚŐĞŶƚůǇĨŽƌϭϬŵŝŶƵƚĞƐĂŶĚƚŚĞĞǆĐĞƐƐŽĨĂůŬĂůŝǁĂƐƟƚƌĂƚĞĚ
ǁŝƚŚϬ͘ϱDŚǇĚƌŽĐŚůŽƌŝĐĂĐŝĚƵƐŝŶŐƉŚĞŶŽů red solution as indicator. The 
operation was Repeat without the substance under analysis. The calculation was 
ŵĂĚĞĂŶĚƚŚĞƋƵĂŶƟƚǇŝĚĞŶƟĮĞĚĂƐϵϱ͘ϴйŽĨƚŚĞƐƚĂƚĞĚĐŽŶĐĞŶƚƌĂƟŽŶ͘ 
Ϯ. Modifications of the method: 
· None. 
Serial Number Ϯ 
Generic Name Amoxicillin Trihydrate 
Dosage Form Capsule 
Concentration ϱϬϬŵŐ 
Reference Pharmacopeia BP 
Limits for Contents ϵϮ͘ϱƚŽϭϭϬ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
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Chemical Analysis: 
ϭ. Procedures: 
· The analysis was conducted using liquid chromatography method. Mobile phase 
A wĂƐƉƌĞƉĂƌĞĚĂƐĨŽůŽǁƐ͗ϭŵůŽĨĂĐĞƚŽŶŝƚƌŝůĞĂŶĚϵϵŵůŽĨĂϮϱйǀͬǀƐŽůƵƟŽŶ
ŽĨϬ͘ϮDƉŽƚĂƐƐŝƵŵĚŝŚǇĚƌŽŐĞŶŽƌƚŚŽƉŚŽƐƉŚĂƚĞǁĂƐŵŝǆĞĚĂŶĚĂĚũƵƐƚĞĚƚŽƉ,
ϱ͘ϬǁŝƚŚϮDƐŽĚŝƵŵŚǇĚƌŽǆŝĚĞ͘DŽďŝůĞƉŚĂƐĞǁĂƐƉƌĞƉĂƌĞĚĂƐĨŽůŽǁƐ͗ϮϬŵůŽĨ
ĂĐĞƚŽŶŝƚƌŝůĞĂŶĚϴϬŵůŽĨĂ ϮϱйǀͬǀƐŽůƵƟŽŶŽĨϬ͘ϮDƉŽƚĂƐƐŝƵŵĚŝŚǇĚƌŽŐĞŶ
ŽƌƚŚŽƉŚŽƐƉŚĂƚĞǁĂƐŵŝǆĞĚĂŶĚĂĚũƵƐƚĞĚƚŽƉ,ϱ͘ϬǁŝƚŚϮDƐŽĚŝƵŵŚǇĚƌŽǆŝĚĞ͘
ϴϬŵůŽĨŵŽďŝůĞƉŚĂƐĞǁĂƐĂĚĚĞĚƚŽĂƋƵĂŶƟƚǇŽĨƚŚĞŵŝǆĞĚĐŽŶƚĞŶƚƐŽĨϮϬ
ĐĂƉƐƵůĞƐĐŽŶƚĂŝŶŝŶŐƚŚĞĞƋƵŝǀĂůĞŶƚŽĨϲϬŵŐŽĨĂŵŽǆŝĐŝůŝŶƚŚĂƚƐŚĂĐŬĞĚĨŽƌϭϱ
ŵŝŶƵƚĞƐ͘dŚĞƌĞƐƵůƚĞĚƐŽůƵƟŽŶǁĂƐŵŝǆĞĚǁŝƚŚƚŚĞĂŝĚŽĨƵůƚƌĂƐŽƵŶĚĨŽƌϭ
ŵŝŶƵƚĞ͕ĂŶĚƐƵĸĐŝĞŶƚŵŽďŝůĞƉŚĂƐĞǁĂƐĂĚĚĞĚƚŽƉƌŽĚƵĐĞϭϬϬŵů͕ƚŚĞ
ƌĞƐƵůƚĂŶƚƐŽůƵƟŽŶǁĂƐŵŝǆĞĚĂŶĚĮůƚĞƌĞĚ͘ϱϬђůŽĨƚŚŝƐƐŽůƵƟŽŶǁĞƌĞŝŶũĞĐƚĞĚ͘
Ϭ͘ϬϳϬйǁͬǀ ŽĨĂŵŽǆŝĐŝůŝŶƚƌŝŚǇĚƌĂƚĞǁŽƌŬŝŶŐƐƚĂŶĚĂƌĚ;ƉŽƚĞŶĐǇϭϬϬйͿǁĂƐŵŝǆĞĚ
ŝŶŵŽďŝůĞƉŚĂƐĞĂŶĚϮϬђůŽĨƚŚŝƐƐŽůƵƟŽŶǁĞƌĞŝŶũĞĐƚĞĚ͘ The calculation was 
ŵĂĚĞĂŶĚƚŚĞƋƵĂŶƟƚǇŝĚĞŶƟĮĞĚĂƐϭϬϯ͘ϭйŽĨƚŚĞƐƚĂƚĞĚĐŽŶĐĞŶƚƌĂƟŽŶ͘ 
Ϯ. Modifications of the method: 
· None. 
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Serial Number ϯ 
Generic Name Ceftriaxone sodium 
Dosage Form Powder for injection 
Concentration ϭŐŵ 
Reference Pharmacopeia USP 
Limits for Contents ϵϮ͘ϬƚŽϭϬϴ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
Chemical Analysis: 
ϭ. Procedures: 
· A quantity of powder containinŐϭϬϬŵŐŽĨĞŌƌŝĂǆŽŶĞƐŽĚŝƵŵǁŽƌŬŝŶŐƐƚĂŶĚĂƌĚ
ǁŝƚŚƉŽƚĞŶĐǇϵϵ͘ϳйŚĂƐďĞĞŶƚĂŬĞŶĂŶĚĚŝƐƐŽůǀĞĚŝŶƐƵĸĐŝĞŶƚƋƵĂŶƟƚǇŽĨǁĂƚĞƌ
ƚŽƉƌŽĚƵĐĞĂƐŽůƵƟŽŶĞƋƵŝǀĂůĞŶƚƚŽϭйǁͬǀŽĨƚŚĞǁŽƌŬŝŶŐƐƚĂŶĚĂƌĚ͘^ĞƌŝĞƐŽĨ
ĚŝůƵƟŽŶƉƌŽĐĞƐƐŚĂƐďĞĞŶĚŽŶĞƚŽƉƌŽĚƵĐĞŽƚŚĞƌϲdifferent solutions in 
ĐŽŶĐĞŶƚƌĂƟŽŶƐϬ͘ϭй͕Ϭ͘Ϭϱй͕Ϭ͘Ϭϭй͕Ϭ͘ϬϬϱй͕Ϭ͘ϬϬϮϱĂŶĚϬ͘ϬϬϭй;ǁͬǀͿŽĨƚŚĞ
working standard. The absorbance of the produced solutions was measured at 
ƚŚĞŵĂǆŝŵƵŵĂƚϮϳϬ͘dŚĞĂďƐŽƌƉƟŽŶŽĨĞĂĐŚƐŽůƵƟŽŶǁĂƐƉůŽƩĞĚǀĞƌƐƵƐƚŚĞ
relevant concentration and the calibration cure then was drown. This process has 
ďĞĞŶƌĞƉĞĂƚĞĚĨŽƌϯƟŵĞƐƚŽĞŶƐƵƌĞƚŚĞǀĂůŝĚĂƟŽŶŽĨƚŚĞŵĞƚŚŽĚ͕ĂŶĚƚŚĞƌĞƐƵůƚƐ
obtained were reproducible and relevant in linearity. A quantity of powder 
ĐŽŶƚĂŝŶŝŶŐϭϬϬŵŐŽĨƚŚĞƐĂmpled powder containing Ceftriaxone sodium has 
been taken and dissolved in sufficient quantity of water to produce a solution 
ĞƋƵŝǀĂůĞŶƚƚŽϭйǁͬǀŽĨĞŌƌŝĂǆŽŶĞƐŽĚŝƵŵ͘dŚĞƌĞƐƵůƟŶŐƐŽůƵƟŽŶǁĂƐĚŝůƵƚĞĚƚŽ
ƉƌŽĚƵĐĞƐŽůƵƟŽŶĞƋƵŝǀĂůĞŶƚƚŽϬ͘ϬϭйǁͬǀŽĨĞŌriaxone sodium. The absorbance 
ŽĨƚŚĞƉƌŽĚƵĐĞĚƐŽůƵƟŽŶǁĂƐŵĞĂƐƵƌĞĚĂƚƚŚĞŵĂǆŝŵƵŵĂƚϮϳϬ͘ The calculation 
ǁĂƐŵĂĚĞĂŶĚƚŚĞƋƵĂŶƟƚǇŝĚĞŶƟĮĞĚĂƐϭϬϯ͘ϴййŽĨƚŚĞƐƚĂƚĞĚĐŽŶĐĞŶƚƌĂƟŽŶ͘ 
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Ϯ. Modifications of the method: 
· The official method in the pharmacopeia for chemical assay of Ceftriaxone 
chloride using HPLC analysis has been replaced by this especial method due to 
difficulty to obtain all chemicals and reagents needed for Pharmacopoeial test.  
 
Serial Number ϰ 
Generic Name Chlorphenarmine Maleate 
Dosage Form Tablet 
Concentration ϰŵŐ 
Reference Pharmacopeia BP 
Limits for Contents ϵϮ͘ϱƚŽϭϬϳ͘ϱйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
Chemical Analysis: 
ϭ. Procedures: 
· ƋƵĂŶƟƚǇŽĨƚŚĞƉŽǁĚĞƌĐŽŶƚĂŝŶŝŶŐϯŵŐŽĨŚůŽƌƉŚĞŶĂƌŵŝŶĞDĂůĞĂƚĞǁĂƐ
ǁĞŝŐŚƚĞĚĂŶĚƐŚĂŬĞŶǁŝƚŚϮϬŵůŽĨϬ͘ϬϱDƐƵůƉŚƵƌŝĐĂĐŝĚĨŽƌϱŵŝŶƵƚĞƐ͘ϮϬŵůŽĨ
ether was added and shake carefully. The acid layer was filtered into a second 
ƐĞƉĂƌĂƟŶŐĨƵŶŶĞů͕ƚŚĞĞƚŚĞƌůĂǇĞƌǁĂƐĞǆƚƌĂĐƚĞĚǁŝƚŚƚǁŽϭϬ-ml quantities of 
Ϭ͘ϬϱDƐƵůƉŚƵƌŝĐĂĐŝĚ͕ĞĂĐŚĂĐŝĚůĂǇĞƌĮůƚĞƌĞĚŝŶƚŽƚŚĞsecond separating funnel 
ĂŶĚƚŚĞĮůƚĞƌǁĂƐǁĂƐŚĞĚǁŝƚŚϬ͘ϬϱDƐƵůƉŚƵƌŝĐĂĐŝĚ͘dŚĞĐŽŵďŝŶĞĚĂĐŝĚĞǆƚƌĂĐƚƐ
ǁĞƌĞǁĂƐŚĞĚƚŽďĞŵĂĚĞũƵƐƚĂůŬĂůŝŶĞƚŽůŝƚŵƵƐƉĂƉĞƌǁŝƚŚϭDƐŽĚŝƵŵ
ŚǇĚƌŽǆŝĚĞ͕ĂŶĚϮŵůŝŶĞǆĐĞƐƐǁĂƐĂĚĚĞĚĂŶĚƚŚĞŵŝǆƚƵƌĞǁĂƐĞǆƚƌĂĐƚĞĚǁŝƚŚƚǁŽ
ϱϬ ŵůƋƵĂŶƟƟĞƐŽĨĞƚŚĞƌ͘ĂĐŚĞƚŚĞƌĞǆƚƌĂĐƚǁĂƐǁĂƐŚĞĚǁŝƚŚƚŚĞƐĂŵĞϮϬŵůŽĨ
ǁĂƚĞƌĂŶĚƚŚĞŶĞǆƚƌĂĐƚĞĚǁŝƚŚƐƵĐĐĞƐƐŝǀĞƋƵĂŶƟƟĞƐŽĨϮϬ͕ϮϬĂŶĚϱŵůŽĨϬ͘ϮϱD
ƐƵůƉŚƵƌŝĐĂĐŝĚ͘dŚĞĐŽŵďŝŶĞĚĂĐŝĚĞǆƚƌĂĐƚƐĚŝůƵƚĞĚƚŽϱϬŵůǁŝƚŚϬ͘ϮϱDƐƵůƉŚƵƌŝĐ
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ĂĐŝĚ͕ϭϬŵůŽĨƚŚŝƐƐŽůƵƟŽŶǁĂƐĚŝůƵƚĞĚƚŽϮϱŵůǁŝƚŚϬ͘ϮϱDƐƵůƉŚƵƌŝĐĂĐŝĚĂŶĚ
ƚŚĞĂďƐŽƌďĂŶĐĞŽĨƚŚĞƌĞƐƵůƟŶŐƐŽůƵƟŽŶǁĂƐŵĞĂƐƵƌĞĚĂƚŵĂǆŝŵƵŵĂƚϮϲϱŶŵ͘ 
dŚĞĐĂůĐƵůĂƟŽŶǁĂƐŵĂĚĞĂŶĚƚŚĞƋƵĂŶƟƚǇŝĚĞŶƟĮĞĚĂƐϵϱ͘ϲйŽĨƚŚĞƐƚĂƚĞĚ
concentration. 
Ϯ. Modifications of the method: 
· None. 
 
Serial Number ϱ 
Generic Name Ciprofloxacin Hydrochloride 
Dosage Form Tablet 
Concentration ϱϬϬŵŐ 
Reference Pharmacopeia BP 
Limits for Contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
Chemical Analysis: 
ϭ. Procedures: 
· The mobile phase was prepareĚďǇĂĚĚŝŶŐĂŵŝǆƚƵƌĞŽĨϭϯǀŽůƵŵĞƐŽĨĂĐĞƚŽŶŝƚƌŝůĞ
ĂŶĚϴϳǀŽůƵŵĞƐŽĨĂϬ͘ϮϰϱйǁͬǀƐŽůƵƟŽŶŽĨŽƌƚŚŽƉŚŽƐƉŚŽƌŝĐĂĐŝĚĂŶĚƚŚĞŶƚŚĞ
Ɖ,ŚĂƐďĞĞŶĂĚũƵƐƚĞĚƚŽϯ͘ϬǁŝƚŚƚƌŝĞƚŚǇůĂŵŝŶĞ͘dŽĂƋƵĂŶƟƚǇŽĨƚŚĞƉŽǁĚĞƌĞĚ
ƚĂďůĞƚƐĐŽŶƚĂŝŶŝŶŐƚŚĞĞƋƵŝǀĂůĞŶƚŽĨϮŐŽĨĐŝƉƌŽŇŽǆĂĐŝŶϳϱϬŽĨƚŚĞŵŽďŝůĞƉŚĂƐĞ
ǁĂƐĂĚĚĞĚĂŶĚƚŚĞŵŝǆƚƵƌĞƚŚĞŶƐƵďũĞĐƚĞĚƚŽƵůƚƌĂƐŽƵŶĚĨŽƌϮϬŵŝŶƵƚĞƐƚŚĞ
ĐŽŵƉůĞƚĞĚƚŽϭϬϬϬŵůƵƐŝŶŐƚŚĞŵŽďŝůĞƉŚĂƐĞ͘dŚĞƌĞƐƵůƟŶŐƐŽůƵƟŽŶǁĂƐĮůƚĞƌĞĚ
and the filtrate was diluted using sufficient quantity of the mobile phase to 
ƉƌŽĚƵĐĞƐŽůƵƟŽŶǁŝƚŚĮŶĂůĐŽŶĐĞŶƚƌĂƟŽŶŽĨϬ͘ϬϱйǁͬǀŽĨĐŝƉƌŽŇŽǆĂĐŝŶĂŶĚϮϬђů
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ŽĨƚŚŝƐƐŽůƵƟŽŶǁĂƐŝŶũĞĐƚĞĚ͘ϮϬђůŽĨĂƐŽůƵƟŽŶĐŽŶƚĂŝŶŝŶŐϬ͘ϬϱϴйǁͬǀŽĨ
ĐŝƉƌŽŇŽǆĂĐŝŶŚǇĚƌŽĐŚůŽƌŝĚĞǁŽƌŬŝŶŐƐƚĂŶĚĂƌĚǁŝƚŚĂƉŽƚĞŶĐǇŽĨϵϵ͘ϴйǁĂƐ
injected with the mobile phase. The calculation was made and the quantity 
ŝĚĞŶƟĮĞĚĂƐϵϵ͘ϯйŽĨƚŚĞƐƚĂƚĞĚĐŽŶĐĞŶƚƌĂƟŽŶ͘ 
Ϯ. Modifications of the method: 
· None 
 
Serial Number ϲ 
Generic Name Diclofenac Sodium 
Dosage Form Tablet 
Concentration ϮϱŵŐ 
Reference Pharmacopeia BP 
Limits for Contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
Chemical Analysis: 
ϭ. Procedures: 
· The analysis was conducted using liquid chromatography method. The mobile 
ƉŚĂƐĞǁĂƐƉƌĞƉĂƌĞĚĂƐĨŽůŽǁƐ͗ĂŵŝǆƚƵƌĞŽĨϯϰŵůŽĨĂŵŝǆƚƵƌĞŽĨϯϰŵůŽĨĂϬ͘ϭй
w/v soůƵƟŽŶŽĨŽƌƚŚŽƉŚŽƐƉŚŽƌŝĐĂĐŝĚĂŶĚĂϬ͘ϭϲйǁͬǀƐŽůƵƟŽŶŽĨƐŽĚŝƵŵ
ĚŝŚǇĚƌŽŐĞŶŽƌƚŚŽƉŚŽƐƉŚĂƚĞǁĞƌĞŵŝǆĞĚĂŶĚƉ,ĂĚũƵƐƚĞĚƚŽϮ͘ϱ͕ĂŶĚĂĚĚĞĚƚŽϲϲ
ŵůŽĨŵĞƚŚĂŶŽů͘ϭϬƚĂďůĞƚƐŽĨƚŚĞƉƌŽĚƵĐƚŚĂǀĞďĞĞŶƐŚĂŬĞŶǁŝƚŚϳϬϬŵůŽĨ
ŵĞƚŚĂŶŽů;ϱϬйͿĨŽƌϯϬŵŝŶƵƚĞƐǁŝƚŚƚŚĞaid of ultrasound. Sufficient mobile phase 
ǁĂƐĂĚĚĞĚƚŽƉƌŽĚƵĐĞϭϬϬϬŵůĂŶĚƚŚĞŶŵŝǆĞĚ͕ĂŶĂůŝƋƵŽƚĐĞŶƚƌŝĨƵŐĞĚĂŶĚƚŚĞ
ƐƵƉĞƌŶĂƚĂŶƚůŝƋƵŝĚǁĂƐĮůƚĞƌĞĚƚŚƌŽƵŐŚĂϬ͘ϰϱ-µm filter. The filtrate was diluted 
with the mobile phase to produce a solution containing Ϭ͘ϬϬϱйǁͬǀŽĨŝĐůŽĨĞŶĂĐ
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Ž^ĚŝƵŵ͘ϮϬђůŽĨƚŚŝƐƐŽůƵƟŽŶǁĞƌĞŝŶũĞĐƚĞĚ͘Ϭ͘ϬϬϱйǁͬǀŽĨŝĐůŽĨĞŶĂĐƐŽĚŝƵŵ
ǁŽƌŬŝŶŐƐƚĂŶĚĂƌĚ;ƉŽƚĞŶĐǇϵϵ͘ϴйͿŝŶƚŚĞŵŽďŝůĞƉŚĂƐĞ͘ϮϬђůŽĨƚŚŝƐƐŽůƵƟŽŶǁĂƐ
injected. dŚĞĐĂůĐƵůĂƟŽŶǁĂƐŵĂĚĞĂŶĚƚŚĞƋƵĂŶƟƚǇŝĚĞŶƟĮĞĚĂƐϭϬϰ͘ϳ % of the 
stated concentration. 
Ϯ. Modifications of the method: 
· None 
Serial Number ϳ 
Generic Name Glibenclamide 
Dosage Form Tablet 
Concentration ϱϬϬŵŐ 
Reference Pharmacopeia BP 
Limits for Contents Glibenclamide 
 
Chemical Analysis: 
ϭ. Procedures: 
· The analysis was conducted using liquid chromatography method. The mobile 
ƉŚĂƐĞǁĂƐƉƌĞƉĂƌĞĚĂƐĨŽůŽǁƐ͗ĂŵŝǆƚƵƌĞŽĨϰϳŵůŽĨĂĐĞƚŽŶŝƚƌŝůĞĂŶĚϱϯŵůŽĨĂ
ϭ͘ϯϲйǁͬǀƐŽůƵƟŽŶŽĨƉŽƚĂƐƐŝƵŵĚŝŚǇĚƌŽŐĞŶŽƌƚŚŽƉŚŽƐƉŚĂƚĞƉƌĞǀŝŽƵƐůǇĂĚũƵƐƚĞĚ
ƚŽƉ,ϯ͘ϬǁŝƚŚŽƌƚŚŽƉŚŽƐƉŚŽƌŝĐĂcid. Quantity of the powdered tablets containing 
ϱŵŐŽĨ'ůŝďĞŶĐůĂŵŝĚĞǁĂƐŵŝǆĞĚ͕ǁŝƚŚƚŚĞĂŝĚŽĨƵůƚƌĂƐŽƵŶĚ͕ǁŝƚŚĂŵŝǆƚƵƌĞŽĨϮ
ŵůŽĨǁĂƚĞƌĂŶĚϮϬŵůŽĨŵĞƚŚĂŶŽůƵŶƟůĨƵůǇĚŝƐƉĞƌƐĞĚƚŚĞŶĮůƚĞƌĞĚƚŚƌŽƵŐŚĂ
Ϭ͘Ϯ-µm membrane filter (Anatop LC is suitable) ͘ϮϬђůŽĨƚŚĞƌĞƐƵůƟŶŐƐŽůƵƟŽŶǁĂƐ
ŝŶũĞĐƚĞĚǁŝƚŚŵŽďŝůĞƉŚĂƐĞ͘ϱϬŵŐŽĨ'ůŝďĞŶĐůĂŵŝĚĞWZ^ĚŝƐƐŽůǀĞĚŝŶϭϬŵůŽĨ
ŵĞƚŚĂŶŽůǁŝƚŚƚŚĞĂŝĚŽĨƵůƚƌĂƐŽƵŶĚĨŽƌϮϬŵŝŶƵƚĞƐ͕ƐƵĸĐŝĞŶƚŵĞƚŚĂŶŽůǁĂƐ
ĂĚĚĞĚƚŽƉƌŽĚƵĐĞϱϬŵů͘ϭϬŵůŽĨƚŚŝƐƐŽůƵƟŽŶǁĂƐĚŝůƵƚĞĚƚŽϰϬŵůǁŝƚŚŵĞƚŚĂŶŽů
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ĂŶĚϮŵůŽĨǁĂƚĞƌǁĂƐĂĚĚĞĚƚŽϮϬŵůŽĨƚŚŝƐƐŽůƵƟŽŶĂŶĚƚŚĞŶŵŝǆĞĚ͘ϮϬђůŽĨƚŚĞ
resulting solution was injected with mobile phase. The calculation was made and 
ƚŚĞƋƵĂŶƟƚǇŝĚĞŶƟĮĞĚĂƐϵϱ͘ϯйŽĨƚŚĞƐƚĂƚĞĚĐŽŶĐĞŶƚƌĂƟŽŶ͘ 
Ϯ. Modifications of the method: 
· None 
 
Serial Number ϴ 
Generic Name Mefenamic Acid 
Dosage Form Tablet 
Concentration ϱϬϬŵŐ 
Reference Pharmacopeia BP 
Limits for Contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
Chemical Analysis: 
ϭ. Procedures: 
· Quantity of the powdered tabůĞƚƐĐŽŶƚĂŝŶŝŶŐϬ͘ϱŐŽĨDĞĨĞŶĂŵŝĐĐŝĚǁĂƐ
ĚŝƐƐŽůǀĞĚŝŶĂďŽƵƚϴϬŵůŽĨǁĂƌŵĂďƐŽůƵƚĞĞƚŚĂŶŽůƉƌĞǀŝŽƵƐůǇneutralized to 
phenol red solution. The solution resulted was subjected to alternation between 
heating and ultrasound to aid dissolution the cooled. Sufficient quantity of the 
neutralized ĂďƐŽůƵƚĞĞƚŚĂŶŽůǁĂƐĂĚĚĞĚƚŽƉƌŽĚƵĐĞϭϬϬŵů͖ƚŚĞŶŵŝǆĞĚĂŶĚ
ƟƚƌĂƚĞĚǁŝƚŚϬ͘ϭDƐŽĚŝƵŵŚǇĚƌŽǆŝĚĞs^ƵƐŝŶŐƉŚĞŶŽůƌĞĚƐŽůƵƟŽŶĂƐŝŶĚŝĐĂƚŽƌ͘ 
dŚĞĐĂůĐƵůĂƟŽŶǁĂƐŵĂĚĞĂŶĚƚŚĞƋƵĂŶƟƚǇŝĚĞŶƟĮĞĚĂƐϵϵ͘ϰйŽĨƚŚĞƐƚĂƚĞĚ
concentration. 
Ϯ. Modifications of the method: 
· None 
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Serial Number ϵ 
Generic Name Metronidazole 
Dosage Form Tablet 
Concentration ϮϱϬŵŐ 
Reference Pharmacopeia BP 
Limits for Contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
Chemical Analysis: 
ϭ. Procedures: 
· QuantiƚǇŽĨƚŚĞƉŽǁĚĞƌĐŽŶƚĂŝŶŝŶŐϬ͘ϮŐŽĨDĞƚƌŽŶŝĚĂǌŽůĞǁĂƐƚƌĂŶƐĨĞƌƌĞĚƚŽĂ
sintered-ŐůĂƐƐĐƌƵĐŝďůĞĂŶĚĞǆƚƌĂĐƚĞĚǁŝƚŚƐŝǆϭϬŵůƋƵĂŶƟƟĞƐŽĨŚŽƚĂĐĞƚŽŶĞĂŶĚ
ƚŚĞĐŽŽůĞĚ͘ϱϬŵůŽĨĂĐĞƟĐĂŶŚǇĚƌŝĚĞĂŶĚϬ͘ϭŵůŽĨĂϭйǁͬǀƐŽůƵƟŽŶŽĨďƌŝůŝĂŶƚ
green in anhydrous acetic acid was added to the combined extracts. The resulting 
ƐŽůƵƟŽŶǁĂƐƟƚƌĂƚĞĚǁŝƚŚϬ͘ϭDƉĞƌĐŚůŽƌŝĐĂĐŝĚs^ƚŽĂǇĞůŽǁŝƐŚ-green end point. 
The operation was repeated without the powdered tablets and the difference was 
calculated. The calculation was ŵĂĚĞĂŶĚƚŚĞƋƵĂŶƟƚǇŝĚĞŶƟĮĞĚĂƐϵϱ͘ϭйŽĨƚŚĞ
stated concentration. 
Ϯ. Modifications of the method: 
· None. 
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Serial Number ϭϬ 
Generic Name Paracetamol 
Dosage Form Tablet 
Concentration ϱϬϬŵŐ 
Reference Pharmacopeia BP 
Limits for Contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
Chemical Analysis: 
ϭ. Procedures: 
· YƵĂŶƟƚǇŽĨƚŚĞƉŽǁĚĞƌĐŽŶƚĂŝŶŝŶŐϬ͘ϭϱŐŽĨWĂƌĂĐĞƚĂŵŽůǁĂƐĂĚĚĞĚƚŽϱϬŵůŽĨ
Ϭ͘ϭDƐŽĚŝƵŵŚǇĚƌŽǆŝĚĞĂŶĚĚŝůƵƚĞĚǁŝƚŚϭϬϬŵůŽĨǁĂƚĞƌ͘dŚĞƌĞƐƵůƟŶŐ
ƐŽůƵƟŽŶŚĂƐďĞĞŶƐŚĂŬĞŶĨŽƌĂďŽƵƚϭϱŵŝŶƵƚĞƐĂŶĚsufficient amount of water 
ǁĂƐĂĚĚĞĚƚŽƉƌŽĚƵĐĞϮϬϬŵůƚŚĞŶƚŚĞƐŽůƵƟŽŶǁĂƐŵŝǆĞĚĂŶĚĮůƚĞƌĞĚ͘ϭϬŵů
ŽĨƚŚĞĮůƚƌĂƚĞǁĂƐĚŝůƵƚĞĚƚŽϭϬŵůǁŝƚŚǁĂƚĞƌ͘ϭϬŵůŽĨƚŚĞƌĞƐƵůƟŶŐƐŽůƵƟŽŶ
ǁĂƐĂĚĚĞĚƚŽϭϬŵůŽĨϬ͘ϭDƐŽĚŝƵŵŚǇĚƌŽǆŝĚĞĂŶĚĚŝůƵƚĞĚǁŝƚŚǁĂƚĞƌƵƉƚŽ 
ϭϬϬŵů͘dŚĞĂďƐŽƌďĂŶĐĞŽĨƚŚĞƌĞƐƵůƟŶŐƐŽůƵƟŽŶǁĂƐŵĞĂƐƵƌĞĚĂƚƚŚĞ
ŵĂǆŝŵƵŵĂƚϮϱϳŶŵ͘ The calculation was made and the quantity identified as 
ϵϴ͘ϰйŽĨƚŚĞƐƚĂƚĞĚĐŽŶĐĞŶƚƌĂƟŽŶ͘ 
Ϯ. Modifications of the method: 
· None. 
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ϰ͘ϭEquipments and materials 
ϱйĚĞǆƚƌŽƐĞ/sƐŽůƵƟŽŶŝŶǁĂƚĞƌ͕Ϭ͘ϵйƐŽĚŝƵŵĐŚůŽƌŝĚĞ/sƐŽůƵƟŽŶŝŶǁĂƚĞƌ͕ϭϬйĚĞǆƚƌŽƐĞ
IV injection, heparinised blood containers, plane serum containers, QBC Horizon Model 
ϳϱϱs^ĞŶƚƌŝĨƵŐĞ͕ŶŽŶ-volumetric pipettes, ϱŵů^ǇƌŝŶŐĞƐ͕Accu-chek® Glucometer, 
methanol, acetonitrile, dihydrogen, ortho-phosphate and ortho-phosphoric acid in 
addition to water for analytical purpose. 
ϰ͘ϮStudy rationale 
This study designed to provide necessary information in order to evaluate the quality of 
two Glibenclamide products available in the market to inform the decision makers about 
the registration of this drug in Sudan. 
ϰ͘ϯStudy objectives 
· To investigate factors affecting the quality of clinical outcomes of Glibenclamide in 
Khartoum using different investigation methods; and 
· To estimate the bioavailability and to evaluate bioequivalence of a single dose of 
the test ĨŽƌŵƵůĂƟŽŶ;ĐŽŶƚĂŝŶŝŶŐ'ůŝďĞŶĐůĂŵŝĚĞϱŵŐ tablet, manufactured by 
ĐŽŵƉĂŶǇϬϲ- Sudan) and to compare it with a single dose of reference 
formulation ;ĐŽŶƚĂŝŶŝŶŐ'ůŝďĞŶĐůĂŵŝĚĞϱŵŐ tablet, manufactured by company 
Ϭϵ- Germany) under fasting conditions. 
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ϰ͘ϰStudy design & methods 
WHO guidance on bioavailability and bioequivalence stated the following “Two medicinal 
products are bioequivalent if they are pharmaceutically equivalent or pharmaceutical 
alternatives AND if their bioavailability after administration in the same molar dose are 
similar to such degree that their effects, with respect to both efficacy and safety, will be 
essentially the same” ;t,K͕ϮϬϬϯͿ. 
This study intended to provide evidence for action; accordingly its design provided 
comprehensive data and evidence. Comparative in-vivo bioavailability (bioequivalence) 
study, in which Glibenclamide concentration in plasma was measured according to WHO 
guidelines for bioavailability and bioequivalence studies as described below ;t,K͕ϮϬϬϯͿ. 
The study design benefited from the experience and guidance of other bodies as well 
;&͕ϮϬϬϬͿ. In this study there are two formulations under investigation. The study was 
designed basically as a comparative framework, so, single dose study was applied with a 
two-period, two-sequence crossover design (as recommended for this kind of studies). 
This was applied as two phases of treatment separated by ϭϰĚĂǇƐ as washing period. 
The volunteers received a dose of ϱ mg of Glibenclamide (from test and standard 
products) under fasting conditions in two separate sessions using a randomized crossover 
design. Plasma samples were ŽďƚĂŝŶĞĚĂƚƐĞůĞĐƚĞĚƟŵĞƐŽǀĞƌϮϰŚŽƵƌƐĂŶĚƐƚŽƌĞĚĨƌŽǌĞŶ
until analyzed using basic HPLC technique. Pharmacokinetic parameters were compared 
using the analysis of variance for a cross-ŽǀĞƌĚĞƐŝŐŶĂŶĚƌĂƟŽƐŽĨhϮϰŚĂŶĚŵĂǆ͕
ϵϬйĐŽŶĮĚĞŶĐĞŝŶƚĞƌǀĂls were obtained for summery of the results. Results were 
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considered positively if the confidence intervals did not exceed the limits of acceptance 
;ϴϬ--ϭϮϬйͿĨŽƌhϮϰŚĂŶĚŵĂǆ͘ 
ϰ͘ϱSubjects 
Most of the published studies in this area adopt sample size beƚǁĞĞŶϭϮ– ϮϲƐƵďũĞĐƚƐ
(depends on the variability of drug under study) and this number showed sufficient 
statistical significant evidence ;ƵŝĐĞ͕ϮϬϬϱͿ͘ĐĐŽƌĚŝŶŐůǇ͕ϭϮ^ƵĚĂŶĞƐĞŵĂůĞͬĨĞŵĂůĞ
healthy volunteers were recruited in this study. The detailed process of selecting these 
subjects followed the recommendations of Helsinki Declaration regarding the ethical 
principles for medical research involving human subjects ;tD͕ϮϬϬϴͿ. 
The following issues were considered while selecting the subjects: 
Ø  All subjects were residents of Khartoum State; 
Ø  ϲŵĂůĞƐ ĂŶĚϲĨĞŵĂůĞƐǁĞƌĞƐĞůĞĐƚĞĚ͖ 
Ø  Females were not pregnant nor lactating; 
Ø  The range of age was (чϭϴƚŽϱϱшǇĞĂƌƐͿ; and 
Ø  The health status of the subjects was evaluated based on information obtained 
from each volunteer regarding the following: 
- Free from history of DM (both types) 
- No smoking history 
- EŽƌĞĐĞŶƚŚŝƐƚŽƌǇŽĨŚŽƐƉŝƚĂůŝǌĂƟŽŶƐŝŶƚŚĞůĂƐƚϭϮŵŽŶƚŚƐ 
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Other health considerations which were verified for each volunteer and only those with 
normal parameters for the following investigations were selected: 
- ECGs 
- Clinical blood chemistry 
- Measuring Blood Pressure 
- Subject has no evidence of burns 
- No evidences for impaired renal or hepatic functions 
As part of inclusion criteria, the volunteers during the study period (or ǁŝƚŚŝŶϭŵŽŶƚŚͿ
were not taking any of the following medicines: Allopurinol, Captopril, Enalapril, 
Anticoagulants, coumarin or indandione derivative, Miconazole, Fluconazole, Appetite 
suppressants, Corticosteroids thiazide Diuretics, Barbiturates, Beta-adrenergic blocking 
agents, Cimetidine, Ranitidine, Fluoroquinolones, Quinine, Rifampin, Chloramphenicol, 
NSAIDs, Sulfonamides or Hyperglycemia-causing agents ;<ĂƚǌƵŶŐ͕ϮϬϬϭͿ.  
A check list was used to record the above information for each participant (for further 
details of this check see annex XXX)  
ϰ͘ϲSampling 
ϰ͘ϲ͘ϭSelection of the volunteers: 
The selection process of the volunteers was aimed to minimize the variations between 
the individuals participated in this study. Age, weight, gender and health status of the 
participants all were taken into considerations. The recruitment of the subjects in this 
study was on voluntary basis and all the ethical considerations were taken into account. 
This process designed to avoid the selection bias of the subject as much as possible. 
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Volunteers received a welcoming package to orient them about the study (its objectives, 
methods, instructions for preparations, sample collection and other relevant 
information). Besides that, they received basic information sheet about them to fill (for 
more details see annex XXX). 
ϰ͘ϲ͘ϮMedicines selection criteria: 
The process of selecting medicines for this part of the study was based principally on the 
findings generated ĨƌŽŵƉĂƌƚϭĂŶĚƉĂƌƚϮŽĨŵĞĚŝĐŝŶĞƐƋƵĂůŝƚǇĂƐƐĞƐƐŵĞŶƚ͘ Selected 
product under testing represented the main trade product which health professionals in 
Khartoum were concerned about its quality in term of clinical outcomes. This was linked 
to the results obtained from the laboratory analysis regarding the chemical contents. The 
standard product was the originator’s product, as it has been normally associated with 
good therapeutic outcomes ;ďĂƐĞĚŽŶƚŚĞĨĞĞĚďĂĐŬĨŽƌŵƉĂƌƚϭŽĨƚŚĞƐƚƵĚǇͿ. 
ϰ͘ϲ͘ϯStudy site: 
The study was taken place in University of Khartoum Hospital after getting the permission 
from the hospital administration. The hospital staffs were very cooperative and support 
the provision of quality care for the participants and the collection and storage of the 
samples. 
ϰ͘ϳOther considerations 
The factors that expected to affect the study were considered and monitored carefully 
during the study course. This includes environment, diet, fluids intake, physical conditions 
and blood sampling scheme during the day (day or night). Standardized information 
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sheet, annexXXX, was developed and distributed to all of the participants prior to the 
starting date. This aimed to ensure the consistency of all affecting factors to minimize the 
variations between subjects included and hence the results obtained.  
ϰ͘ϴ Ethical considerations 
· This study was conducted by independent professionals from the academic sector 
and was designed for scientific and academic purposes only. The investigators 
express no conflict of interest in selecting the products or suppliers under testing.  
· The principal investigator was committed prior to start the study for his 
responsibility to ensure the protection of the rights, safety and well-being of 
subjects involved in this study. This was planned to be attained, among other 
things, by reviewing, approving, and providing continuing review of this study 
protocol and the methods and material used in obtaining and documenting 
informed consent of the study subjects. The ethical approval has been obtained 
from the National Board for Ethical Review of Health Research. In addition to that, 
the study team included certified medical doctor in order to monitor the subjects 
closely during their admission in the hospital. 
· All study subjects after receiving the information sheet and upon agreement to 
taken part of the study; were asked to sign a consent form before considering 
him/her as study subject. This was kept well with other confidential documents 
under this study. 
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ϰ͘ϵBlood sampling scheme 
The purpose of this proposed sampling scheme is to get representative samples of blood 
concentration from selected subjects based on known pharmacokinetic properties of 
Glibenclamide. This includes mainly the half-life that play critical role in determining the 
elimination profile of Glibenclamide. Accordingly its dose response curve in addition to 
the elapsed time to reach the maximum concentration (absorption and elimination 
period) were the determinant factors for this sampling scheme (Meyer, Muller, Luus, & 
ĐŬĞƌƚ͕ϭϵϴϵͿ. 
The sampling period and schedule were determined to cover ϮϰŚŽƵƌƐĨŽůŽǁŝŶŐĚƌƵŐ
ĂĚŵŝŶŝƐƚƌĂƟŽŶ͘ůŽŽĚƐĂŵƉůĞƐ;ϭϯ samples) were ĐŽůĞĐƚĞĚĂƚϬ͘Ϯϱ͕Ϭ͘ϱϬ͕Ϭ͘ϳϱ͕ϭ͘Ϭ͕ϭ͘ϱ͕
Ϯ͘Ϭ͕Ϯ͘ϱ͕ϯ͕ϯ͘ϱ͕ϰ͕ϰ͘ϱ͕ ϲĂŶĚϮϰŚŽƵƌƐĂŌĞƌĂĚŵŝŶŝƐƚƌĂƟŽŶŽĨƚŚĞĚŽƐĞ͘ 
hƐŝŶŐϱŵůƐǇƌŝŶŐĞƐ͕ƚŚĞƐĂŵƉůĞƐǁĞƌĞƚƌĂŶƐĨĞƌƌĞĚƚŽŚĞƉĂƌŝŶŝƐed tubes after labeling. 
Each sample ǁĂƐƚŚĞŶĐĞŶƚƌŝĨƵŐĞĚĨŽƌϱŵŝŶƵƚĞƐƵƐŝŶŐƌĞŐƵůĂƌĐĞŶƚƌŝĨƵŐĞĂƚϯϬϬϬƌƉŵ͘
Ğ^ƌƵŵǁĂƐƐĞƉĂƌĂƚĞĚĨƌŽŵƚŚĞƌĞƐŝĚƵĂůƉĂƌƚĂŶĚƚŚĞŶƚƌĂŶƐĨĞƌƌĞĚŝŶƚŽϯŵůƉůĂŝŶ
containers. The samples were re-labeled using the final codes, carefully transported and 
frozen up to the time of analysis based on the proposed schedule. 
Parallel with the collection of blood sample, sample collectors used small amount of 
blood ;Ϭ͘ϭŵůͿto measure the glucose level in the sample using Accu-chek® Glucometer. 
This provided additional useful data for the comparisons between the two products. 
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ϰ͘ϭϬSamples preparation and analysis 
In order to analyze the collected samples, basic HPLC techniques were used to measure 
targeted parameters. The analysis was done in collaboration with the Central Laboratory 
in Faculty of Science – University of Khartoum.  
ϰ͘ϭϬ͘ϭŚƌŽŵĂƚŽŐƌĂƉŚŝĐĐŽŶĚŝƟŽŶƐ͗ 
The method adopted for this process was developed by SD Rajendran and others with 
some minor modifications as needed (RajendraŶΘŽƚŚĞƌƐ͕ϮϬϬϱͿ. The HPLC system 
consisted of a Shimadzu LC-ϭϬdůŝƋƵŝĚĐŚƌŽŵĂƚŽŐƌĂƉŚŝĐƉƵŵƉ͕^/>-ϭϬĂŵĂŶƵĂůŝŶũĞĐƚŽƌ
and SPD-ϭϬhsͬsŝƐhsĂďƐŽƌďĂŶĐĞĚĞƚĞĐƚŽƌ;^ŚŝŵĂĚǌƵ͕<ǇŽƚŽ͕:ĂƉĂŶͿ͘ĂƚĂĐŽůĞĐƟŽŶ͕
integration and calibration were accomplished using Class VP Chromatography Data 
Ǉ^ƐƚĞŵsĞƌƐŝŽŶϲ͘ϭϰĐŽŵƉƵƚĞƌƐŽŌǁĂƌĞ;^ŚŝŵĂĚǌƵ͕<ǇŽƚŽ͕:ĂƉĂŶͿ͘dŚĞĐŚƌŽŵĂƚŽŐƌĂƉŚŝĐ
separations of Glibenclamide and internal standard (glimepride) were accomplished using 
ĂϭϱϬŵŵпϰ͘ϲŵŵ/^Śŝŵ-Pack VP-ODS analytical column (SHIMADZU). A Guard-Pak 
precolumn module (Phenomenex, USA) containing an ODS cartridge insert was placed 
ƐĞƌŝĂůǇũƵƐƚďĞĨŽƌĞƚŚĞĂŶĂůǇƟĐĂůĐŽůƵŵŶ͘dŚĞŵŽďŝůĞƉŚĂƐĞĐŽŶƐŝƐƚĞĚŽĨĂĐĞƚŽŶŝƚƌŝůĞ͗Ϯϱ
ŵDƉŚŽƐƉŚĂƚĞďƵīĞƌ;Ɖ,͗ϯ͘ϱͿŝŶĂĐŽŵďŝŶĂƟŽŶŽĨϴϬ͗ϮϬǀͬǀ͘ Before use the mobile 
ƉŚĂƐĞǁĂƐĚĞŐĂƐƐĞĚďǇƉĂƐƐŝŶŐŝƚƚŚƌŽƵŐŚĂϬ͘ϮϮʅŵĮůƚĞƌ͘ The mobile phase was pumped 
ĂƚĂŶŝƐŽĐƌĂƟĐŇŽǁƌĂƚĞŽĨϭŵůͬŵŝŶĂƚƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞ͘dŚĞhsĚĞƚĞĐƟŽŶǁĂǀĞůĞŶŐƚŚ
ǁĂƐƐĞƚĂƚϮϱϯŶŵ͘dŚĞǁĂǀĞ-ůĞŶŐƚŚŽĨϮϯϲŶŵƌĞƉƌĞƐĞŶƚĞĚƚhe UV maximum of 
'ůŝďĞŶĐůĂŵŝĚĞŝŶĂĐĞƚŽŶŝƚƌŝůĞ͗ǁĂƚĞƌŝŶϭ͗ϭƌĂƟŽ͘ 
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ϰ͘ϭϬ͘ϮAssay procedure: 
ƐƚŽĐŬƐŽůƵƟŽŶƌĞƉƌĞƐĞŶƟŶŐϭϬϬђŐͬŵůŽĨ'ůŝďĞŶĐůĂŵŝĚĞǁĂƐƉƌĞƉĂƌĞĚŝŶĂĐĞƚŽŶŝƚƌŝůĞ͗
ǁĂƚĞƌŝŶϭ͗ϭƌĂƟŽ͘dŚĞƐĞƐŽůƵƟŽŶƐǁĞƌĞƐƚŽƌĞĚĂƚ-ϮϬŽƵŶƟůƵƐĞ͘dŚĞǁŽƌking standard 
solutions were prepared prior to use from the stock solution by sequential dilution with a 
ĐŽŵďŝŶĂƟŽŶŽĨĂĐĞƚŽŶŝƚƌŝůĞ͗ǁĂƚĞƌŝŶϵϬ͗ϭϬƌĂƟŽƚŽǇŝĞůĚĮŶĂůĐŽŶĐĞŶƚƌĂƟŽŶƐŽĨϱϬ͕ϭϬϬ͕
ϮϬϬ͕ϰϬϬ͕ĂŶĚϱϬϬŶŐͬŵůŽĨ'ůŝďĞŶĐůĂŵŝĚĞ͘dŚĞŝŶƚĞƌŶĂůƐƚĂŶdard stock solution was 
ƉƌĞƉĂƌĞĚďǇĚŝƐƐŽůǀŝŶŐϭŵŐŽĨŐůŝŵĞƉƌŝĚĞŝŶϭϬϬŵůŽĨĂĐĞƚŽŶŝƚƌŝůĞ͗ǁĂƚĞƌŝŶϭ͗ϭƌĂƟŽ͘dŚŝƐ
solution was stored at -ϮϬŽƵŶƟůƵƐĞ͘/ŶĂϮŵůŵŝĐƌŽĐĞŶƚƌŝĨƵŐĞƚƵďĞ͕ϱϬϬʅůŽĨƐĞƌƵŵǁĂƐ
ĂĚĚĞĚĂůŽŶŐǁŝƚŚϱϬϬʅůŽĨŝŶƚĞƌŶĂůƐƚĂŶĚĂƌĚƐolution. The serum was precipitated by the 
ĂĚĚŝƟŽŶŽĨϱϬϬʅůŽĨŵĞƚŚĂŶŽů͕ĂŶĚƚŚĞŶƚŚĞƚƵďĞƐǁĞƌĞǀŽƌƚĞǆĞĚĨŽƌϯϬƐĂŶĚ
ĐĞŶƚƌŝĨƵŐĞĚĂƚϱϬϬϬŐĨŽƌϴŵŝŶ͘dŚĞƐƵƉĞƌŶĂƚĂŶƚǁĂƐƚƌĂŶƐĨĞƌƌĞĚƚŽĂĐůĞĂŶ͕ƐŝŵŝůĂƌůǇ
labeled tube and was subsequently re-centrifuged ĨŽƌϮŵŝŶ͘dŚĞƌĞƐƵůƚĞĚƐŽůƵƟŽŶǁĂƐ
injected in to the HPLC.  
ϰ͘ϭϬ͘ϯAssay parameters: 
The extraction efficiency was determined by comparing the peak area of known amounts 
Glibenclamide (unextracted) in mobile phase directly injected to peak area of samples 
containing the same amounts of Glibenclamide in plasma after extraction. Quantification 
was based on calibration curves constructed using peak area ratios of drug to internal 
standard vs. nominal concentration. The procedure was repeated on three separate days 
to allow determination of inter-day precision and accuracy. Intra-day accuracy was 
estimated based on the mean percentage error, and the inter-day accuracy was 
calculated as the mean of the intra-day accuracy determinations. The precision, 
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expressed as a percentage, was evaluated by calculating the intra- and inter-day relative 
standard deviations. The standard drug solutions in varying concentrations ranging from 
ϱϬŶŐͬŵůƚŽϱϬϬŶŐͬŵůǁĞƌĞĞǆĂŵŝŶĞĚďǇƚŚĞĂƐƐĂǇƉƌŽĐĞĚƵƌĞ͘dŚĞƉĞĂŬĂƌĞĂǁĂƐ
calculated. The calibration curve was plotted using peak area vs. concentration of the 
standard solutions.  
 
ϰ͘ϭϭData Management and Analysis Plan 
The data analysis process was done using mixed analysis methods according to the type 
of data and the tool of data collection, but in general it was done using the following: 
· Manual analysis; 
· Computer programs e.g. SPSS and MS Excel 
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Microbiological sensitivity test of Amoxicillin 
 
Materials: Sterile throat swabs, Microscope slides, Bunsen burner, Inoculating loop, Blood 
agar,  
ϲ͘ϭStudy rationale 
This study was designed to provide necessary information to evaluate the outcomes of 
Amoxicillin available in the market to inform the decision-making about the registration 
of this drug. This was especially planned to provide evidence to inform a comprehensive 
policy directions to review Amoxicillin registration, uses and monitoring in the country. 
The focus of this study is to investigate factors affecting the quality of clinical outcomes of 
Amoxicillin in Khartoum using antimicrobial sensitivity approach. 
ϲ͘ϮSpecific objectives 
To investigate the incidence of microbial resistance for Amoxicillin using the 
microbiological assay experiment on throat clinical isolates. 
ϲ͘ϯStudy design 
Study area: Khartoum city was divided into four geographical areas and the samples 
divided between these areas. 
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Study population: Targeted populations were selected and included based on the 
following criteria: 
· Only patients living in Khartoum locality were considered in this study; 
· Patients approaching the private pharmacies in the study area were the only 
targeted study population; and  
· Patients complaining from symptoms of upper respiratory tract infection asking 
for treatment with or without a prescription. 
Patients with the following criteria were excluded: 
· Recent administration of sub-optimal dose of antibiotics or incomplete treatment 
ĚƵƌĂƟŽŶǁŝƚŚŝŶϮǁĞĞŬƐ͖ 
· ZĞĐĞŶƚƵƐĞŽĨĂŶƟŵŝĐƌŽďŝĂůƚƌĞĂƚŵĞŶƚĚƵƌŝŶŐƚŚĞůĂƐƚϯŵŽŶƚŚƐ;ĞƐƉĞĐŝĂůǇ
cephalosporin derivatives); 
· hŶĚĞƌϭϰǇĞĂƌƐĂŶĚŽǀĞƌ ϲϬǇĞĂƌƐŽĨĂŐĞ͖ 
· Underlying diabetes; 
· History of recent hospitalization 
ϲ͘ϰSample size 
The purpose of sampling, in this part of the study, was to get rapid description of the 
current situation regarding the incidence of resistance to Amoxicillin among targeted 
population. In Sudan there is no drug utilization review completed recently to show any 
data about the quantitative use of medicines in the country (uses, quantities, sources 
...ect). Accordingly, for this study the sample size was determined using a technique of 
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ƚŽƚĂůĐŽǀĞƌĂŐĞŽĨĞůŝŐŝďůĞƉĂƟĞŶƚƐĚƵƌŝŶŐϭϬǁŽƌŬŝŶŐĚĂǇƐ͘ Accordingly ϭϬϮ samples were 
collected from the study sites. 
ϲ͘ϱSampling technique 
Samples were obtained from patients approaching the retail pharmacies in Khartoum 
city.  Pharmacists working in the selected pharmacies were asked to collaborate with the 
study team to identify the patients receiving Amoxicillin product (based on the inclusion 
criteria as above). The pharmacists were trained on collecting the samples. Patients 
selected as part of the study received verbal information about the study and its purpose. 
They were informed about the reasons behind the request for biological samples from 
their throat using a piece of swab. Upon acquiring the verbal consent from the patients, 
disposable swaps were used to collect the throat sample from the patients and then 
ŝŶĐƵůĐĂƚĞĚŝŶƚŽϭϱ-ϮϬŵůŽĨĂƌǇ-Blair transport media. The samples stored at room 
temperature at the collection site and then it was transported on daily basis to the 
Central Laboratory in Faculty of Pharmacy or Faculty Science – University of Khartoum. 
ϲ͘ϲPreparation of blood agar media 
The method adopted for this process was developed by Bendict L. and others with some 
minor modifications as needed. Blood was drawn from sheep’s neck area which was 
shaved and swabbed with iodine ;ĞŶĞĚŝĐƚΘŽƚŚĞƌƐ͕ϭϵϳϰͿ. A venipuncture was 
ƉĞƌĨŽƌŵĞĚŝŶƚŚĞũƵŐƵůĂƌǀĞŝŶƵƐŝŶŐĂϯϲ-inch blood collection set. The blood was 
ĐŽůĞĐƚĞĚŝŶĂĞĐƚŽŶŝĐŬŝŶƐŽŶsĂĐƵƚĂŝŶĞƌďŽƩůĞĐŽŶƚĂŝŶŝŶŐϭŵůŽĨϱй^W^;/ŵĂĚĂ͕/ŶĚŝĂͿ
ĨŽƌĞĂĐŚϭϬϬ ml of blood to be drawn. The bottle was inverted occasionally to facilitate 
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mixing. The blood was stored ĂƚϰƉƌŝŽƌƚŽƵƐĞ͘^ƚĞƌŝůŝƚǇƚĞƐƟŶŐǁĂƐƉĞƌĨŽƌŵĞĚďǇ 
ŝŶŽĐƵůĂƟŶŐϱŵůŽĨďůŽŽĚŝŶƚŽƚǁŽĞǀĂĐƵĂƚĞĚďŽƩůĞƐ͘dŚĞďŽttles were then incubated at 
ϯϳĨŽƌ Ϯ days and checked daily for visible evidence of microbial growth, prior to use. 
ϭϱ-ml sample of blood was used in performing a hematocrit and for sterility testing as 
described previously. The blood was aseptically added to the cooled agar to give a final 
ĐŽŶĐĞŶƚƌĂƟŽŶŽĨϱй͘ƉƉƌŽǆŝŵĂƚĞůǇϭϴŵůŽĨ ďůŽŽĚĂŐĂƌǁĂƐĚŝƐƉĞŶƐĞĚŝŶƚŽƐƚĞƌŝůĞϭϬϬ-
mm Petri dishes and allowed to harden. All prepared plates ǁĞƌĞƐƚŽƌĞĚĂƚϰ͘ 
ϲ͘ϳPreparation of bacterial isolates for sensitivity tests 
Subcultures of collected Cary-Blair transport media was prepared by inoculating a sterile 
loop ͘ĂĐŚŝƐŽůĂƚĞǁĂƐŝŶŽĐƵůĂƚĞĚŝŶƚŽϮŵůŽĨ Trypticase soy broth (BBL), and the turbidity 
was adjusted to the barium sulphate standard used in the Kirby-Bauer method of 
antibiotic susceptibility testing. A loopful from this broth was streaked onto the blood 
agar plate for all samples. All plates were incubated at ϯϳ͘ZĞĂĚŝŶŐƐĂŶĚŵŽŶŝƚŽƌŝŶŐŽĨ
the growth was done in a continuous process. 
ϲ͘ϴData Management and Analysis Plan 
The data analysis process was done using mixed analysis methods according to the type 
of data and the tool of data collection, but in general it was done using the following: 
· Manual analysis; 
· Computer programs e.g. SPSS and MS Excel 
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ϲ͘ϵEthical Considerations 
· This study was conducted by independent professionals from the academic sector 
and was designed for scientific and academic purposes only. The investigators 
express no conflict of interest doing this research. 
· The principal investigator was committed prior to start the study for his 
responsibility to ensure the protection of the rights, safety and well-being of 
subjects involved in this study. This was planned to be attained, among other 
things, by reviewing, approving, and providing continuing review of this study 
protocol and the methods and material used in obtaining and documenting 
informed consent of the study subjects. The ethical approval has been obtained 
from the National Board for Ethical Review of Health Research.  
· All study subjects after receiving the information verbally and upon agreement to 
taken part of the study; were asked to sign a consent form before considering 
him/her as study subject. This was kept well with other confidential documents 
under this study. 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  Page͹ͻ 
B͵ͳ 
 
Materials: Ceftriaxone powder for solution, nutrient agar, nutrient broth, standardized 
suspensions of; Escherichia coli, Staphylococcus aureus and Klebsiella pneumoniae, 
normal saline, cork-ďŽƌĞƌ;ŶŽ͘ϳͿ͕ƉŝƉĞƩĞĂŶĚĚŝƐƟůĞĚŶŽŶŝŽŶŝǌĞĚǁĂƚĞƌ͘ 
The experiment was conducted in Faculty of Science – University of Khartoum. 
ϱ͘ϭProcedure for microbial methods 
Solutions of different concentrations from the powdered form of three products were 
subjected to antimicrobial activity tests. The organisms used were of American Type 
Culture Collection (ATCC). They were obtained from stock culture of National Sanitary 
Laboratory and maintained on slang agar in a refrigerator. The organisms subject for the 
tests were; Streptococcus pneumoniae dϮϱϵϮϮ;S.p), Staphylococcus aureus 
dϮϱϵϮϯ;^͘ĂͿĂŶĚ<ůĞďƐŝĞůĂƉŶĞƵŵŽŶŝĂĞdϯϱϲϱϳ;<͘ƉͿ͘ 
ϱ͘ϮPreparation of culture media 
The media used for antibacterial screening tests were nutrient agar and nutrient broth. 
Twenty six grams of nutrient agar (from Scharlau Chemie, Spain) were suspended in one 
liter of distilled water and heated on a boiling water bath to dissolve the media 
ĐŽŵƉůĞƚĞůǇĂŶĚƚŚĞŶĚŝǀŝĚĞĚŝŶƚŽϮϬŵůƉŽƌƟŽŶƐŝŶƐŵĂůǀŝĂůƐ͘dŚŝƌƚĞĞŶŐƌĂŵƐŽĨnutrient 
broth (from Fine-Chem. LTD. India) were dissolved in one liter distilled water, heated on a 
ǁĂƚĞƌďĂƚŚƚŽĚŝƐƐŽůǀĞƚŚĞŵĞĚŝĂĂŶĚĚŝǀŝĚĞĚŝŶƚŽϭϬŵůƉŽƌƟŽŶƐŝŶƐŵĂůǀŝĂůƐ͘dŚĞ
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prepared nutrient agar and nutrient broth media were sterilized by autŽĐůĂǀŝŶŐĂƚϭϮϭ
ĚĞŐƌĞĞ;ĂƚĂƚŵŽƐƉŚĞƌŝĐŽĨϭϱƉŽƵŶĚƐͿĨŽƌϭϱŵŝŶƵƚĞƐ͘ 
ϱ͘ϯPreparation of standard bacterial suspensions 
ĂĐŚϭϬŵůƉŽƌƟŽŶƐŽĨƐƚĞƌŝůŝǌĞĚŶƵƚƌŝĞŶƚďƌŽƚŚǁĞƌĞŝŶĐƵůĐĂƚĞĚǁŝƚŚůŽŽƉĨƵůŽĨĞĂĐŚ
bacterial slant agar culture and were incubated for ϭϴ-ϮϰŚŽƵƌƐĂƚƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞ͘
ϭϬйĚŝůƵƟŽŶĨƌŽŵĞĂĐŚůŝƋƵŝĚĐƵůƚƵƌĞǁĂƐƉƌĞƉĂƌĞĚŝŶƐƚĞƌŝůŝǌĞĚŶŽƌŵĂůƐĂůŝŶĞĂŶĚŬĞƉƚŝŶ
a refrigerator. 
ϱ͘ϰPreparation of serial dilutions of extracts 
Ğ^ƌŝĂůĚŝůƵƟŽŶƐŚĂǀŝŶŐƚŚĞĐŽƌƌĞƐƉŽŶĚŝŶŐĐŽŶĐĞŶƚƌĂƟŽŶƐĨŽƌƚŚĞϭ͕ ϰĂŶĚϴĨŽůĚƐŽĨ
Minimum Inhibitory Concentration (MIC) of Ceftriaxone against the bacteria under 
testing. In the table below the MIC for different bacteria was shown, this was used for the 
serial dilution purposes ;WĂůŵĞƌΘŽƚŚĞƌƐ͕ϭϵϵϱͿ. 
Organism MICϵϬmg/ml 
Streptococcus pneumoniae Ϭ͘ϬϲϬ 
Klebsiella pneumoniae Ϭ͘ϭϮϱ 
Staphylococcus aureus ϰ͘ϬϬϬ 
  
Table ϯ: Corresponding MIC for targeted microorganisms 
 
The equivalent amount of powder from different products was dissolved in distilled water 
to obtain the required dilutions. 
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ϱ͘ϱAntibacterial assay 
The cup-plate agar diffusion method adopted in this study was that of Murray and others 
with some minor modifications to assess the antibacterial activity of the products [ZĞĨϯϭ]. 
From ĞĂĐŚŽĨƚŚĞƐƚĂŶĚĂƌĚƐƚŽĐŬƐƵƐƉĞŶƐŝŽŶϬ͘ϭŵůǁĂƐƚŚŽƌŽƵŐŚůǇŵŝǆĞĚǁŝƚŚϮϬŵůŽĨ
sterile Petri dishes and left to solidify on a plain surface. Then, four cup-ƐŚĂƉĞǁĞůƐ;ϭϬ
mm diameter/each) were made in each plate using sterile cork-borer (no.ϳͿ͘dŚĞĂŐĂƌ 
ĚŝƐĐƐǁĞƌĞƌĞŵŽǀĞĚĂŶĚƚŚĞĂůƚĞƌŶĂƚĞĐƵƉƐǁĞƌĞĮůĞĚǁŝƚŚϬ͘ϬϴŵůƐĂŵƉůĞŽĨĞĂĐŚ
concentration from the solution of one product at time. The forth alternate cup was filled 
with the solvent used (water) for control purposes using sterile adjusted pipette. The 
ƉůĂƚĞƐǁĞƌĞƚŚĞŶŝŶĐƵďĂƚĞĚŝŶƚŚĞƵƉƌŝŐŚƚƉŽƐŝƟŽŶĨŽƌϭϴ-ϮϰŚŽƵƌƐĂƚƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞ͘
Three replicates were carried out for each solution against each tested organisms. After 
incubation periods, the inhibition zones diameters were measure and the mean value 
were tabulated. 
ϱ͘ϲData Management and Analysis Plan 
The data analysis process was done using mixed analysis methods according to the type 
of data and the tool of data collection, but in general it was done using the following: 
· Manual analysis; 
· Computer programs e.g. SPSS and MS Excel 
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Qualitative evaluation of reconstitution practices of Ceftriaxone powder for 
ʹͲͳͲ 
 
Materials: PowerPoint presentation, checklist 
ϲ͘ϭStudy rationale 
Some of available literature related to Ceftriaxone effectiveness considered the 
reconstitution practices as essential factor that could play determinant effect on its 
quality. Ceftriaxone has the tendency to formulate precipitation product if mixed with 
any solutions containing salts of Calcium or Magnesium or any other trivalent cations 
;DƵƌŶĞǇ͕ϮϬϬϴͿ, ;,ĂǇǁĂƌĚΘŽƚŚĞƌƐ͕ϭϵϵϲͿ. Accordingly the reconstitution practices of 
Ceftriaxone powder for injection in Khartoum hospitals need to be evaluated to figure out 
whether or not it could contribute to poor quality and outcomes of Ceftriaxone injections. 
ϲ͘ϮSpecific objectives 
To evaluate the reconstitution practices of Ceftriaxone powder for injection by nurses in 
<ŚĂƌƚŽƵŵŚŽƐƉŝƚĂůƐŝŶϮϬϭϬ͘ 
ϲ͘ϯStudy design 
The study was designed as cross sectional study using qualitative approaches. 
Study area: The study focus on Khartoum locality and hospitals for this locality were 
included in this evaluation. 
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Study population: 
Selection of hospitals: As the study include qualitative component, only one hospital was 
included in this study. In this case Khartoum Teaching Hospital was selected because it is 
the largest hospital in the city. 
ϲ͘ϰSample size 
ĂƐĞĚŽŶƚŚĞĐƌŝƚĞƌŝĂĂďŽǀĞϮϮŶƵƌƐĞƐĨƌŽŵďŽƚŚƐĞǆĞƐĂƩĞŶĚĞĚƚŚĞŐƌŽƵƉĚŝƐĐƵƐƐŝŽŶ͘ 
ϲ͘ϱSampling technique 
Selection of nurses: 
The selection of nurses was random; the announcement for the group discussion was 
sent to Matron in each hospital ward. The Matron was asked to pick the first two nurses 
complied with the criteria below and presented their interest to join the group. Targeted 
nurses were selected and included based on the following criteria: 
· All nurses worked as fulltime in Khartoum Teaching Hospital; 
· The nurse should have at least two years working experience in the field; 
· One of the nurses from each ward should work for at least one year in the private 
sector;  
· Both female and male nurses could be selected; 
ϲ͘ϴData management 
The data analysis process was done using manual analysis techniques for qualitative data. 
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͵: Results 
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Health professionals’ survey 
 
For all of the following results, and in the processing of statistical analysis, the results were 
ĐŽŶƐŝĚĞƌĞĚƐƚĂƟƐƟĐĂůǇƐŝŐŶŝĮĐĂŶƚĨŽƌĂWǀĂůƵĞŽĨůĞƐƐƚŚĂŶϬ͘Ϭϱ͘dŚĞϵϬ% confidence 
intervals of all parameters under testing were also estimated. 
ϭ. Sample size 
 Retail pharmacies Doctors Clinics 
Total Number in the area ϯϮϴ ϰϮϬ 
Sample Size ϴϮ ϵϱ 
 
Ϯ. Classifications - pharmacies: 
Ø  Response: 
ThĞƌĞƐƉŽŶƐĞƌĂƚĞĂŵŽŶŐƉŚĂƌŵĂĐŝƐƚƐŝƐƌĞůĂƟǀĞůǇŚŝŐŚĞƌƚŚĂŶĚŽĐƚŽƌƐ͘ϭϬϬйŽf the targeted 
ƉŚĂƌŵĂĐŝƐƚƐƌĞƐƉŽŶĚĞĚƚŽƚŚĞƋƵĞƐƟŽŶŶĂŝƌĞǁŚŝůĞϳϴйŽĨƚŚĞĚŽĐƚŽƌƐĂŐƌĞĞĚƚŽƌĞƐƉŽŶĚŝŶ
the questionnaires sent to them. 
 
Ø  Area in Khartoum: 
Area Pharmacies 
й;ŶсϴϮͿ 
Doctors 
й;ŶсϵϱͿ 
Centre – hospital street ϭϬ͘ϭ ϰϳ͘ϯ 
Centre - other ϭϳ͘ϳ ϴ͘ϴ 
East ϭϳ͘ϳ ϴ͘ϴ 
South ϰϱ͘ϲ Ϯϱ͘ϯ 
Peripherals ϴ͘ϵ ϵ͘ϵ 
 
 
 
Ø  Information providers - pharmacies: 
/ŶƚŚĞƚĂƌŐĞƚĞĚƉŚĂƌŵĂĐŝĞƐ͕ƚŚĞƌĞƐƉŽŶĚĞŶƚƐǁŚŽŵǁĞƌĞƉŚĂƌŵĂĐŝƐƚƐƌĞƉƌĞƐĞŶƚĂďŽƵƚϵϮй
of the sample while other categories (including pharmacy assistants) represent the rest of the 
sample. 
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Ø  Pharmacy type: 
The distribution of the pharmacies was relatively equal between the pharmacies in 
ŚŽƵƐĞŚŽůĚĂƌĞĂƐ;ϱϬ͘ϲйͿĂŶĚƚŚĂƚůŽĐĂƚĞĚŶĞĂƌĐůŝŶŝĐƐĂŶĚŚŽƐƉŝƚĂůƐ;ϰϵ͘ϰйͿ͘ 
Ø  Experience of information providers - pharmacies: 
Experience й;ŶсϴϮͿ 
ϭǇĞĂƌ– ϮǇĞĂƌƐ ϯϭ͘ϲ 
ϯǇĞĂƌƐ– ϱǇĞĂƌƐ ϯϬ͘ϰ 
DŽƌĞƚŚĂŶϱǇĞĂƌ ϯϴ͘Ϭ 
 
Ø  Information providers - doctors: 
Category й;ŶсϵϱͿ 
Specialists ϱϲ͘Ϭ 
Registrars Ϯϱ͘ϯ 
General physicians ϭϴ͘ϳ 
 
Ø  Information providers specialty ;ŶсϵϱͿ: 
 
Figure ϭ: Distribution of doctors by specialties in the sample 
 
ϮϮ%
ϭϴ.ϳϬ%
ϭϲ.ϱϬ%
ϴ.ϴϬ%
ϳ.ϳϬ%
ϰ.ϰϬ% ϰ.ϰϬ% ϰ.ϰϬ%
ϯ.ϯϬ% ϯ.ϯϬ% Ϯ.ϰϬ% Ϯ.ϮϬ%
Ϭ%
ϱ%
ϭϬ%
ϭϱ%
ϮϬ%
Ϯϱ%
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 The existence of substandard medicines problem
 
ďŽƵƚϴϬйŽĨƉŚĂƌŵĂĐŝƐƚƐďĞůŝĞǀĞĚƚŚĞƌĞĂƌĞƐƵďƐƚĂŶĚĂƌĚŵĞĚŝĐŝŶĞƐĂǀĂŝůĂďůĞŝŶƚŚĞŵĂƌŬĞƚ
ǀĞƌƐƵƐϳϬйŽĨĚŽĐƚŽƌƐ͘WŚĂƌŵĂĐŝƐƚƐƵƐƵĂů
feedback from the patients about it unlike the doctors.
Response
Yes 
No 
No Comment
 
ϭ. Level of the problem 
Figure Ϯ
 
The great difference and variety in the results between pharmacists & doctors seems to be 
due to differences in definition of (
may play obvious effect on how each profession define that. This one of known observations 
about self versus non-self administrated questionnaires.
the meaning depends solely
Ϭ
ϭϬ
ϮϬ
ϯϬ
ϰϬ
ϱϬ
ϲϬ
ϳϬ
ϴϬ
Pharmacists
 
y deal directly with medicines and gets direct 
 
 % of pharmacists 
EсϴϮ 
% of doctors 
Eсϵϱ 
ϴϮ͘ϯ ϳϬ͘ϯ 
ϭϳ͘ϳ ϯ͘ϯ 
 Ϭ ϰ͘ϰ 
: Professionals’ evaluation - Level of the problem 
major/minor). The way the data 
 For doctors the determination of 
 on the perception of the information provider rather than the 
Doctors
 Page͹ͺ 
 
was actually collected 
Major
Minor
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 standard definition in the study. This justification is clear
of doctors who don’t respond to this question.
Effectiveness problems 
 
The aim of this part of the questionnaires is to assess, (
the problem of substandard medicines usually implies on ineffectiveness and/or therapeutic 
failure problems that facing the
on patients’ monitoring and
A. Patients complaints to 
ůWŚĂƌŵĂĐŝĞƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ
,ŽƵƐĞŚŽůĚƐƌĞĂŶсϰϮ
EĞĂƌůŝŶŝĐƐŽƌ,ŽƐƉŝƚĂůƐŶсϰϬ
 
Figure ϯ: Classification of complaints reported by pharma
 
Majority due to 
patients related 
 when we consider the proportion 
 
based on professionals’ opinion), if 
m. This may be direct observation from them 
/or patients’ complaints. 
pharmacist about ineffective medicines: 
Pharmacies type Yes No 
 ϵϳ͘ϱ Ϯ͘ϱ 
 ϭϬϬ Ϭ 
 ϵϰ͘ϵ ϱ͘ϭ 
cists
Majority due to 
medicine itself
ϯϮ%
objects
ϲϴ%
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and/or based 
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Pharmacies 
type 
Medicine 
itself 
Patients 
related 
No 
comment 
All pŚĂƌŵĂĐŝĞƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϯϭ͘ϲ ϲϱ͘ϴ Ϭ 
Households aƌĞĂŶсϰϮ ϯϮ͘ϱ ϲϳ͘ϱ Ϭ 
Near clinics or hŽƐƉŝƚĂůƐŶсϰϬ ϯϬ͘ϴ ϲϰ͘ϭ ϱ͘ϭ 
 
One of the pharmacists in the hospital street; who don’t receive any recent complaints from 
the patients; refer to the fact that: “patients usually take their medicines as the doctor 
prescribed it without any complaints, even if they complain at all they refer that most likely 
to pharmacies near their residency”. This in fact was supported by the results obtained from 
pharmacies located in household areas, as all of it without exception received complaints 
from the patients. 
On the other hand most oĨƉŚĂƌŵĂĐŝĞƐ͕ϲϲйŽĨƚŚĞƚŽƚĂů͕ refer the problems in these 
complaints to factors related to the patients rather than to factors related to medicines 
itself. The following summaries these mentioned factors: 
ϭ. Factors related to the administration method and its impact on effectiveness; 
Ϯ. Factors related to the selection of right medicine for specific case (rational 
prescribing or rational dispensing); 
ϯ. Factors related to subject-to-subject variability and different response for same 
drug. 
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B. Classifications of complaints: 
Complaints йŶсϳϵ 
Symptoms not relieved ϳϴ͘ϱ 
Alternative trade was not effective ϯϴ͘Ϭ 
Side effects ϯϱ͘ϰ 
Physical appearance ϴ͘ϵ 
Other ϮϬ͘ϯ 
 
The above table indicates the frequency of receiving each category of complaints from the 
ƉĂƟĞŶƚƐ͘&ŽƌĞǆĂŵƉůĞ͕ϯϴйŽĨƉŚĂƌŵĂĐŝĞƐƌĞĐĞŝǀĞĚĐŽŵƉůĂŝŶƚƐĨƌŽŵƚŚĞƉĂƟĞŶƚs about 
certain alternative trade they used instead of another trade they custom themselves to use 
ƌĞŐƵůĂƌůǇ͘KŶƚŚĞŽƚŚĞƌŚĂŶĚ͕ϯϱйŽĨƉŚĂƌŵĂĐŝĞƐƌĞĐĞŝǀĞĐŽŵƉůĂŝŶƚƐĂďŽƵƚƐŝĚĞĞīĞĐƚƐŽĨ
medicines. These results when combined with the other data and findings this will support 
of considering the feedback from the patients, of special interest the feedback received by 
pharmacies. They will be important source of information and one of the channels to detect 
substandard medicines.  
C. Therapeutic failures - doctors : 
The table below showed the response for the question about the regularity of receiving 
cases with treatment failure. 
Category Yes always Not always No 
All dŽĐƚŽƌƐ;ĐŽůĞĐƟǀĞͿŶсϵϱ ϭϰ͘ϯ ϲϬ͘ϰ ϯ͘ϯ 
Ɖ^ĞĐŝĂůŝƐƚƐŶсϱϯ ϭϱ͘ϳ ϲϬ͘ϴ Ϯ͘Ϭ 
ZĞŐŝƐƚƌĂƌƐŶсϮϰ ϭϳ͘ϰ ϱϲ͘ϱ ϰ͘ϯ 
General pŚǇƐŝĐŝĂŶƐŶсϭϴ ϱ͘ϵ ϲϰ͘ϳ ϱ͘ϵ 
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Unlike the pharmacists, ϰϱйŽĨƚŚĞ doctors believed that the quality of medicines itself is 
the major factor in cases in which there is therapeutic failure. This figure is critical as these 
doctors assume that they prescribe the right medicines for right cases and the 
administration of medicines was also perfect. If this is the case then the quality of medicines 
will be the determinant factor for such failure reports. 
 
Figure ϰ: Classification of therapeutic failure reports 
 
Category Subjects variability Drugs quality 
ůŽĐƚŽƌƐ;ĐŽůĞĐƟǀĞͿŶсϵϱ ϮϬ͘ϵ ϰϱ͘ϭ 
Ɖ^ĞĐŝĂůŝƐƚƐŶсϱϯ Ϯϭ͘ϲ ϰϭ͘Ϯ 
ZĞŐŝƐƚƌĂƌƐŶсϮϰ Ϯϭ͘ϳ ϱϮ͘Ϯ 
General pŚǇƐŝĐŝĂŶƐŶсϭϴ ϮϬ͘ϵ ϰϱ͘ϭ 
 
Looking to the trend in the above table, registrars were more extreme than other categories 
regarding the primary justification for cases with treatment failure. 
 
Majority due to 
subjects 
variability; ϮϬ.ϵ
Majority due to 
drugs quality; ϰϱ.ϭ
Both; ϭ.ϭ
No Comments; ϴ.ϴ
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Medicines which pharmacists and doctors complain about 
 
The following data represents the generics which health professionals complained about it 
(either in terms of its quality, efficacy problems or complaints from the patients). 
A. Pharmacists: 
 
Figure ϱ: Medicines with top complaints from pharmacists 
Other medicines: 
· Salbutamol, Nifedipine, Mefenamic Acid, Cephalexin, Multivitamins, Ampiclox, 
Omeprazole, Amox-clav and Clarithromycin 
Pharmacological groups: 
Groups йŶсϴϭ 
Anti-infectives ϰϰ͘ϯ 
Respiratory tract ϭϱ͘Ϯ 
NSAIDs ϳ͘ϲ 
Cardiovascular system ϱ͘ϭ 
Endocrine ϱ͘ϭ 
Anti-Malarial ϯ͘ϴ 
Gastrointestinal tract ϯ͘ϴ 
Blood preparations Ϯ͘ϱ 
Vitamins ϭ͘ϯ 
Other ϭ͘ϯ 
Ϭ
ϱ
ϭϬ
ϭϱ
ϮϬ
Ϯϱ
ϯϬ
ϯϱ
ϰϬ
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Origin йŶсϴϭ 
Sudan ϱϯ͘Ϯ 
India ϭϬ͘ϭ 
Some countries in Europe ϭϬ͘ϭ 
Other Asian countries ϲ͘ϯ 
Other Arab countries ϱ͘ϭ 
Jordan Ϯ͘ϱ 
Syria ϭ͘ϯ 
 
B. Doctors: 
 
Figure ϲϲ: Medicines with top complaints from doctors 
Other Medicines: 
Carbamazepine, Cefuroxime, Diclofenac Na, Omeprazole, Prednisolone and Salbutamol 
Pharmacological Groups йŶсϳϰ 
Anti-infectives Ϯϱ͘ϯ 
Cardiovascular system ϱ͘ϱ 
Endocrine ϱ͘ϱ 
Central Nervous system Ϯ͘Ϯ 
Anti-Malarial Ϯ͘Ϯ 
Gastrointestinal tract ϭ͘ϭ 
NSAIDs ϭ͘ϭ 
Other ϭ͘ 
 
Ϭ
Ϯ
ϰ
ϲ
ϴ
ϭϬ
ϭϮ
ϭϰ
ϭϲ
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Shifting practices patients from “Product A” to “Product B” 
This part of the results represents the major indicators that describe the practice and 
attitude of health professionals when they take decisions to shift their patients from one 
product to another and the criteria around their decision. The generics reported in shifting 
process generally similar to those mentioned by the pharmacists’ response including 
(Ciprofloxacin, Amoxicillin and other antibiotics). 
A. Pharmacists: 
Ø  Shifting attitudes: 
Pharmacologically йŶсϳϭ 
Shifting within the same generics ϱϰ͘ϰ 
Shifting not within the same generic but same group ϭϯ͘ϵ 
Shifting not within the same generic and not same group ϭϳ͘ϳ 
 
 
Figure ϳ: Pharmacists shifting attitude 
 
Ϭ ϱ ϭϬ ϭϱ ϮϬ Ϯϱ ϯϬ
High income to high income country
High income to local
High income to low income country
Low income country to local
Low income to high income country
Low income to low income country
Local to local
Local to high income country
Local to low income country 
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DŽƐƚŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚƐ;ϴϱйͿĞǆƉĞƌŝĞŶĐĞĚĂƚůĞĂƐƚŽŶĞƐŚŝŌŝŶŐĚĞĐŝƐŝŽŶĨŽƌŽŶĞƉĂƟĞŶƚ
from one product to another different product. DŽƐƚŽĨƚŚĞƐĞĚĞĐŝƐŝŽŶƐ;ϱϰйͿŚĂǀĞďĞĞŶ
taken to shift the treatment within the same generics using different trade product. In other 
aspect, most of the shŝŌŝŶŐĚĞĐŝƐŝŽŶƐ;ϰϲйͿŝŶĐůƵĚĞ substitution of locally produced products 
by other imported products. This is important findings as pharmacists stated different 
attitude about their trust in the local products in comparison to low income countries 
ƉƌŽĚƵĐƚƐ;ϰϲйprefer the local products over products manufactured in low income 
countries). Still in ϰϬйŽĨƚŚĞĚĞĐŝƐŝŽŶƐthe shifts occur among products that manufactured 
in low income countries. The issue of generics substitution is currently burning issue on the 
agenda of global pharmaceutical sector as it has very critical impact on the shape of the 
global markets ;DĞƌĞĚŝƚŚW͘͕ϮϬϬϯͿ. 
Ø  Generic names “Product A”: 
Generic Name йŶсϳϭ 
Amoxicillin Ϯϳ͘ϴ 
Ciprofloxacin ϭϮ͘ϳ 
Glibenclamide ϭϭ͘ϰ 
Diclofenac ϱ͘ϭ 
Amox-clav ϯ͘ϴ 
Erythromycin Ϯ͘ϱ 
Cephalexin Ϯ͘ϱ 
Omeprazole Ϯ͘ϱ 
Ibuprofen ϭ͘ϯ 
Other medicines ϭϳ͘ϴ 
Other medicines: 
· Amilodipine, Aspirin, Atenolol, Hydrocortisone, Mefenamic Acid, Ranitidine, 
Tetracycline, Lisinopril, Prednisolone and Laxative 
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Ø  Generic names “Product B”: 
Generic Name йŶсϳϭ 
Ciprofloxacin ϭϱ͘Ϯ 
Glibenclamide ϭϭ͘ϰ 
Amox-clav ϴ͘ϵ 
Azithromycin ϴ͘ϵ 
Erythromycin ϳ͘ϲ 
Amoxicillin ϱ͘ϭ 
Diclofenac Na ϯ͘ϴ 
Omeprazole Ϯ͘ϱ 
Other medicines: 
· Ampiclox, Ibuprofen, Amilodipine, Aspirin, Atenolol, Anti Flu, Ranitidine, Lisinopril 
and Laxative 
 
Ø  Origins of “Product A”: 
Origin йŶсϳϭ 
Sudan ϱϵ͘ϱ 
India ϭϮ͘ϳ 
Other Arab countries ϯ͘ϴ 
Europe ϯ͘ϴ 
Jordan Ϯ͘ϱ 
Egypt ϭ͘ϯ 
Other Asian countries ϭ͘ϯ 
Syria ϭ͘ϯ 
 
Ø  Origins of “Product B”: 
Origin йŶсϳϭ 
Europe Ϯϳ͘ϴ 
Jordan ϮϮ͘ϴ 
Sudan ϮϬ͘ϯ 
Egypt ϯ͘ϴ 
India ϯ͘ϴ 
Other Arab countries ϯ͘ϴ 
Other Asian countries Ϯ͘ϱ 
Syria ϭ͘ϯ 
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B. Doctors: 
Ø  Shifting attitudes: 
Pharmacologically % Ŷсϯϲ 
Shifting within the same generics ϴϱ͘ϳ 
Shifting not within the same generic but same group ϵ͘ϱ 
Shifting not within the same generic and not same group ϰ͘ϴ 
 
 
Figure ϴ: Doctors shifting attitude 
 
Unlike the feedback obtaineĚĨƌŽŵƚŚĞƉŚĂƌŵĂĐŝƐƚƐ͕ϴϲйŽĨĚŽĐƚŽƌƐƚŽŽŬĚĞĐŝƐŝŽŶƐƚŽƐŚŝŌ
their patients from one product to another product but within the same generic. It is also 
ĐůĞĂƌƚŚĂƚϴϰйŽĨƚŚĞĚĞĐŝƐŝŽŶƐƚĂŬĞŶďǇƚŚĞĚŽĐƚŽƌƐto direct their patients from products 
manufactured in low income countries to other manufactured in high income countries. 
 
 
Ϭ ϱ ϭϬ ϭϱ ϮϬ Ϯϱ ϯϬ ϯϱ ϰϬ ϰϱ ϱϬ
Local to local
Local to low income country 
Low income country to local
High income to local
High income to low income country
High income to high income country
Local to high income country
Low income to low income country
Low income to high income country
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Ø  Generic names “Product A”: 
Generic name йŶсϯϲ 
Ceftriaxone ϱ͘ϱ 
Ciprofloxacin ϯ͘ϯ 
Amox-clav Ϯ͘Ϯ 
Azithromycin Ϯ͘Ϯ 
Other Antibiotics ϯ͘ϯ 
Other medicines ϯ͘ϯ 
No comments ϭϵ͘ϴ 
Not applicable ϳϱ͘ϭ 
 
Ø  Generic names “Product B”: 
Generic Name йŶсϯϲ 
Ceftriaxone ϲ͘ϲ 
Amox-clav ϯ͘ϯ 
Ciprofloxacin Ϯ͘Ϯ 
Other Antibiotics Ϯ͘Ϯ 
Other medicines Ϯ͘Ϯ 
No comments Ϯϰ͘Ϯ 
Not applicable ϱϯ͘ϴ 
 
Ø  Origins of “Product A”: 
Origin йŶсϯϲ 
India ϳ͘ϳ 
Sudan ϱ͘ϱ 
Other Arab countries ϯ͘ϯ 
Other Asian countries Ϯ͘Ϯ 
Syria ϭ͘ϭ 
No comments ϭϵ͘ϴ 
Not applicable ϱϳ͘ϯ 
 
Ø  Origins of “Product B”: 
Origin йŶсϯϲ 
Europe ϭϯ͘Ϯ 
Other Arab countries ϲ͘ϲ 
India ϭ͘ϭ 
No comments ϭϵ͘ϴ 
Not applicable ϱϵ͘ϯ 
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Trust of the professionals in local products as alternatives 
 
This component of the questionnaire addressing the concerns usually rose about the quality 
of locally manufactured products, especially when compared with the imported products. In 
few questions the information providers were asked to evaluate their trust and opinion 
regarding the local production and whether or not they will use it as alternative if it is 
available in the market. The results showed that ϴϬйŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚƐƚƌƵƐƚƚŚĞůŽĐĂů
products versus ŽŶůǇϱϱйŽĨƚŚĞƐƵƌǀĞǇĞĚĚŽĐƚŽƌƐtrust the local products and they used as 
alternative. 
In more depth analysis, it seems that the degree of trust is related to the experience of 
information provider. Experienced professionals trust the local production more than the 
younger professionals (whether pharmacists or doctors). 
A. Pharmacists: 
Category Yes No 
ůƉŚĂƌŵĂĐŝƐƚƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϳϵ͘ϳ ϭϲ͘ϱ 
ϭǇĞĂƌ– ϮǇĞĂƌƐ;ŶсϮϲͿ ϳϮ͘Ϭ Ϯϰ͘Ϭ 
ϯǇĞĂƌƐ– ϱǇĞĂƌƐ;ŶсϮϱͿ ϳϵ͘Ϯ ϭϲ͘ϳ 
DŽƌĞƚŚĂŶϱǇĞĂƌƐ;ŶсϯϭͿ ϴϲ͘ϳ ϭϬ͘Ϭ 
 
B. Doctors: 
Category Yes  No No comments 
ůŽĐƚŽƌƐ;ĐŽůĞĐƟǀĞͿŶсϵϱ ϱϯ͘ϴ ϭϱ͘ϰ ϴ͘ϴ 
Ɖ^ĞĐŝĂůŝƐƚƐŶсϱϯ ϲϬ͘ϴ ϳ͘ϴ ϵ͘ϴ 
ZĞŐŝƐƚƌĂƌƐŶсϮϰ ϯϰ͘ϴ ϯϰ͘ϴ ϴ͘ϳ 
General pŚǇƐŝĐŝĂŶƐŶсϭϴ ϱϴ͘ϴ ϭϴ͘ϴ ϱ͘ϵ 
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Price as indicator of quality 
 
“Product of high price usually has good quality than that of low price product” 
This aphorism is not uncommon among health professionals; and it is associates usually with 
the fevering one product over other products just according to this rule. The feedback from 
pharmacists and doctors regarding this subject indicate that, pharmacists were divided in 
their approaches as some were objectors, some agree totally while other agreed with some 
reservations. On other hand ϰϰйof the doctors believed the saying generally true “but not 
always”. 
A. Pharmacists: 
Category Yes always Not always No 
ůƉŚĂƌŵĂĐŝƐƚƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ Ϯϵ͘ϭ ϯϵ͘Ϯ ϯϭ͘ϲ 
ϭǇĞĂƌ– ϮǇĞĂƌƐ;ŶсϮϲͿ Ϯϰ͘Ϭ ϱϮ͘Ϭ Ϯϰ͘Ϭ 
ϯǇĞĂƌƐ– ϱǇĞĂƌƐ;ŶсϮϱͿ ϮϬ͘ϴ ϱϬ͘Ϭ Ϯϵ͘Ϯ 
DŽƌĞƚŚĂŶϱǇĞĂƌƐ;ŶсϯϭͿ ϰϬ͘Ϭ ϮϬ͘Ϭ ϰϬ͘Ϭ 
 
B. Doctors: 
 
Category Yes always Not always No No comments 
ůŽĐƚŽƌƐ;ĐŽůĞĐƟǀĞͿŶсϵϱ ϭϳ͘ϲ ϰϰ͘Ϭ ϭ͘Ϭ ϱ͘ϱ 
Ɖ^ĞĐŝĂůŝƐƚƐŶсϱϯ ϭϳ͘ϲ ϰϭ͘Ϯ ϭϯ͘ϳ ϱ͘ϵ 
ZĞŐŝƐƚƌĂƌƐŶсϮϰ ϴ͘ϳ ϱϰ͘Ϯ ϴ͘ϳ ϴ͘ϳ 
General pŚǇƐŝĐŝĂŶƐŶсϭϴ Ϯϵ͘ϰ ϰϭ͘Ϯ ϱ͘ϵ Ϭ 
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Relations with the regularity bodies 
 
The role of pharmacy or health regularity bodies is very important and vital in the linkage 
between the professional practitioners and the products they use during their work. The 
feedback of the practitioners about the products efficacy, safety and quality should be 
communicated with the authority. Still the final assessment of these products should be 
referred to these bodies. &ĞǁƉƌŽƉŽƌƟŽŶŽĨŚĞĂůƚŚƉƌŽĨĞƐƐŝŽŶĂůƐ;ŽŶůǇϭϱйŽĨƉŚĂƌŵĂĐŝƐƚƐ
ĂŶĚϭϬйŽĨĚŽĐƚŽƌƐͿŚĂǀĞďĞĞŶĞǀĞƌŶŽƟĮĞĚĂŶǇĐŽŵƉůĂŝŶƚƐŽƌƌĞƉŽƌƚƐto any regularity 
body regarding medicines related problems. Upon surveying those who communicate with 
the authorities regarding the response to their reports; the majority of the reporters 
received no response to their reports. 
Many of the information providers refer this probably due to: 
- Inefficient complaints receiving and management system; 
- Poor documentation system within the authorities; 
- Weak decision making procedures  
A. Notification of complains to any Regulatory Body regarding medicines related problem: 
Ever notify WŚĂƌŵĂĐŝƐƚƐŶсϴϮ Doctors Ŷсϵϱ 
Yes ϭϱ͘Ϯ ϵ͘ϵ 
No ϳϵ͘ϳ ϱϬ͘ϱ 
No comment ϱ͘ϭ ϭϮ͘ϭ 
 
B. If yes; what was the response: 
Response Pharmacists Doctors 
Prompt & good response ϭϲ͘ϳ - 
Delayed response - - 
Weak response - - 
No response ϳϱ͘Ϭ ϰϰ͘ϰ 
No comment ϴ͘ϯ ϱϱ͘ϲ 
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Comments of providers on the quality of medicines from particular origins 
 
This part of the questionnaires discussed the possible relation between the country of origin 
and the quality of medicines. The information providers were asked to evaluate and 
comment on products originated in different sources. This included Sudan, other low income 
countries, high income countries and products manufactured by multinational industries; 
this classification of countries was based on World Bank classifications ;t͕ϮϬϬϳͿ. They 
were asked to classify products generally either of “good quality” or of “low quality” for 
specified origins. This question reflected their impression about the relation between the 
origin and the quality in their perception. ϲϳйĂŶĚϰϴйŽĨƉŚĂƌŵĂĐŝƐƚƐĂŶĚĚŽĐƚŽƌƐ
respectively believed that products manufactured in low income countries were general 
worse than that from high income countries and products from multinational companies. In 
ŐĞŶĞƌĂůϲϰйĂŶĚϯϱйŽĨƉŚĂƌŵĂĐŝƐƚƐĂŶĚĚŽĐƚŽƌƐƌĞƐƉĞĐƟǀĞůǇďĞůŝĞǀĞƚŚĂƚƚŚĞůŽĐĂůǇ
produced products are of good quality. With in-ĚĞƉƚŚĂŶĂůǇƐŝƐ͕ϰϲйŽĨƉŚĂƌŵĂĐŝƐƚƐĂŶĚϯϬй
of doctors consider locally manufactured products are better in its quality than that 
produced in low income countries. This again reflects the trust of health professionals in the 
local production of pharmaceuticals. 
A. General: 
Product Type 
Pharmacists 
Good 
quality 
Low 
quality 
No 
comment 
Original brand name (international Companies) ϵϳ͘ϱ Ϯ͘ϱ Ϭ 
Generic product from high income countries ϵϳ͘ϱ Ϯ͘ϱ Ϭ 
Generic product from low income countries ϯϮ͘ϵ ϲϳ͘ϭ Ϭ 
Generic product locally produced in Sudan ϲϰ͘ϲ ϯϱ͘ϰ Ϭ 
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Product type 
Doctors 
Good 
quality 
Low 
quality 
No 
comment 
Original brand name (international companies) ϱϲ͘Ϭ Ϭ ϭϲ͘ϱ 
Generic product from high income countries ϱϬ͘ϱ ϮϬϮ ϭϵ͘ϴ 
Generic product from low income countries ϱ͘ϱ ϰϴ͘ϰ ϭϴ͘ϳ 
Generic product locally produced in Sudan ϯϱ͘Ϯ ϭϲ͘ϱ ϮϬ͘ϵ 
 
B. Providers consider: “the locally produced products were better than that produced 
in low income countries” 
 WŚĂƌŵĂĐŝƐƚƐŶсϴϮ DŽĐƚŽƌƐŶсϵϱ 
Local product is better than low income 
countries products 
ϰϱ͘ϲ Ϯϵ͘ϳ 
 
Other specific indictors 
 
A. Pharmacists: 
ϭ͘Physical appearance problems 
Observing change in the physical appearance of pharmaceuticals is not uncommon 
experience among the pharmacists. ϵϵйŽĨƉŚĂƌŵĂĐŝƐƚƐĞǆƉĞƌŝĞŶĐĞd this problem at least 
once during their practice and cross the sample taken all categories of pharmacists 
experienced it equally. Amoxicillin & Multivitamins (especially capsules for both generics) 
were the generics in which there is obvious problem. Most of the pharmacists notice distinct 
physical changes in different dosage forms, whether this in the dosage unit and/or the inner 
packages and/or outer packages. From the results it was very difficult to judge whether the 
problem was mainly due to inappropriate storage conditions or it is related to poor 
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manufacturing specifications. In general capsules as dosage form (soft gelatin & hard gelatin) 
represents the major source of complaints under this heading. 
Area type Yes 
ůƉŚĂƌŵĂĐŝĞƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϵϵ͘Ϯй 
Centre – ŚŽƐƉŝƚĂů^ƚ;ŶсϭϭͿ ϭϬϬй 
Centre - KƚŚĞƌ;ŶсϭϰͿ ϭϬϬй 
ĂƐƚ;ŶсϭϰͿ ϭϬϬй 
Ž^ƵƚŚ;ŶсϯϲͿ ϵϴ͘ϭй 
WĞƌŝƉŚĞƌĂůƐ;ŶсϳͿ ϭϬϬй 
 
Generic Names: 
Generic Name % ŶсϭϮϮ 
Multivitamins Ϯϭ͘ϭ 
Amoxicillin ϭϳ͘ϭ 
Cough syrup ϳ͘ϯ 
Ampiclox ϰ͘ϵ 
Metronidazole ϰ͘ϵ 
Chloroquine ϰ͘ϭ 
Other antibiotics ϰ͘ϭ 
Cephalexin Ϯ͘ϰ 
Azithromycin Ϯ͘ϰ 
Antihistamine Ϯ͘ϰ 
Mefenamic Acid Ϯ͘ϰ 
 
Other medicines: 
Cotrimoxazole, Paracetamol, Diclofenac Na, Doxacycline, Tetracycline, Ar+SP, ϲ, Aspirin, 
Benzyl penicillin, Anti Flu, Clarithromycin, Furosemide, Gentamycin, K-citrate, Ketotifen, 
Metformin, Metoclopramide, Promethazine, Salbutamol, Timolol, Vit K 
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Pharmacological groups: 
Groups 
 
%  
ŶсϭϮϮ 
Anti-infectives ϰϮ͘ϯ 
Vitamins ϮϮ͘Ϭ 
Respiratory tract ϰ͘ϴ 
NSAIDs ϳ͘ϯ 
Anti-malarial ϰ͘ϵ 
Blood preparations ϭ͘ϲ 
Cardiovascular system Ϭ͘ϴ 
Central nervous system Ϭ͘ϴ 
Dermatology Ϭ͘ϴ 
Other ϳ͘ϯ 
 
Dosage Forms: 
 
Figure ϵ: Classification of physical appearance problems 
Observation source: 
Observation source йŶсϭϮϮ 
Himself / Herself ϵϭ͘ϵ 
Doctors Ϯ͘ϰ 
Patients ϰ͘ϭ 
Other Ϭ͘ϴ 
 
Capsule
ϯϵ%
Liquids (Syrup & 
Suspension)
ϯϵ%
Tablet
ϭϭ%
Parental
ϳ%
Topical 
preparations
Ϯ%
Other
Ϯ%
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Problem classification: 
Package type Problem йŶсϭϮϮ 
Stripe Contents leakage ϮϬ͘ϯ 
Stripe Units missed ϭϲ͘ϯ 
Bottle Separation or precipitation ϭϲ͘ϯ 
Bottle Contents leakage ϭϱ͘ϰ 
Stripe Units crashed ϵ͘ϴ 
Other Color changes ϰ͘ϵ 
Stripe Deformation ϯ͘ϯ 
Bottle Color changes Ϯ͘ϰ 
Other Contents leakage ϭ͘ϲ 
Stripe Color changes Ϭ͘ϴ 
Bottle Crashed Ϭ͘ϴ 
Other Crashed Ϭ͘ϴ 
Other Other ϳ͘ϯ 
Ϯ͘ Post Marketing Surveillance System 
Post-marketing surveillance system has been developed by the Federal Directorate of 
Pharmacy in Sudan few years ago. Until this study was completed the system was well 
established only at the federal level. “NMPB” distributed some promotional posters and 
materials to raise the awareness about the existence of this system. The materials also 
aimed to open a sort of communication channel with pharmacies and pharmacists. KŶůǇϮϯй
of surveyed pharmacies received these materials, and most of these pharmacies were 
located in the hospital street and in the eastern areas in Khartoum (no materials seen in 
other areas). Among different categories of pharmacists; those with more than ϱǇĞĂƌƐŽĨ
ĞǆƉĞƌŝĞŶĐĞĂŶĚƚŚŽƐĞŚĂǀŝŶŐĞǆƉĞƌŝĞŶĐĞďĞƚǁĞĞŶϭ-ϮǇĞars know about the system more 
ƚŚĂŶƚŚŽƐĞŝŶƚŚĞƌĂŶŐĞďĞƚǁĞĞŶϯ-ϱǇĞĂƌƐŽĨĞǆƉĞƌŝĞŶĐĞ͘ŵŽŶŐƉŚĂƌŵĂĐŝƐƚƐŚĂǀŝŶŐ
ĂĚĞƋƵĂƚĞŝŶĨŽƌŵĂƟŽŶŝŶŐĞŶĞƌĂůĂďŽƵƚƚŚĞƐǇƐƚĞŵ͖ϱϳйŽĨƚŚĞŵƚŚŝŶŬƚŚĂƚƚŚĞƐǇƐƚĞŵŝƐ
ĞīĞĐƟǀĞĂŶĚϮϮйŚĂǀĞƐŽŵĞĐŽŶĐĞƌŶƐĂďŽƵƚƚŚĞƐǇƐƚĞŵĞĨficacy. 
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A. Availability of drug safety poster: 
Area type Yes No 
ůƉŚĂƌŵĂĐŝĞƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϮϮ͘ϴ ϲϰ͘ϲ 
Centre – ŚŽƐƉŝƚĂů^ƚ;ŶсϭϭͿ ϱϬ͘Ϭ ϯϳ͘ϱ 
Centre - oƚŚĞƌ;ŶсϭϰͿ Ϯϴ͘ϲ ϲϰ͘ϯ 
ĂƐƚ;ŶсϭϰͿ ϰϮ͘ϵ ϱϬ͘Ϭ 
Ž^ƵƚŚ;ŶсϯϲͿ ϭϭ͘ϭ ϲϵ͘ϰ 
WĞƌŝƉŚĞƌĂůƐ;ŶсϳͿ Ϭ ϭϬϬ 
 
B. Awareness about post-marketing surveillance system: 
Area type Yes No 
ůƉŚĂƌŵĂĐŝĞƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϰϭ͘ϴ ϱϳ͘Ϭ 
Centre – ŚŽƐƉŝƚĂů^ƚ;ŶсϭϭͿ ϱϬ͘Ϭ ϱϬ͘Ϭ 
Centre - oƚŚĞƌ;ŶсϭϰͿ ϰϮ͘ϵ ϱϬ͘Ϭ 
ĂƐƚ;ŶсϭϰͿ ϱϬ͘Ϭ ϱϬ͘Ϭ 
Ž^ƵƚŚ;ŶсϯϲͿ ϰϭ͘ϳ ϱϴ͘ϳ 
WĞƌŝƉŚĞƌĂůƐ;ŶсϳͿ ϭϰ͘ϯ ϴϱ͘ϳ 
 
Category Yes No 
ůƉŚĂƌŵĂĐŝƐƚƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϰ͘ϴ ϱϳ͘Ϭ 
ϭǇĞĂƌ– ϮǇĞĂƌƐ;ŶсϮϲͿ ϰϰ͘Ϭ ϱϲ͘Ϭ 
ϯǇĞĂƌƐ– ϱǇĞĂƌƐ;ŶсϮϱͿ ϯϯ͘ϯ ϲϮ͘ϱ 
DŽƌĞƚŚĂŶϱǇĞĂƌƐ;ŶсϯϭͿ ϲϰ͘ϳ ϱϯ͘ϯ 
 
C. Comments on the usefulness of the system: 
Efficacy zĞƐŶсϴϮ 
Effective ϱϳ͘Ϭ 
Partially effective Ϯϭ͘ϱ 
Not effective ϭϲ͘ϱ 
 
Category Effective 
Partially 
Effective 
Not 
Effective 
ůƉŚĂƌŵĂĐŝƐƚƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϱϳ͘Ϭ Ϯϭ͘ϱ ϭϲ͘ϱ 
ϭǇĞĂƌ– ϮǇĞĂƌƐ;ŶсϮϲͿ ϲϬ͘Ϭ Ϯϰ͘Ϭ ϭϮ͘Ϭ 
ϯǇĞĂƌƐ– ϱǇĞĂƌƐ;ŶсϮϱͿ ϱϴ͘ϯ Ϯϱ͘Ϭ ϭϮ͘ϱ 
DŽƌĞƚŚĂŶϱǇĞĂƌƐ;ŶсϯϭͿ ϱϯ͘ϯ ϭϲ͘ϳ Ϯϯ͘ϯ 
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ϯ͘ Medicines recall 
Most of the surveyed pharmacies experienced recall process at least once in the last period. 
All pharmacies in Hospital Street and those in the peripherals go through this process either 
through Pharmacy Directorate or through direct contact with the concerned companies. In 
ϮϳйŽĨƌĞĐĂůĐĂƐĞƐ͞ŶŽŽĸĐŝĂůůĞƩĞƌ͟ǁĂƐƌĞĐĞŝǀĞĚĨƌŽŵ“NMPB" (previously it was 
Pharmacy Directorate which is the responsible body) to the pharmacies as endorsement to 
carry out the recall procedure. Upon the revision of the records from Pharmacy Directorate 
ŝŶĐŽŵƉĂƌŝƐŽŶǁŝƚŚƚŚĞĚĂƚĂŽďƚĂŝŶĞĚĨƌŽŵƚŚĞĮĞůĚ͕ĨŽƌϭϳйŽĨƚŚĞƌĞƉŽƌƚĞĚĐĂƐĞƐŶŽ
records have been found. This was very critical and significant data. 
A. Dealing with recall process: 
Area type Yes No 
ůƉŚĂƌŵĂĐŝĞƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϵϮ͘ϰ ϲ͘ϯ 
Centre – ŚŽƐƉŝƚĂů^ƚ;ŶсϭϭͿ ϭϬϬ͘Ϭ Ϭ 
Centre - oƚŚĞƌ;ŶсϭϰͿ ϵϮ͘ϵ ϳ͘ϭ 
ĂƐƚ;ŶсϭϰͿ ϴϱ͘ϳ ϭϰ͘ϯ 
Ž^ƵƚŚ;ŶсϯϲͿ ϵϭ͘ϳ ϱ͘ϲ 
WĞƌŝƉŚĞƌĂůƐ;ŶсϳͿ ϭϬϬ͘Ϭ Ϭ 
 
 
Recall 
Yes No 
Deal with physical problems ϳϰ͘Ϭ ϭϬϬ͘Ϭ 
Not deal with physical problems ϭϯ͘ϳ Ϭ 
 
B. Reference from the authorities for approving the recall: 
Efficacy Yes 
With written letter ϱϯ͘Ϯ 
Without written letter Ϯϲ͘ϲ 
No comments ϱ͘ϭ 
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C. Examples of medicines recalled recently: 
Generic name йŶсϳϵ 
Cough syrup ϰϬ͘ϱ 
Multivitamins ϴ͘ϵ 
Ferrous preparation ϴ͘ϵ 
Antihistamine ϳ͘ϲ 
Aspirin ϱ͘ϭ 
Ciprofloxacin ϭ͘ϯ 
Other antibiotics ϯ͘ϴ 
Other medicines ϭϱ͘Ϯ 
Other medicines: 
Antacid, Bisacodyl, Chloramphenicol, Diclofenac, Indomethazine, Captopril, K-citrate, 
Metformin, Paracetamol and Salbutamol 
Pharmacological Groups йŶсϳϵ 
Respiratory tract ϰϭ͘ϴ 
NSAIDs ϭϬ͘ϭ 
Blood preparations ϴ͘ϵ 
Vitamins ϴ͘ϵ 
Cardiovascular system ϱ͘ϭ 
Anti-infectives ϯ͘ϴ 
Other ϭϬ͘Ϯ 
 
Dosage Form йŶсϳϵ 
Liquids (syrup & suspension) ϱϭ͘ϵ 
Tablet Ϯϱ͘ϯ 
Capsule ϭϬ͘ϭ 
Parental ϭ͘ϯ 
Other Ϯ͘ϱ 
 
Origin % n=ϳϵ 
EAU ϰϭ͘ϴ 
Europe ϭϬ͘ϭ 
Jordan ϴ͘ϵ 
India ϴ͘ϵ 
Sudan ϳ͘ϲ 
Other Arab countries ϭϭ͘ϰ 
Other Ϯ͘ϱ 
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ϰ͘Prioritization of pharmacological groups according to pharmacists 
 
Pharmacists were asked about thĞŝƌƉƌŝŽƌŝƟǌĂƟŽŶĨŽƌƚŽƉϯƉŚĂƌŵĂĐŽůŽŐŝĐĂůŐƌŽƵƉƐƚŚĞǇ
think it represents the most essential groups in their pharmacies in terms of consumption, 
importance and quality concerns. According to the results obtained; cardiovascular 
medicines, anti-infective medicines and gastrointestinal medicines represents the main 
groups. Pharmacists relatively prioritize these groups in their pharmacies and they think that 
the government should consider it carefully in its quality assurance plans. 
 
Figure ϭϬ: Prioritization of pharmacological groups according to pharmacists’ feedback 
 
B. Doctors: 
ϭ͘ Doctors’ awareness & knowledge about substandard medicines 
Some questions were asked to doctors for specific purposes; one of the questions designed 
to evaluate the knowledge of doctors about the problem of substandard medicines and its 
negative impacts. ϰϬйŽĨƚŚĞĚŽĐƚŽƌƐŵĞŶƟŽŶĞĚƚŚĂƚƚŚĞŝŵŵĞĚŝĂƚĞĞīĞĐƚŽĨƐƵďƐƚĂŶĚĂƌĚ
Ϭ ϱ ϭϬ ϭϱ ϮϬ Ϯϱ
Cardiovascular System
Anti-infectives
Gastrointestinal Tract
Respiratory Tract
Central Nervous System
Diabetic drugs
Urinary Tract
Blood preparations
Dermatology
NSAIDs
OBS & GYN
Other
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medicines could lead to patient’s death. Same results to this one was also shown in another 
survey done by press newsletter in India about this area ;ĂƐƚƌŽ͕ϮϬϬϱͿ. In general results 
indicated that more educational interventions about substandard medicines should be 
developed and implemented; that aimed to increase their awareness by the impact of 
substandard medicines problem and how to deal with it ;WĂůĂŵƉƵƌ͕ϮϬϬϯͿ. 
 
a) Substandard drawbacks: 
tŚĂƚŶсϵϱ Yes No No comment 
Additional cost for your patients ϲϮ͘ϲ ϲ͘ϲ ϯ͘ϯ 
Prolong your patients’ illness ϱϵ͘ϯ ϳ͘ϳ ϱ͘ϱ 
Could be contributed to drugs resistance  ϱϰ͘ϵ ϭϭ͘Ϭ ϱ͘ϱ 
Decrease your patients trust on your practice ϱϮ͘ϳ ϭϭ͘Ϭ ϴ͘ϴ 
Could lead to patient death ϯϴ͘ϱ Ϯϰ͘ϱ ϵ͘ϵ 
All of these ϯϬ͘ϴ - - 
None of these ϯ͘ϯ - - 
 
b) Reasons to recall (withdrawal) medicines from the market: 
The awareness of doctors about recall system and what are the reasons for it showed very 
weak knowledge among them about it. Other suggested different reasons to take a recall 
decision. 
tŚǇŶсϵϱ Yes No No comment 
Chemical problems (active and in-
active contents problems) 
ϱϴ͘Ϯ ϯ͘ϯ ϭϭ͘Ϭ 
Changes in color ϱϴ͘Ϯ ϯ͘ϯ ϭϭ͘Ϭ 
Fracture of tablets or capsules ϱϰ͘ϵ ϱ͘ϱ ϭϮ͘ϭ 
Repeated doctors and or patients 
complaints 
ϱϰ͘ϵ ϲ͘ϲ ϭϮ͘ϭ 
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Ϯ͘Insistence to prescribe particular trade products 
ϲϯйŽĨĚŽĐƚŽƌƐ͕ƉĂƌƟĐƵůĂƌůǇƚŚĞƐƉĞĐŝĂůŝƐƚƐ͕ report that they insist to prescribe certain trade 
products to their patients. Most of them refer this to the successful experience with these 
trades relative to ŽƚŚĞƌƚƌĂĚĞƐĂǀĂŝůĂďůĞŝŶƚŚĞŵĂƌŬĞƚ͘KŶƚŚĞŽƚŚĞƌŚĂŶĚŽŶůǇϭϰйŽĨ
doctors refer this to the price considerations as factor that could influence their decision to 
select certain reasonably affordable product. 
 Yes No No comment 
ůŽĐƚŽƌƐ;ĐŽůĞĐƟǀĞͿŶсϵϱ ϲϮ͘ϲ ϵ͘ϵ ϱ͘ϱ 
Ɖ^ĞĐŝĂůŝƐƚƐŶсϱϯ ϲϰ͘ϳ ϵ͘ϴ ϯ͘ϵ 
ZĞŐŝƐƚƌĂƌƐŶсϮϰ ϲϬ͘ϵ ϰ͘ϯ ϯ͘Ϭ 
General physicianƐŶсϭϴ ϱϴ͘ϴ ϭϳ͘ϲ Ϭ 
 
Reasons if he/she insists to prescribe certain medicines: 
Why Yes No No comment 
Success experience with those trades ϱϬ͘ϱ Ϯϭ͘ϭ Ϯ͘Ϯ 
Failure experience with other trades ϭϴ͘ϳ ϰϰ͘Ϭ Ϯ͘Ϯ 
Price considerations ϭϰ͘ϯ ϰϴ͘ϰ Ϯ͘Ϯ 
Other ϭϬϭ ϲϭ͘ϱ Ϯ͘Ϯ 
 
3. Availability versus Quality 
“Available low quality drug is better than the drug is not available at all” 
ĐĐŽƌĚŝŶŐƚŽƚŚĞƌĞƐƵůƚƐ͕ϯϬйŽĨƚŚĞĚŽĐƚŽƌƐĂŐƌĞĞĚǁŝƚŚƚŚĞĂďŽǀĞĐŽŶĐĞƉƚ͘/ĨŶŽĂǀĂŝůĂďůĞ
alternative they may prescribe low quality product to safe the patients. This result was 
significant as many theories consider that low quality medicines could be regarded as not 
available for effective and safe human use under any circumstances ;D ,^͕ϮϬϬϭͿ, (Videau, 
ϮϬϬϭͿ. This result could be evaluated only under the personal experiences of doctors in 
Sudan. Despite the fact this should be combined with consideration to that relatively there 
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are small number of registered medicines in Sudan [around ϯϳϬϬƚƌĂĚĞƐ΁ (NMPB, Sudan - 
National Medicines and PoisŽŶƐĂŽƌĚ͕ϮϬϭϬͿ. This obviously affects the decisions of the 
doctors because of small available options to take. One third of the doctors will go for the 
unique drug drugs regardless its quality. 
Category Yes No Some times No comment 
All Doctors (collecƟǀĞͿŶсϵϱ Ϯϵ͘ϳ ϭϱ͘ϰ Ϯϰ͘Ϯ ϰ͘ϰ 
Ɖ^ĞĐŝĂůŝƐƚƐŶсϱϯ Ϯϯ͘ϱ ϭϵ͘ϲ Ϯϭ͘ϲ ϱ͘ϵ 
ZĞŐŝƐƚƌĂƌƐŶсϮϰ ϯϰ͘ϴ Ϭ ϯϵ͘ϭ ϰ͘ϯ 
'ĞŶĞƌĂůWŚǇƐŝĐŝĂŶƐŶсϭϴ ϰϭ͘Ϯ Ϯϯ͘ϱ ϭϭ͘ϴ Ϭ 
I. Other 
· The problem of substandard medicines is worse in case of: 
Type of medicines йŶсϵϱ 
OTC medicines Ϯϵ͘ϳ 
Rx medicines Ϯϴ͘ϲ 
Both types ϰ͘ϰ 
No comment ϭϭ͘Ϭ 
· Information sharing with pharmacists about quality: 
Why Yes No No comment 
ůŽĐƚŽƌƐ;ĐŽůĞĐƟǀĞͿŶсϵϱ ϱϳ͘ϭ ϭϭ͘Ϭ ϰ͘ϰ 
Ɖ^ĞĐŝĂůŝƐƚƐŶсϱϯ ϰϵ͘Ϭ ϭϱ͘ϳ ϯ͘ϵ 
ZĞŐŝƐƚƌĂƌƐŶсϮϰ ϲϱ͘Ϯ ϰ͘ϯ ϴ͘ϳ 
General pŚǇƐŝĐŝĂŶƐŶсϭϴ ϳϬ͘ϲ ϱ͘ϵ Ϭ 
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General discussion 
 
Despite the fact that medicines inspection function in Sudan was improved largely in last few 
years, it is still true the unexpected failure of most inspectors to identify significantly 
substandard products put in question the training programs and/or testing protocols. The 
main concern whether these were adequate to build up the sufficient capacity for the 
inspectors to gain the skills required ;t,K͕ϭϵϵϵͿ. 
It has been mentioned before, there is a post marketing surveillance system implemented 
for registered medicines in Sudan. It aims to track different distribution channels of 
medicines through the country. It was designed to consider differential factors that affect 
the quality of marketed medicines. One of the basic conceptions for any PMS system, which 
considered as important anchor, is the sampling technique or methodology regarding the 
selection of targeted medicines or the collection of samples from the field. Both areas are 
critical so as to ensure that a representative sample of targeted medicines was collected 
from the distribution channels to support any future decision could be taken based on the 
results. 
There are different approaches worldwide considering the PMS system development and 
some countries have unique system regarding the selection of medicines and its sample 
collection; as examples: 
· In Australia complementary medicines and non-prescription drugs were routinely 
examined based on the Pharmacovigilance reports obtained from the field (Fracchia 
& others, ϮϬϬϬͿ; 
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· In Malaysia all types of products were subjected to PMS analysis as the number of 
medicines available in the market was limited and easy to be tracked regarding it 
quality; 
· In Cyprus products containing sensitive substances, products used for serious 
diseases and generic products posing interchangeability problems were considered 
as the primary targets for the system; 
· In Cuba the PMS focuses on samples collected from manufacturers in connection 
with GMP inspection, rather than on samples collected directly from the “market 
base on the limited capacity of the quality control laboratory ;h^W͕ϮϬϬϱͿ. 
It is valid that the conceptual believes of the medical professionals regarding the 
substandard medicines affect to large extent the curative process in any medical field 
(whether in the public or private sectors). Health professional believes could be of potential 
importance as it has been driven from years of experience and repeated practical 
knowledge. But this also could be of possible drawbacks effect on the health provision 
process when these pre-judgments weren’t supported by evidence based indications (ICN, 
ϮϬϬϱͿ. This survey aimed to express out the conceptual understanding of the health 
professionals in Khartoum city regarding the issue of substandard medicines circulated in the 
private market in Khartoum, and to link these thoughts to what was really taken place in the 
marketed medicines. Results of this survey showed the major issues regarding the 
professionals’ ideas and how they deal with the substandard medicines. It was obvious there 
are different concepts regarding these issues among doctors surveyed and other significantly 
different concepts among the pharmacists. One of the possible reasons for that could be 
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referred to the basic educational background that allow the pharmacists to deal with 
medicines objectively regarding its quality despite its sources of origin, its prices or any other 
associated factors other than evidence based quality problems ;ŽĚŽŽ͕ϮϬϬϳͿ. This reflected 
the needs for developing educational programs to address the problems of counterfeit and 
substandard in the curriculums of pharmacy and medicines schools as part of essential 
medicines concept. On the other hand the judgment of doctors regarding the quality of any 
product used for the patients will be always concluded with slightly subjective evaluation 
which could be generated from their experiences in the field. As an example for that the use 
of substandard, narrow-spectrum antibiotics may lead practitioners to believe that the 
medicines are ineffective, and unnecessarily prescribing new/more expensive broad-
spectrum antibiotic, which places additional financial pressures on the health care system 
and the patient as well ;ŶĚƌĞŽƫΘƌĞĂ͕ϮϬϬϱͿ. Another example with similar scenario 
applied for life saving drugs with narrow therapeutic index which were considered and taken 
seriously for patients with ischemic heart diseases and other life threatening diseases (Das, 
ϭϵϵϮͿ ;ZĞĂŶĞǇ͕ϮϬϬϱͿ. 
It was obtained from the results ƚŚĂƚϴϬйĂŶĚϳϬйŽĨƉŚĂƌŵĂĐŝƐƚƐĂŶĚĚŽĐƚŽƌƐƌĞƐƉĞĐƟǀĞůǇ
believes that there are substandard medicines available in the market. The awareness about 
the impact of this problem and its effects was different among health professionals. The 
educational background and the experience seem to play important role in these 
differences. The message that may be conveyed from medical professionals to the public, 
about the quality of medicines, sometimes become extremely misleading information and 
affect the overall handling of this issue. Concepts linked the quality of medicines to its price 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  Pageͳͳ͹ 
and/or their origins are relevant in this case. It has been argued that increasing the 
awareness about poor quality drugs may cause patients to worry excessively about whether 
the medicines they are taking are genuine. On the other hand, lack of vigilance may generate 
a lack of trust in both consumers and professionals. Still the question about this matter will 
persist regarding the opinions to bring the issue of substandard medications to public 
attention as an essential first step towards reinforcing current methods of surveillance, with 
consideration to what extend this will affects the patients trust in the health system in 
general. 
Based on the results obtained it was clear that the complaints received by the pharmacists 
from the patients were most likely due to factors related to the patients. Among the 
complaints received by pharmacists; the utmost issue of the complaints from the patients 
that they administer medicines that were not effective or, sometimes, the symptoms were 
not relieved after using some medicines. Although this was subjective issue, but still his was 
significant findings since that part of these medicines were medicines for chronic use e.g. 
antihypertensive anti-diabetic medicines. 
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Feedback about the quality 
 
The following results obtained from the survey of health professionals. They were asked to 
account if they have any quality concerns regarding the selected generic names (refer to 
medicines selection criteria in pages ϯϴΘϯϵ). These results gives the overall summery of the 
feedback about the following medicines: 
ϭ. Ciprofloxacin 
Ϯ. Amoxicillin susp/cap 
ϯ. Paracetamol 
ϰ. Metronidazole 
ϱ. Glibenclamide 
ϲ. Mefenamic Acid 
ϳ. Artesunate + SP 
ϴ. Chlorphenarmine 
ϵ. Chlorphenarmine 
ϭϬ. Ampiclox 
ϭϭ. Aspirin 
ϭϮ. Ethinylestradiol/levonorgestrel 
ϭϯ. Carbimazole tab 
ϭϰ. Cefuroxime  
ϭϱ. Atenolol 
ϭϲ. Co- trimoxazole 
ϭϳ. Furosemide 
ϭϴ. Nifedipine 
ϭϵ. Chloramphenicol 
ϮϬ. Hydrocortisone 
Ϯϭ. Digoxin 
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ϭ. General 
Table ϰ: Overall summery of the feedback about surveyed generics 
Order Generics 
Quality concerns 
% Yes % No 
ϭ Ciprofloxacin ϰϲ͘ϴ ϱϬ͘ϰ 
Ϯ Amoxicillin susp/cap ϰϯ͘Ϯ ϱϯ͘Ϯ 
ϯ Paracetamol ϰϭ͘ϳ ϱϯ͘Ϯ 
ϰ Metronidazole susp/tab ϯϵ͘ϲ ϱϲ͘ϴ 
ϱ Glibenclamide tab ϯϱ͘ϯ ϱϳ͘ϲ 
ϲ Mefenamic Acid ϯϭ͘ϳ ϱϳ͘ϲ 
ϳ Artesunate + SP ϯϬ͘ϵ ϲϵ͘ϭ 
ϴ Chlorphenarmine Ϯϱ͘ϵ ϲϭ͘Ϯ 
ϵ Ampiclox Ϯϲ͘ϲ ϲϵ͘ϭ 
ϭϬ Aspirin Ϯϰ͘ϱ ϲϵ͘ϴ 
ϭϭ Ethinylestradiol/levonorgestrel ϮϮ͘ϯ ϱϵ͘Ϭ 
ϭϮ Carbimazole tab Ϯϯ͘ϳ ϲϴ͘ϯ 
ϭϯ Cefuroxime Inj Ϯϯ͘ϳ ϲϵ͘ϭ 
ϭϰ Atenolol tab Ϯϭ͘ϲ ϳϭ͘Ϯ 
ϭϱ Co- trimoxazole ϭϲ͘ϱ ϲϵ͘ϴ 
ϭϲ Furosemide ϭϱ͘ϴ ϲϵ͘ϭ 
ϭϳ Nifedipine ϭϱ͘ϭ ϳϮ͘ϳ 
ϭϴ Chloramphenicol ϭϯ͘ϳ ϳϵ͘ϭ 
ϭϵ Hydrocortisone ϭϭ͘ϱ ϴϯ͘ϱ 
ϮϬ Digoxin Inj/tab ϳ͘Ϯ ϴϮ͘ϳ 
                ΎŶсϭϭϳ 
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Ϯ. Classification of the feedback based on providers type 
Table ϱ: Feedback about surveyed generics disaggregated by information provider 
Order Generics 
Answering “Yes” 
Pharmacists Doctors 
ϭ Ciprofloxacin tab ϰϯ͘ϲ ϱϬ͘ϴ 
Ϯ Amoxicillin susp/cap ϰϲ͘Ϯ ϯϵ͘ϯ 
ϯ Paracetamol ϰϯ͘ϲ ϯϵ͘ϯ 
ϰ Metronidazole susp/tab ϯϳ͘Ϯ ϰϮ͘ϲ 
ϱ Glibenclamide tab ϯϴ͘ϱ ϯϭ͘ϭ 
ϲ Mefenamic Acid Ϯϴ͘Ϯ ϯϲ͘ϭ 
ϳ Artesunate +SP Ϯϴ͘Ϯ ϯϰ͘ϰ 
ϴ Ampiclox Ϯϭ͘ϴ ϯϮ͘ϴ 
ϵ Chlorphenarmine Ϯϲ͘ϵ Ϯϰ͘ϲ 
ϭϬ Cefuroxime sodium Inj ϭϵ͘Ϯ Ϯϵ͘ϱ 
ϭϭ Aspirin Ϯϱ͘ϲ Ϯϯ͘Ϭ 
ϭϮ Carbimazole tab Ϯϰ͘ϰ Ϯϯ͘Ϭ 
ϭϯ Atenolol tab ϭϳ͘ϵ Ϯϲ͘Ϭ 
ϭϰ Ethinylestradiol/levonorgestrel ϯϰ͘ϲ ϲ͘ϲ 
ϭϱ Co- trimoxazole ϲ͘ϰ Ϯϵ͘ϱ 
ϭϲ Furosemide ϲ͘ϰ ϮϮ͘ϵ 
ϭϳ Nifedipine ϭϮ͘ϴ ϭϴ͘Ϭ 
ϭϴ Chloramphenicol ϭϰ͘ϭ ϭϯ͘ϭ 
ϭϵ Hydrocortisone ϱ͘ϭ ϭϵ͘ϳ 
ϮϬ Digoxin Inj/tab ϲ͘ϰ ϴ͘ϯ 
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ϯ. Classification of providers answers about ineffectiveness 
Table ϲ: Feedback about surveyed generics disaggregated by problem category 
Order Generics 
Answering the problem in 
Drug itself patients 
ϭ Co- trimoxazole ϲϵ͘ϲ ϯϬ͘ϰ 
Ϯ Nifedipine ϲϲ͘ϳ Ϯϴ͘ϲ 
ϯ Aspirin ϲϰ͘ϳ ϯϱ͘ϯ 
ϰ Atenolol tab ϲϯ͘ϯ ϯϬ͘Ϭ 
ϱ Ciprofloxacin tab ϲϬ͘Ϭ ϯϵ͘ϲ 
ϲ Digoxin Inj/tab ϲϬ͘Ϭ ϰϬ͘Ϭ 
ϳ Paracetamol ϱϲ͘ϵ ϰϯ͘ϭ 
ϴ Furosemide ϱϵ͘ϭ ϯϲ͘ϰ 
ϵ Mefenamic Acid 
ϱϵ͘ϭ ϯϴ͘ϲ 
ϭϬ Hydrocortisone ϱϲ͘ϯ ϰϯ͘ϴ 
ϭϭ Glibenclamide tab ϱϱ͘ϭ ϰϰ͘ϵ 
ϭϮ Amoxicillin susp/cap ϱϱ͘Ϭ ϰϱ͘Ϭ 
ϭϯ Carbimazole tab ϱϰ͘ϱ ϰϮ͘ϰ 
ϭϰ Metronidazole susp/tab 
ϱϮ͘ϳ ϰϱ͘ϱ 
ϭϱ Ampiclox Inj ϱϭ͘ϰ ϰϱ͘ϵ 
ϭϲ Cefuroxime sodium Inj ϰϴ͘ϱ ϱϭ͘ϱ 
ϭϳ Ethinylestradiol/levonorgestrel ϰϴ͘ϰ ϱϭ͘ϲ 
ϭϴ Artesunate ϰϲ͘ϱ ϱϯ͘ϵ 
ϭϵ Chlorphenarmine ϰϰ͘ϰ ϱϱ͘ϲ 
ϮϬ Chloramphenicol  ϯϲ͘ϴ ϲϯ͘Ϯ 
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Based on the above results which was obtained from the questionnaires; certain criteria 
have been set to select particular medicines which will be the subject of Quality Control 
laboratory analysis. The criteria set were as follows: 
ϭ. dŽƉϭϬŐĞŶĞƌŝĐƐ;ŝŶйͿƚŚĂƚƉƌŽĨĞƐƐŝŽŶĂůƐĐŽŶĐĞƌŶƐĂďout it; 
Ϯ. Feedback obtained from the professionals about specific medicines related 
ƉƌŽďůĞŵƐ;dŽƉϱŐĞŶĞƌŝĐƐͿ͘ 
ϯ. Distribution of selected medicines (the ϭϱŐĞŶĞƌŝĐƐ ĨƌŽŵϭΘϮĂďŽǀĞ) in terms of 
pharmacological groups, number of registered items per each generic, quantitative 
assay methodology and type of dosage form; 
ϰ. Availability and possibility to access suitable analytical settings. 
According to these criteria the following medicines came as a result if this appraisal: 
Generics Dosage  Assay Pharmacology Registered  
Ciprofloxacin Tablet LC Antibiotic ϯϮ 
Amoxicillin Capsule LC Antibiotic ϰϴ 
Paracetamol Tablet UV NSAIDs ϮϮ 
Metronidazole Tablet Titration Ant infective ϭϴ 
Glibenclamide Tablet LC Endocrinology ϭϴ 
Mefenamic Acid Tablet Titration NSAIDs ϳ 
Artesunate +SP Tablet - Antimalarials ϲ 
Chlorphenarmine  Tablet UV Other ϴ 
Ampiclox Capsule LC Antibiotic ϭϮ 
Aspirin Tablet Titration NSAIDs ϭϲ 
Cough Syrup Syrup - Other - 
Erythromycin Tablet LC Antibiotic ϭϯ 
Ceftriaxone Injection LC Antibiotic ϭϮ 
Diclofenac Tablet Titration NSAIDs Ϯϴ 
Amox-clav Tablet LC Antibiotic ϭϮ 
Table ϳ: Summery of primary selected medicines 
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The screening process was made to select the final list of generic medicines. Based on that 
ϭϬŐĞŶĞƌŝĐƐǁĞƌĞfinally selected according to the above mentioned criteria as follows: 
ϭ. Ciprofloxacin 
Ϯ. Aspirin 
ϯ. Metronidazole 
ϰ. Glibenclamide 
ϱ. Mefenamic Acid 
ϲ. Chlorphenarmine  
ϳ. Paracetamol 
ϴ. Diclofenac 
ϵ. Amoxicillin 
ϭϬ. Ceftriaxone 
dŚĞƐĞϭϬŐĞŶĞƌŝĐƐƌĞƉƌĞƐĞŶƚƚŚĞĐŽƌĞlist for quality control analysis. The next step was the 
selection of representative trade products registered in Sudan. The way the trades were 
selected in this part developed to avoid any sort of bias so as to ensure the selection of 
representative samples correspond to the situation as much as possible. 
Based on the questionnaire analysis and upon the response of the targeted groups, it was 
noted that the respondents sometimes relate and link the products quality by its countries 
of origin. This observation was considered in order to select the sample of trade products 
and also this could help in verifying the validity of this assumption. 
In Sudan there are large number or registered source origins of pharmaceuticals that shaped 
the market in Sudan. Based on that, the study team decided to categorize the countries of 
origin based on the country income according to the World Bank reports ;t͕ϮϬϬϳͿ. This 
assisted the investigators to systematize the sampling process. 
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There are major classifications for countries income level according to World Bank reports 
and this include: 
ϭ. High income countries. 
Ϯ. Upper-middle income countries. 
ϯ. Lower-middle income countries. 
ϰ. Low income countries. 
Countries of origin of selected generics were sorted out according to these classes, ŶŶĞǆŶŽ͘ϲ͘ 
The following criteria were considered in the selection process: 
ϭ. Country income category; 
Ϯ. Company of manufacturing and/or distribution; 
ϯ. Availability in other pharmaceutical dosage form; 
ϰ. Subjection of the trade product to Post Marketing Surveillance (PMS) analysis 
process by pharmacy directorate; 
ϱ. If any, the results of PMS; 
ϲ. Actual availability of the products in the market; 
ϳ. Most likely used products in the market (pharmacies’ feedback); 
 
According to this method ϯƚƌĂĚĞƉƌŽĚƵĐƚƐ were selected randomly for each generic with a 
ƚŽƚĂůŽĨϯϬƚƌĂĚĞƉƌŽĚƵĐƚƐĂƐĨŽůŽǁƐ͗- 
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Generic: Acetylsalicylic Acid                                              
ŽŶĐĞŶƚƌĂƟŽŶ͗ϯϬϬŵŐtablet 
Trade Company 
Country 
of origin 
Origin 
classification 
Available in 
other form 
PMS 
'ϬϮϭϯdϬϭ Cϭϯ Sudan Local Yes Yes/+ 
'ϬϮϭϳdϬϮ ϭϳ Lebanon Low income No Yes/- 
'ϬϮϬϲdϬϯ Ϭϲ Sudan Local Yes No 
 
Generic: Amoxicillin Trihydrate                                          
ŽŶĐĞŶƚƌĂƟŽŶ͗ϱϬϬŵŐcapsule 
Trade Company 
Country 
of origin 
Origin classification 
Available in 
other form 
PMS 
'ϬϭϬϯdϬϭ Ϭϯ Sudan Local Yes No 
'ϬϭϭϭdϬϮ ϭϭ India Low income Yes Yes/+ 
'ϬϭϮϭdϬϯ Ϯϭ Jordan Higher-middle-income Yes No 
 
Generic: Ceftriaxone sodium 
ŽŶĐĞŶƚƌĂƟŽŶ͗ϭΘϬ͘ϱŐŵpowder for injection 
Trade Company 
Country of 
origin 
Origin classification 
Available in 
other form 
PMS 
'ϬϯϭϬdϬϮ ϭϬ India Low income No No 
'ϬϯϭϰdϬϯ ϭϰ Jordan Lower-middle-income Yes No 
'ϬϯϮϬdϬϭ ϮϬ Switzerland High income Yes No 
 
Generic: Chlorphenarmine Maleate 
ŽŶĐĞŶƚƌĂƟŽŶ͗ϰŵŐtablet 
Trade Company 
Country 
of origin 
Origin 
classification 
Available in 
other form 
PMS 
'ϬϰϭϯdϬϮ ϭϯ Sudan Local No No 
'ϬϰϭϱdϬϭ ϭϱ Sudan Local No No 
'ϬϰϬϰdϬϮ Ϭϰ Greece High income Yes No 
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Generic: Ciprofloxacin 
ŽŶĐĞŶƚƌĂƟŽŶ͗ϱϬϬŵŐdĂďůĞƚ 
Trade Company 
Country of 
origin 
Origin 
classification 
Available in 
other form 
PMS 
'ϬϱϬϯdϬϯ Ϭϯ Sudan Local Yes NO 
'ϬϱϭϵdϬϮ ϭϵ India Low income Yes NO 
'ϬϱϮϬdϬϭ ϮϬ Switzerland High income Yes Yes/+ 
 
Generic: Diclofenac Sodium                                              
ŽŶĐĞŶƚƌĂƟŽŶ͗ϮϱŵŐdĂďůĞƚ 
Trade Company 
Country of 
origin 
Origin classification 
Available in 
other form 
PMS 
'ϬϲϬϲdϬϭ Ϭϲ Sudan Local NO NO 
'ϬϲϭϰdϬϯ ϭϰ Jordan Lower-middle-income Yes NO 
'ϬϲϮϬdϬϮ CϮϬ Switzerland High income NO NO 
 
Generic: Glibenclamide 
ŽŶĐĞŶƚƌĂƟŽŶ͗ϱŵŐdĂďůĞƚ 
Trade Company 
Country 
of origin 
Origin 
classification 
Available in 
other form 
PMS 
'ϬϳϬϲdϬϭ Ϭϲ Sudan Local NO NO 
'ϬϳϬϴdϬϯ Ϭϴ Pakistan Low income NO NO 
'ϬϳϬϵdϬϮ Ϭϵ England High income NO NO 
 
Generic: Mefenamic Acid 
ŽŶĐĞŶƚƌĂƟŽŶ͗ϱϬϬŵŐdĂďůĞƚ 
Trade Company 
Country 
of origin 
Origin 
classification 
Available in 
other form 
PMS 
'ϬϴϬϲdϬϭ Ϭϲ Sudan Local Yes NO 
'ϬϴϬϴdϬϯ Ϭϴ Pakistan Low income Yes Yes/+ 
'ϬϴϬϵdϬϮ Ϭϵ KSA High income Yes NO 
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Generic: Metronidazole 
Concentration: ϮϱϬ mg Tablet 
Trade Company 
Country 
of origin 
Origin classification 
Available in 
other form 
PMS 
'ϬϵϮϮdϬϯ ϮϮ Sudan Local No NO 
'ϬϵϭϲdϬϭ Ϯϱ Jordan Lower-middle-income Yes NO 
'ϬϵϭϲdϬϭ ϭϲ KSA High income No NO 
 
Generic: Paracetamol 
ŽŶĐĞŶƚƌĂƟŽŶ͗ϱϬϬŵŐdĂďůĞƚ 
Trade Company 
Country 
of origin 
Origin 
classification 
Available in 
other form 
PMS 
'ϭϬϭϮdϬϮ ϭϮ Sudan Local No No 
'ϭϬϬϮdϬϯ ϬϮ UAE High income Yes No 
'ϭϬϬϳdϬϭ Ϭϳ UK High income Yes No 
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Collection of samples for chemical analysis 
 
Sampling Quality Assurance 
 
Sample collection process was considered as one of the critical steps in this study. For this 
reason a set of measures have been taken and applied based on the sampling protocol 
described previously. 
The following measures were considered as quality assurance plan (Syhakhang & others, 
ϮϬϬϲͿ. This included the following:  
ϭ. The sampling sites were only within Khartoum city; 
Ϯ. The samples have been collected from the retail private pharmacies only; 
ϯ. The sampling technique considered different geographical areas; 
ϰ. The sampling process consider the following classification of locations: 
· Household areas. 
· Areas near clinics and hospitals. 
ϱ. The sampling process was based on the availability of the trade products 
authorized to be available in the market; 
ϲ. The samples were stored as indicated by the supplier before, during and after 
the laboratory analysis ;h^W͕ϮϬϬϯͿ. 
 
Sample collection form 
 
Pre-prepared sample collection form (see annex ϳ) was used to gather information about 
each sample. This was done to ensure the traceability of each sample collected during the 
whole process and to collect in-depth information regarding each samples. Accordingly 
the following information was generated from such analysis to get clear background 
regarding each sample: 
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v  Distribution of sample: 
· By area: 
Area йŶсϰϲ 
Centre – hospital Street Ϯϲ͘ϭй 
Centre - other ϰ͘ϯй 
East ϭϱ͘Ϯй 
South ϯϳ͘Ϭй 
Peripherals ϭϳ͘ϰй 
· By field: 
Type йŶсϰϲ 
Household areas ϯϬ͘ϰй 
Near clinics or hospitals ϲϵ͘ϲй 
 
v  Trade products: 
As it was mentioned that the availability of the selected medicines in the market was one 
of the important factors that affect the process of sample collection process from the 
ƌĞƚĂŝůƉŚĂƌŵĂĐŝĞƐ͘/ƚǁĂƐƉůĂŶŶĞĚƚŽĐŽůĞĐƚϯϬĚŝīĞƌĞŶƚƚƌĂĚĞproducts, ŝ͘Ğ͘ϯƚƌĂĚĞƐƉĞƌ
each generic. The list of the trade medicines was obtained from the registration 
department in National Medicines and Poisons Board as indictor for registration. But due 
to many reasons the availability of the selected trades was not found as expected, so the 
PIs decided to select alternative trades based on the same selection criteria described 
earlier. KƵƚŽĨϯϬƉƌĞ-ĚĞƚĞƌŵŝŶĞĚƚƌĂĚĞƐϯǁĞƌĞŶŽƚĂǀĂŝůĂďůĞŝŶƚŚĞŵĂƌŬĞƚĂƚƚŚĞƟŵĞŽĨ
sample collection and it was replaced randomly by other products within the same 
selected generics. 
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v  Suppliers: 
It is well understood that for each imported medicine there is a legally registered agent 
should be responsible for the distribution that product in the market. Different original 
oversees manufacturers could have the same distribution agent in Sudan. Accordingly, as 
expected there was difference between the number of manufacturers and the agents in 
the collected samples. The supplier classification was as follows: 
Classification No 
Manufacturers (importation) ϭϱ 
Manufacturers (local) ϳ 
Distribution agents ϭϬ 
 
v  Dosage form & concentrations: 
Form % 
Tablet ϴϮ͘ϲй 
Capsule ϴ͘ϳй 
Injection ϴ͘ϳй 
 
v  Pharmacological groups: 
The sample collected from different kinds of pharmacological groups, this includes the 
following: 
Group % 
Anti-infectives ϯϵ͘ϭй 
NSAIDs ϰϭ͘ϯй 
Anti diabetic ϭϬ͘ϵй 
Anti histamine ϴ͘ϳй 
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v  Number of batches: 
This part was also affected by the availability of each product in the market and the 
distribution power of each product. It is generally noted highly consumed products were 
characterized by the availability of several batches in the market and in different 
geographical areas through the study area. The sampling protocol was built on that; one 
batch for each trade product should be collected and on exceptions additional one could 
be collected to complete the total sample required units ;h^W͕ϮϬϬϲͿ. The total number of 
ďĂƚĐŚĞƐĐŽůĞĐƚĞĚǁĂƐϰϲ͕ĂƐŽŶĂǀĞƌĂŐĞŽŶĞďĂƚĐŚŽĨĞĂĐŚƉƌŽĚƵĐƚǁĂƐĐŽůĞĐƚĞĚĨƌŽŵ
the field. 
v  Shelf Life: 
It is true that the quality of any product in the market could be affected directly or 
indirectly by its remaining shelf life in addition to conditions under which the product was 
stored ;zŽƌŬ͕ϭϵϳϳͿ, ;ĂƌŵĂŶŝĂ͕ϭϵϵϬͿ. 
Origin Median  Minimum Maximum 
Products from high income countries ϯϰDŽŶƚŚƐ ϭϵDŽŶƚŚƐ ϱϯDŽŶƚŚƐ 
Products from low income countries ϮϯDŽŶƚŚƐ ϮDŽŶƚŚƐ ϱϭDŽŶƚŚƐ 
Products locally produced in Sudan ϭϴDŽŶƚŚƐ ϴDŽŶƚŚƐ ϯϯDŽŶƚŚƐ 
 
According to the results obtained during the sample collection process from the field it 
was noted that: 
ϭ. dŚĞŵĂǆŝŵƵŵƌĞŵĂŝŶŝŶŐƐŚĞůĨůŝĨĞǁĂƐϱϯŵŽŶƚŚƐĨŽƌa product produced in 
ǁ^ŝƚǌĞƌůĂŶĚ͕ĂŶĚƚŚĞŵŝŶŝŵƵŵƌĞŵĂŝŶŝŶŐƉĞƌŝŽĚǁĂƐϮŵŽŶƚŚƐĨŽr Indian and 
Jordanian products; 
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Ϯ. The overall median remaining shelf life of the products in the market at the time 
of ƐĂŵƉůĞĐŽůĞĐƟŽŶǁĂƐϮϭŵŽŶƚŚƐ͖ 
ϯ. ϳϱйŽĨƚŚĞƉƌŽĚƵĐƚƐĐŽůĞĐƚĞĚŚĂǀĞƌĞŵĂŝŶŝŶŐƐŚĞůĨůŝǀĞŵŽƌĞƚŚĂŶϯϯŵŽŶƚŚƐ͖ 
ϰ. /ŶϯďĂƚĐŚĞƐƚŚĞŵĂŶƵĨĂĐƚƵƌŝŶŐĚĂƚĞǁĂƐŶ͛ƚŝŵƉƌŝŶƚĞĚŽŶƚŚĞŝŶƚĞƌŶĂl packages 
ϮďĂƚĐŚĞƐǁĞƌĞůŽĐĂůǇƉƌŽĚƵĐĞĚ͖ 
ϱ. Imported products generally have longer remaining shelf life than that local 
products; 
ϲ. The tablet dosage forms characterized by remaining shelf life longer than other 
dosage forms  
 
v  Source of origin: 
Product type йŶсϰϲ 
Products from high income countries ϯϵй 
Products from low income countries Ϯϰй 
Products locally produced in Sudan ϯϳй 
 
v  Registered shelf life: 
Based on data obtained from “NMPB”, it haƐďĞĞŶĨŽƵŶĚƚŚĂƚ;ϭϲйͿŽĨbatches collected 
from the market weren’t complied with the registered period in “NMPB”. The causes of 
this observation weren’t clear. As example, some products were subjected to self life 
expansion, so, ϮďĂƚĐŚĞƐĨƌŽŵƚŚĞƐĂŵĞƉƌŽĚƵĐƚǁŝƚŚĚŝīĞƌĞŶƚƐŚĞůĨůŝǀĞƐĐŽƵůĚďĞ
available at the same time in the market. Still this indicates some degree of weaknesses in 
the ability of the inspection system to detect such kind of practices.  
v  Shelf life expansion: 
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ŵŽŶŐƚŚĞƉƌŽĚƵĐƚƐĐŽůĞĐƚĞĚĨƌŽŵƚŚĞĮĞůĚ͖ϯƉƌŽĚƵĐƚƐǁĞƌĞƐƵďũĞĐƚĞĚƚŽĞǆƉĂŶƐŝŽŶŽĨ
the shelf life periods as requested from “NMPB”. Most of these products were 
manufactured in high income countries in its origin. 
v  Registration number: 
FBPP as requirements was asking the manufactures to print the registration number 
(product specific) on the outer package. Upon analysis, and on averaŐĞ͕ϰϲй samples 
were distributed with pre-printed registration number. 
Product with pre-printed registration number % 
Products from high income countries ϱϬй 
Products from low income countries ϳϯй 
Products locally produced in Sudan Ϯϰй 
 
v  Pre-marketing test: 
The availability of reports regarding this part and according to “NMPB” was very limited 
for products targeted in this study. Especially the products subjected to pre-marketing 
test before its distribution in the market as pre-requisite for the first batch. 
v  Post-marketing test: 
According to “NMPB ͟ƌĞƉŽƌƚƐƌĞŐĂƌĚŝŶŐƚŚĞƉƌŽĚƵĐƚƐƚĂƌŐĞƚĞĚŝŶƚŚŝƐƐƚƵĚǇ͖;ϮϮйͿŽĨƚŚĞ
products under this study were subjected to post-marketing test considering different 
product batches. Among these it was reported that in (ϵϰйͿŽĨƉƌŽĚƵĐƚƐƌĞƐƵůƚƐŽďƚĂŝŶĞĚ
were satisfying the “NQCL” ;EDW͕ϮϬϬϴͿ. 
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v  Manufacturers storage conditions: 
Each sample collected from the field was evaluated in terms of storage conditions 
specified in its outer package collected using the following evaluation criteria: 
ϭ. Reach of children; 
Ϯ. Temperature (degree or range); 
ϯ. Humidity (dry... etc). 
ϰ. Light (protection). 
Although in some cases these criteria were not applied for some products, still the 
indication of each specification for this issue is important. 
Storage Conditions % of products 
Reach of Children ϲϬ͘ϵй 
Temperature  ϲϳ͘ϰй 
Humidity  ϯϳ͘Ϭй 
Light ϯϮ͘ϵй 
 
v  Brief physical description: 
This part of the evaluation was based on the general comments regarding the physical 
status of the products collected before it was stored in the laboratory to be subjected for 
official analysis (physical and chemical). /ŶŐĞŶĞƌĂů;ϰйͿŽĨƚŚĞƐĂŵƉůĞƐĐŽůĞĐƚĞĚŚĂǀĞ
clear physical problems, this was varied from one product to another and all of the 
problems were identified in the solid forms. 
v  Laboratory storage period: 
Most of the samples were stored in the laboratory between the collection and the 
analysis. The storage was done based on the manufacturers constructions regarding the 
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conditions required. This was considered so as to minimize that as possible confounding 
factor of the results. This was based on the type of generic products as follows: 
 
Generics No of days 
Ciprofloxacin ϯϲ 
Amoxicillin ϯϯ 
Paracetamol ϱ 
Metronidazole ϭϯ 
Glibenclamide ϯϮ 
Mefenamic Acid ϭϭ 
Chlorphenarmine  ϭϮ 
Aspirin ϭϯ 
Ceftriaxone ϯϳ 
Diclofenac ϯϱ 
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Chemical analysis of selected medicines 
 
After the completion of medicines selection process and sample collection, the medicines 
collected was subjected to different physiochemical tests regarding to evaluate its 
compliance with quality requirements and specifications according to pharmacopeia. The 
analysis done in collaborative manner between the study team, Faculty of Pharmacy – 
University of Khartoum and National Quality Control Laboratory - Federal Board of 
Pharmacy and Poisons.  This study benefit also from such collaboration, because there is 
different capacity in each laboratory and this provided the opportunity to conduct 
different quality control tests in both organizations. This was reflected on the quality of 
the data obtained and the coverage of all targeted tests. 
The study team developed the analysis plan based on the available capacity in each 
laboratory, this result in the following: 
Generics Dosage Form Assay Laboratory 
Ciprofloxacin Tablet LC National Lab 
Glibenclamide Tablet LC National Lab 
Amoxicillin Capsule LC National Lab 
Diclofenac Tablet LC National Lab 
Ceftriaxone Injection UV University Lab 
Paracetamol Tablet UV University Lab 
Chlorphenarmine  Tablet UV University Lab 
Mefenamic Acid Tablet Titration University Lab 
Aspirin Tablet Titration University Lab 
Metronidazole Tablet Titration University Lab 
Table ϴ: Finally selected generics for chemical analysis 
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Due to the sensitivity of the following results will be presented in blind manner the same 
prospect in which the laboratory analysis was conducted to shield the identity of the 
products and its results. 
Overall & detailed results 
 
The following were the overall results obtained from the assay examination of targeted 
medicines followed by detailed results. 
Generic/Source Local Low income country High income country 
Amoxicillin 
ϭϬϯ͘ϭй ϭϬϬ͘ϭй ϭϬϬ͘Ϯй 
Comply  Comply  Comply  
Aspirin 
ϵϱ͘ϴйΘϵϬ͘ϰй ϵϮ͘ϳй NA 
Comply & not comply Not comply NA 
Ceftriaxone 
NA ϵϵ͘ϭйΘϭϬϯ͘ϴй ϵϵ͘ϴй 
NA Comply & comply Comply 
Chlorphenarmine 
ϵϱ͘ϲй ϵϳ͘ϳй ϵϴ͘ϵй 
Comply  Comply  Comply  
Ciprofloxacin 
ϵϵ͘ϯй ϵϯ͘ϴй ϵϵ͘ϭй 
Comply  Not comply  Comply  
Diclofenac 
ϵϴ͘ϱй ϭϬϮ͘Ϭй ϭϬϰ͘ϳй 
Comply  Comply  Comply  
Glibenclamide 
ϵϱ͘ϯй ϵϳ͘ϴй ϵϴ͘Ϯй 
Comply  Comply  Comply  
Mefenamic Acid 
ϵϵ͘ϰй ϵϲ͘ϭй ϭϬϰ͘ϳй 
Comply  Comply  Comply  
Metronidazole 
ϵϱ͘ϭй ϵϴ͘ϱй ϵϴ͘Ϯй 
Comply  Comply  Comply  
Paracetamol 
ϵϴ͘ϰй ϵϴ͘ϭй ϵϵ͘ϭй 
Comply  Comply  Comply  
Table ϵ: Overall results of chemical analysis 
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Detailed results by generic 
 
Results of Acetylsalicylic Acid 
Serial number ϭ 
Generic name Acetylsalicylic Acid 
Product code 'ϬϮϭϯdϬϭ 
Origin Local product 
Dosage form Tablet 
Concentration ϯϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Damage in outer package 
Leakage No leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Not comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number Ϯ 
Generic name Acetylsalicylic Acid 
Product code 'ϬϮϬϲdϬϯ 
Origin Local 
Dosage form Tablet 
Concentration ϯϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form Status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Not comply with specifications 
 
Serial number ϯ 
Generic name Acetylsalicylic Acid 
Product code 'ϬϮϭϳdϬϮ 
Origin Low income country 
Dosage form Tablet 
Concentration ϭϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form Status Satisfactory 
Packaging material status Damage in outer package 
Leakage No leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Not comply with specifications 
Chemical analysis Not comply with specifications 
 
General comments: 
Generic ƐƉŝƌŝŶϯϬϬͬϭϬϬŵŐƚĂď 
- Doctors and pharmacists comparably have fewer concerns about its efficacy and 
quality comparing to other generics; 
- Other studies indicated no significance instability problems if the storage conditions 
were adequate, however, upon poor conditions possible loss of chemical nature 
could be occurred ;EĂǌĞƌĂůŝΘ,ŽŐĞƌǌĞŝů͕ϭϵϵϴͿ; 
- Considerable difference between manufacturers in terms of manufacturing 
specifications; 
- Few trade options available in the market, diminutive shifting decisions 
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Results of Amoxicillin Trihydrate: 
Serial number ϰ 
Generic name Amoxicillin Trihydrate 
Product code 'ϬϭϬϯdϬϭ 
Origin Local 
Dosage form Capsule 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϮ͘ϱƚŽϭϭϬ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϱ 
Generic name Amoxicillin Trihydrate 
Product code 'ϬϭϭϭdϬϮ 
Origin Low income country 
Dosage form Capsule 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits for contents ϵϮ͘ϱƚŽϭϭϬ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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C. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϲ 
Generic name Amoxicillin Trihydrate 
Product code 'ϬϭϮϭdϬϯ 
Origin High income country 
Dosage form Capsule 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits for contents ϵϮ͘ϱƚŽϭϭϬ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic ŵŽǆŝĐŝůŝŶϮϱϬŵŐĐĂƉ 
- The second generic that health professionals widely complain its effectiveness; 
- Top generic that health professionals shift the patient from it to another antibiotic; 
- Questions regarding possibility of developing microbial resistance to this generic in 
Sudan due to wide misuse; 
- Other studies indicate no significance instability problems (Nazerali & Hogerzeil, 
ϭϵϵϴͿ; 
- Among highly consumed products in the market; 
- Expiry remaining period are satisfactory in general; 
- Significant physical appearance problems for most of the trade products 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  PageͳͶʹ 
Results of Ceftriaxone sodium: 
Serial number ϳ 
Generic name Ceftriaxone sodium 
Product code 'ϬϯϭϬdϬϮ 
Origin Low income country 
Dosage form Powder for injection 
Concentration ϭŐŵ 
Reference pharmacopeia USP 
Limits of contents ϵϮ͘ϬƚŽϭϬϴ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No Leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϴ 
Generic name Ceftriaxone sodium 
Product code 'ϬϯϭϰdϬϯ 
Origin High income country 
Dosage form Powder for injection 
Concentration ϭŐŵ 
Reference pharmacopeia USP 
Limits of contents ϵϮ͘ϬƚŽϭϬϴ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  PageͳͶ͵ 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϵ 
Generic name Ceftriaxone sodium 
Product code 'ϬϯϮϬdϬϭ 
Origin High income country 
Dosage form Powder for injection 
Concentration ϭŐŵ 
Reference pharmacopeia USP 
Limits of contents ϵϮ͘ϬƚŽϭϬϴ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic ĞŌƌŝĂǆŽŶĞƐŽĚŝƵŵϭŐŝŶũ 
- Doctors in particular were more complaining about its quality and efficacy; 
- The mostly likely generics that doctors take decisions to shift the patients’ treatment 
either shift in trade products or to another different generic; 
- This generic wasn’t subjected to post marketing analysis in Sudan; 
- No local pharmaceutical manufacturers; 
- Most of the products available in the market have comparably less remaining shelf 
life than other generics; 
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Results of Chlorphenarmine Maleate: 
Serial number ϭϬ 
Generic name Chlorphenarmine Maleate 
Product code 'ϬϰϭϯdϬϮ 
Origin Local 
Dosage form Tablet 
Concentration ϰŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϮ͘ϱƚŽϭϬϳ͘ϱйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϭϭ 
Generic name Chlorphenarmine Maleate 
Product code 'ϬϰϭϱdϬϭ 
Origin Low income country 
Dosage form Tablet 
Concentration ϰŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϮ͘ϱƚŽϭϬϳ͘ϱйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form Status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϭϮ 
Generic name Chlorphenarmine Maleate 
Product code 'ϬϰϬϰdϬϮ 
Origin High income country 
Dosage form Tablet 
Concentration ϰŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϮ͘ϱƚŽϭϬϳ͘ϱйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and Comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic ŚůŽƌƉŚĞŶĂƌŵŝŶĞDĂůĞĂƚĞϰŵŐƚĂď 
- No direct health professionals’ complaints from this generic regarding the efficacy, 
nevertheless considerable physical problem cases have been recorded; 
- Significant number of products has been recalled from the field in the last few years; 
- Most of the products characterized by long remaining shelf life 
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Results of Ciprofloxacin Hydrochloride: 
Serial number ϭϯ 
Generic name Ciprofloxacin Hydrochloride 
Product code 'ϬϱϬϯdϬϯ 
Origin Local 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘Ϭй of the stated amount 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϭϰ 
Generic name Ciprofloxacin Hydrochloride 
Product code 'ϬϱϭϵdϬϮ 
Origin Low income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia USP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞstated amount 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
 
Serial number ϭϱ 
Generic name Ciprofloxacin Hydrochloride 
Product code 'ϬϱϮϬdϬϭ 
Origin High income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia USP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚ amount 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and Comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic ŝƉƌŽŇŽǆĂĐŝŶϱϬϬŵŐƚĂď 
- The leading generic that health professionals have comments and complaints about 
its quality and efficacy; 
- The second generic on which most of the shifting process were taken place among 
the decisions of doctors and pharmacists; 
- Recent studies indicated the possibility of developing microbial resistance for some 
strains of susceptible bacteria ;^ĞǇŽƵŵΘůƵŵ͕ϮϬϬϰͿ, ;WĂůŵĞƌΘŽƚŚĞƌƐ͕ϭϵϵϱͿ; 
- No physical problems usually associated with the products available in the market; 
- Some products have been withdrawn from the market based on post marketing 
analysis results 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  PageͳͶͺ 
Results of Diclofenac Sodium: 
Serial number ϭϲ 
Generic name Diclofenac Sodium 
Product code 'ϬϲϬϲdϬϭ 
Origin Local 
Dosage form Tablet 
Concentration ϮϱŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϭϳ 
Generic name Diclofenac Sodium 
Product code 'ϬϲϭϰdϬϯ 
Origin High income country 
Dosage form Tablet 
Concentration ϮϱŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form Status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
 
Serial number ϭϴ 
Generic name Diclofenac Sodium 
Product code 'ϬϲϬϱdϬϮ 
Origin High income country 
Dosage form Tablet 
Concentration ϮϱŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of Colour Satisfactory 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic ŝĐůŽĨĞŶĂĐ^ŽĚŝƵŵϮϱŵŐƚĂď 
- No serious concerns have been verified during this study regarding the quality of the 
available products in the market; 
- Considerable number of pharmacists shifted their patients from one product to 
another; 
- In products available in the market there is no clear physical problems documented 
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Results of Glibenclamide: 
Serial number ϭϵ 
Generic name Glibenclamide 
Product code 'ϬϳϬϲdϬϭ 
Origin Local 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents Glibenclamide 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number ϮϬ 
Generic name Glibenclamide 
Product code 'ϬϳϬϴdϬϯ 
Origin Low income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents Glibenclamide 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
 
Serial number Ϯϭ 
Generic name Glibenclamide 
Product code 'ϬϳϬϵdϬϮ 
Origin High income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents Glibenclamide 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of colour Satisfactory 
 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic 'ůŝďĞŶĐůĂŵŝĚĞϱŵŐƚĂď 
- Among highly argued chronically used products regarding the effectiveness of some 
products available in the market; 
- Significant cases have been shifted from one product to another as a 
recommendation from pharmacists and doctors as well; 
- No physical problems were defined in the market regarding the registered products 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  Pageͳͷʹ 
Results of Mefenamic Acid: 
Serial number ϮϮ 
Generic name Mefenamic Acid 
Product code 'ϬϴϬϲdϬϭ 
Origin Local 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number Ϯϯ 
Generic name Mefenamic Acid 
Product code 'ϬϴϬϴdϬϯ 
Origin Low income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number Ϯϰ 
Generic name Mefenamic Acid 
Product code 'ϬϴϬϵdϬϮ 
Origin High income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic DĞĨĞŶĂŵŝĐĐŝĚϱϬϬŵŐƚĂď 
- Moderate sort of problems have been associated with the efficacy of registered 
products in Sudan; 
- In some of the available products in the market, physical changes have been 
experienced by some pharmacists; 
- ϮďĂƚĐŚĞƐĨƌŽŵĚŝīĞƌĞŶƚŵĂŶƵĨĂĐƚƵƌĞƌƐ͕ĂǀĂŝůĂďůĞŝŶƚŚĞŵĂƌŬĞƚ͕ǁĞƌĞĚĞƚĞĐƚĞĚƚŚĂƚ
lack the identification of the expiry date  
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Results of Metronidazole: 
Serial number Ϯϱ 
Generic name Metronidazole 
Product code 'ϬϵϮϮdϬϯ 
Origin Local 
Dosage form Tablet 
Concentration ϮϱϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number Ϯϲ 
Generic name Metronidazole 
Product code 'ϬϵϭϲdϬϭ 
Origin High income country 
Dosage form Tablet 
Concentration ϮϱϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number Ϯϳ 
Generic name Metronidazole 
Product code 'ϬϵϭϲdϬϭ 
Origin High income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic MetronidazoůĞϮϱϬŵŐƚĂď 
- There were no major complaints about the efficacy of most available products in the 
market, however, there were significant patients complaints regarding the side 
effects of specific product comparing with other products; 
- The packaging material used for some trade products available in the market hinder 
the possibility of observing physical appearance problems 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  Pageͳͷ͸ 
Results of Paracetamol: 
Serial number Ϯϴ 
Generic name Paracetamol 
Product code 'ϭϬϭϮdϬϮ 
Origin Local 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form Status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
Serial number Ϯϵ 
Generic name Paracetamol 
Product code 'ϭϬϬϮdϬϯ 
Origin High income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form Status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
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B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
 
Serial number ϯϬ 
Generic name Paracetamol 
Product code 'ϭϬϬϳdϬϭ 
Origin High income country 
Dosage form Tablet 
Concentration ϱϬϬŵŐ 
Reference pharmacopeia BP 
Limits of contents ϵϱ͘ϬƚŽϭϬϱ͘ϬйŽĨƚŚĞƐƚĂƚĞĚĂŵŽƵŶƚ 
 
A. Physical properties: 
Dosage form Status Satisfactory 
Packaging material status Satisfactory 
Leakage No leakage 
Uniformity of color Satisfactory 
 
 
B. Results and comments: 
Physical properties Comply with specifications 
Chemical analysis Comply with specifications 
 
General comments: 
Generic WĂƌĂĐĞƚĂŵŽůϱϬϬŵŐƚĂď 
- Being OTC product made it difficult to the doctors to judge its efficacy and the 
feedback was mainly obtained from pharmacists; 
- Over the available products in the market, specific products were identified by the 
patients as the “best quality” and the other were “lower in its quality”; 
- Some physical appearance problems have been recorded many times for certain 
locally manufactured product 
- Other similar study in Bangladesh showed comparable results ;^ĂŚĂ͕ϭϵϵϮͿ 
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Summery discussion 
 
The availability of data regarding the quantities of detected substandard medicines in the 
market is essential information ;&ƌĞŵƉŽŶŐ͕ϮϬϬϯͿ. This is particularly important to assess 
the situation in the country regarding the availability as one dimension of medicines 
access model that supported by quality and accessibility for essential medicines (MSH, 
ϮϬϬϭͿ͘ĞƐƉŝƚĞƚŚĂƚƚŚĞƉƌŝǀĂƚĞƐĞĐƚŽƌƉƌŽǀŝĚĞƐϳϬйŽĨŵĞĚŝĐŝŶĞƐŝŶ the market with 
ĂǀĂŝůĂďŝůŝƚǇŽĨŵŽƌĞƚŚĂŶϵϬйĨŽƌŵĞĚŝĐŝŶĞs in retail pharmacies in Sudan ;&DK,͕ϮϬϬϳͿ. 
The outcomes from quality control tests could be considered as important tool to take 
evidence-based decisions regarding the quality at any level of the supply chain (Seiter, 
ϮϬϬϱͿ. This is especially true when we consider the great revolution in medicines 
production capacity, QC management and the expanded needs for medicines. The QC 
results, including chemical analysis results, should be used only as a tool to improve the 
quality of circulated medicines through the implementation and enforcement of laws and 
regulations ;:ĂǇĂƐƵƌŝǇĂ͕ϭϵϴϱͿ. Usually the resulting data from QC alone were inadequate 
for establishing direct linkage between the findings of QC analysis and the imposition of 
regulatory sanctions to be applied ;ĚŝƚŽƌŝĂů͕ϭϵϵϳͿ. This should be combined with other 
different factors that lead to better understand the cause-effect relationships and to take 
the right decisions based on that (Nicholson ͕ϮϬϬϱͿ. 
It is noted that many factors usually could affect the quality of available medicines in the 
market ;t,K͕ϮϬϬϳͿ. The possible relationships that should be considered:- 
· Pre-marketing surveillance test results; 
· Acceptability of the remaining shelf-life at time of receipt; 
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· The history of the drug and its agent at NQCL before distribution (satisfaction or 
failure); 
· The quality status at time of collection in accordance to Pharmacopeia; 
· The quality at the end of the shelf-life; 
· Drugs most frequently failed the tests; 
· The lost of potency among the time; 
In addition to all of these factors; another study indicated that there are possible effects 
of the quality of starting materials and raw materials used in manufacturing medicines 
and this issue should be considered when evaluating the quality of medicines especially 
when proved to be substandard ;t,K͕ϮϬϬϯͿ. 
The quality of commercially available drugs varies greatly among countries and the focus 
was on the more expensive brands. Substandard drugs found even among cheaper 
products, because some manufacturers wish to avoid costly quality control and good 
manufacturing practices ;KŶĚĂƌŝ͕ϮϬϬϯͿ. Even in one study in India that comparing two 
products within the same generics it has been found that the cheaper product was better 
in its quality than that of the highest price which was almost doubled ;h^W͕ϮϬϬϰͿ. But we 
should also note that when the prices of medicines are high and price differentials 
between identical products exist there is a greater incentive for the consumer to seek 
medicines outside the normal supply system. Poverty, then, is one of the major factors in 
the production and consumption of substandard products ;ƵŬĞƐΘŽƚŚĞƌ͕ϮϬϬϯͿ. 
Despite that the statistics showed the facts that, even some of large multinational firms 
could produce substandard medicines still there is continuous linkage between generic 
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products or products manufactured by small businesses and low quality medicines. In fact 
well-manufactured generics are of as high quality as well-manufactured branded 
medicines ;,/͕ϮϬϬϯͿ. Recent different two studies in India and Bangladesh, regarding 
the linkage between sources of origin and manufacturing sites capacity, indicated that 
most of the substandard medicines were produced from small sized firms in both 
countries. From the observations in both studies it seems that these manufacturers failed 
frequently to meet the MRA standards in some areas ;h^W͕ϮϬϬϰͿ. 
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The products 
 
Glibenclamide products included in this part are two products from part one & two of this 
ƌĞƐĞĂƌĐŚŝŶǁŚŝĐŚǁĂƐƐĞůĞĐƚĞĚďĂƐĞĚŽŶƚŚĞĂƉƉƌŽĂĐŚĚĞƐĐƌŝďĞĚƵŶĚĞƌĐŚĂƉƚĞƌϮ
(methods and materials, please refer to page ϲϳ). These are one product under the code 
'ϬϳϬϵdϬϮǁŚŝĐŚŝƐƚŚĞŽƌŝŐŝŶĂƚŽƌƉƌŽĚƵĐƚƐĂŶĚƚŚĞŽƚŚĞƌŽŶŝƐůŽĐĂůǇŵĂŶƵĨĂĐƚƵƌĞĚ
ƉƌŽĚƵĐƚƵŶĚĞƌƚŚĞĐŽĚĞ'ϬϳϬϲdϬϭ͘ 
The volunteers 
 
dǁĞůǀĞŚĞĂůƚŚǇǀŽůƵŶƚĞĞƌƐ͖ϲŵĞŶĂŶĚϲǁŽŵĞŶ͕ĂŐĞĚďĞƚǁĞĞŶϮϬǇĞĂƌƐĂŶĚϯϲǇĞĂƌƐ͕
and with a range of ǁĞŝŐŚƚďĞƚǁĞĞŶϲϱŬŐĂŶĚϵϰŬŐ͖ǁĞƌĞĞŶƌŽůĞĚƚŽƉĂƌƟĐŝƉĂƚĞŝŶƚŚŝƐ
study. 
Pharmacokinetic analyses 
 
The following parameters will be presented and discussed below: 
ϭ. The maximum plasma concentration (Cmax) as indicator for absorption rate; 
Ϯ. The time to reach the maximum plasma concentration (Tmax) as indictor for the 
elimination rate; 
ϯ. The area under of curve (AUC) as it described the total amount of drugs 
available in plasma after the administration of the dose; 
ϰ. The elimination half life time (TϭͬϮ) as indicator for the elimination; 
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Area Under the Curve (AUC) 
 
The area under the curve (AUCϬ-t) was calculated using the following formula: 
AUCϬ-t = σ ൫࡯࢏ା࡯࢏ି૚૛ ൯ሺ࢚࢏െ࢚࢏െ૚ሻ
࢚
࢏ୀ૚  
The pharmacokinetic parameters were calculated as indicted before. Based on these 
parameters the elimination rate constant (KE) was obtained using the following formula. 
(KEͿсϬ͘ϲϵϯͬdϭͬϮ 
 
Based on the results obtained: 
(KE) Average slope for test product Ϭ͘ϭϬϰ 
(KE) Average slope for reference product Ϭ͘ϭϵϰ 
 
Accordingly the elimination half life (TϭͬϮ) in hours for each product: 
TϭͬϮof test product ϲ͘ϲϲϯ 
TϭͬϮof reference product ϯ͘ϱϳϮ 
 
The area under the curve to the last measurable concentration (AUCϬ-t) was estimated by 
the linear trapezoidal rule. The area under the curve extrapolated to infinity (AUCϬ-8 ) was 
calculated by equation below. 
 (AUCϬ-8 ) = AUCϬ-t + Ct / kE 
* Where Ct is the last measured concentration 
The peak plasma concentration (Cmax) and equivalent time to peak concentration (tmax) 
were determined directly using the data obtained from individual drug serum 
concentration-time profiles. 
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Statistical analyses 
EŽƚĞ͗ƚŚĞƐƚĂƟƐƟĐĂůĂŶĂůǇƐŝƐŽĨƚŚŝƐĚĂƚĂǁĂƐĚŽŶĞƵƐŝŶŐ^W^ ^ϭϲ 
After obtaining AUCϬ-t, AUCϬ-8 , Cmax and Tmax from the data, these parameters were 
further analyzed statistically as primary variables. This was basically carried out using the 
variance analysis for cross-over design. The data from this processing was used to 
evaluate the differences due to treatment, periods, sequences, and subjects. The AUC 
and Cmax values were logarithmically transformed prior to the analysis. Paired samples 
analysis was used to compare the results of Tmax of the test and the reference products. 
dŚĞƌĞƐƵůƚƐǁĞƌĞĐŽŶƐŝĚĞƌĞĚƐƚĂƟƐƟĐĂůǇƐŝŐŶŝĮĐĂŶƚĨŽƌĂWǀĂůƵĞŽĨůĞƐƐƚŚĂŶϬ͘Ϭϱ͘dŚĞ
ϵϬйĐŽŶĮĚĞŶĐĞŝŶƚĞƌǀĂůƐof parameters under testing were also estimated. 
The inter-subject variation of AUCϬ-t, AUCϬ-8 , and Cmax parameters was also obtained by 
calculating the coefficient of variation (CV).  
The results indicated that the mean “C max” of the test product is Ϯ͘ϱϬϴ compared to 
Ϯ͘ϱϮϲ the reference product. On other hand the “AUCϬ- 8 ” of test product is ϯ͘ϱϭϭ 
ĐŽŵƉĂƌĞĚƚŽϰ.ϱϳϮƚŚĞƌĞĨĞƌĞŶĐĞƉƌŽĚƵĐƚ͘ 
Parameters 
Test product 
Mean ± SD 
Reference product 
Mean ± SD 
Intra- subject 
CV% 
C max - (µ g/ml) Ϯ͘ϱϬϴ ± Ϭ͘ϭϬϰ ϯ͘ϱϮϲ ± Ϭ͘ϭϭϴ Ϯ͘ϴй 
T max - (hrs) ϭ͘ϲϯϵцϭ͘ϬϮϰ Ϯ͘ϭϲϳцϭ͘Ϯϳϱ ϲϯ͘ϵй 
AUCϬ-ϲ- (µ g.h/ml) Ϭ͘ϰϵϬ± Ϭ͘ϭϴϴ Ϭ͘ϲϯϴ ± Ϭ͘ϮϱϮ ϱϱ͘ϳй 
AUCϬ- 8  - (µ g.h/ml) ϯ͘ϱϭϭ ± Ϭ͘ϭϱϯ ϰ.ϱϳϮ± Ϭ͘ϮϬϮ Ϯ͘ϰй 
Table ϭϬ: Main pharmacokinetic parameters for test and reference products 
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The table below show the time interval for each of the test and reference products to 
reach the maximum concentration, the numbers showed the frequency of the volunteers. 
Time interval (h) Test Reference 
Ϭ͕Ϭ- Ϭ͕ϵϵ ϯ Ϯ 
ϭ͕Ϭ- ϭ͕ϵϵ ϭ ϭ 
Ϯ͕Ϭ- Ϯ͕ϵϵ Ϯ ϰ 
ϯ͕Ϭ- ϯ͕ϵϵ ϯ ϯ 
ϰ͘Ϭ– ϰ͘ϵϵ ϯ Ϯ 
 
Figure ϭϭƌĞƉƌĞƐĞŶƚƐ the mean serum Glibenclamide levels versus time profile following 
ŝŶŐĞƐƟŽŶŽĨĂƐŝŶŐůĞĚŽƐĞŽĨƚŚĞƚĞƐƚĂŶĚƌĞĨĞƌĞŶĐĞƚĂďůĞƚƉƌŽĚƵĐƚƐƚŽϭϮŚĞĂůƚŚǇǀŽůƵŶƚĞĞƌƐ
 
Figure ϭϭ: Mean serum Glibenclamide levels versus time profile 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  Pageͳ͸ͷ 
The AUCϬ-ϲ͕hϬ-8 , Cmax, and Tmax, for each pair of products (test vs. reference) in this 
study were statistically different (PфϬ͘ϬϱͿ͕ƐƵŐŐĞƐƟŶŐƚŚĂƚƚŚĞƐĞƌƵŵƉƌŽĮůĞƐŐĞŶĞƌĂƚĞĚ
by reference tablets were relatively higher than those produced by the test product 
(Table ϭϬ). 
DŽƌĞŽǀĞƌ͕ϵϬйĐŽŶĮĚĞŶĐĞŝŶƚĞƌǀĂůƐŽĨƚŚĞhϬ-ϲ, AUCϬ-8 , and Cmax of the two 
formulations in the study were not found to be within the relative bioavailability 
acceptable rangĞŽĨϴϬ-ϭϮϱй;dĂďůĞϭϬ). Wilcoxon signed rank test showed distinct 
difference between the untransformed values of Tmax of the test compared to the 
reference products. The intra-subject CV for AUCϬ-ϲ, AUCϬ-8 , and Cmax appeared to be 
varied and relatively large for some AUCϬ-ϲ and Tmax.  
With a difference of about Ϯϰй between the test product and the reference product, the 
results indicate that the test product is not bioequivalent to reference product. The 
results indicated that, the probability that the true ratios with respect to Cmax and AUC 
are not acceptable in bio-ĞƋƵŝǀĂůĞŶĐĞƌĂŶŐĞ;ǁŚŝĐŚŝƐϴϬй- ϭϮϬйͿ͘/ƚŝƐƚŚĞƌĞĨŽƌĞĐůĞĂƌ
that test product cannot be considered bio-equivalent to the reference product with 
respect to the extent of absorption as measured by AUC. The fact that the two products 
also differed with respect to Cmax which is probably due to differences in the extent of 
absorption rather than the difference in the rate of absorption. 
No hazardous side-effects or adverse reactions were noticed during the observation of 
the volunteers; however, several of them experienced unpleasant symptoms relevant to 
hypoglycemia ͘dŚŝƐǁĂƐŶŽƟĐĞĚŝŶϮǀŽůƵŶƚĞĞƌƐĂŌĞƌƚŚĞƚĞƐƚƉƌŽĚƵĐƚĂŶĚŝŶϯǀŽůƵŶƚĞĞƌƐ
after the reference product. 
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The figure below showed the serum glucose level versus time for test and reference 
products. 
 
Figure ϭϮ: Serum glucose level for test and reference products 
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Summery discussion 
 
In part one of this research and according to the results obtained from both data 
collection process and laboratory analysis, it was clear there are other reasons that 
contributed to ineffectiveness problems associated with specific Glibenclamide product in 
the market. This was reported as a problem in controlling blood glucose level among 
patients using this product. Conceptually, any dosage form should contain the amount of 
the drug equal to the dose necessary for clinical effectiveness. Along with that, the 
dosage form also should have the ability to deliver this amount into the body in order to 
ensure the achievement of the desire effects. For instance, the fulfilment of 
Glibenclamide formulations in its chemical contents based on the requirements of 
standard pharmacopeia is not a grantee for the effectiveness of Glibenclamide in 
controlling blood glucose. Glibenclamide is an example of drugs with unique 
characteristics regarding its high-quality formulations ;ŽƉƉĂĐŬΘŽƚŚĞƌƐ͕ϭϵϵϬͿ. Some of 
these specifications need to be considered carefully when describing the product as of 
quality product, specifically talking about bioavailability of non-micronized formulations.  
Glibenclamide is commonly used as a treatment of choice for type II diabetes mellitus. 
Using Glibenclamide in controlling blood glucose level known to be effective and patients 
using Glibenclamide products usually achieve satisfactory blood glucose level. However, 
currently there are ϭϲĚŝīĞƌĞŶƚ pharmaceutical formulations authorized and available in 
Sudan and from different sources and very limited information about their bioavailability 
is known ;EDW͕ϮϬϭϬͿ. Due to lack of information about the interchangeability of these 
products and lack of programs to inform and educate the patients; all of these highlight 
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the concerns about the effectiveness of these products in managing the disease in more 
ƚŚĂŶ;ϱϬ͕ŽŽŽͿĞƐƟŵĂƚĞĚĐĂƐĞƐŽĨĚŝĂďĞƚĞƐŵĞůŝƚƵƐ;ƚǇƉĞ/Ϳ ;&DK,͕ϮϬϬϴͿ. On the other 
hand, Glibenclamide is example of medicines that chronically used; in which the feedback 
from the patients and their doctors is highly important in order to evaluate the quality 
and therapeutic outcomes of the available products in the market.  
As stated by Meredith PA ;DĞƌĞĚŝƚŚW͘͕ϭϵϵϲͿ: “For economic reasons, the use of generic 
substitution is increasingly being supported by health authorities, ......., many developing 
countries do not have the resources or expertise to carry out appropriate quality control 
resulting in widespread distribution of substandard drugs, ........, a number of reports, 
largely anecdotal, of treatment failure or increased adverse events after switching brands 
have cast some doubts upon whether bioequivalence testing is sufficient in all cases. 
These reports have covered cardiovascular, respiratory, hormonal, psychotropic, 
anticonvulsant, anti-infective and anti-inflammatory drugs, ........, until such time as 
means can be provided-first, to enforce internationally accepted production standards, 
and second, to permit uniform testing of therapeutic agents-the safest clinical choice, 
particularly in countries where registration requirements and quality control are minimal, 
must remain the branded product”. On the other hand, Tschabitscher D and his 
colleagues urged: “Since the introduction of generic drugs to the pharmaceutical market a 
sometimes emotional debate exists whether they are well-investigated and of high 
quality. There is some uncertainty about [whether evidence of bioequivalence is enough to 
guarantee efficacy and safety of generic drugs]. Some physicians ask the question if 
competent authorities are able to ascertain that the pharmaceutical quality of generics is 
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acceptable. Doctors and patients sometimes are ill at ease about the interchangeability of 
innovator and generic products......, the importance of bioequivalence studies is increasing 
also due to the large growth of the production and consumption of generic products....., 
the registration of generic products does not demand complicated and expensive clinical 
study contrary to original product. The comparison of the original and the generic product 
via bioequivalence study is suggested as sufficient ;dƐĐŚĂďŝƚƐĐŚĞƌΘŽƚŚĞƌƐ͕ϮϬϬϴͿ 
According to the results obtained both from the survey and from the laboratory analysis 
in this research; the risks associated with weak formulations of Glibenclamide products is 
the major cause behind the complaints reported about this drug. These observations and 
feedback about the specific locally manufactured product support the complaints 
received about the problem. It also supports the hypothesis behind the insufficiency of 
chemical analysis alone to verify the quality as it was shown in this bioequivalence study. 
Although, measuring the quality of pharmaceutical products was changed markedly in the 
last decade, nevertheless, chemical content of pharmaceutical products alone is no 
longer the most important indicator to measure the quality of some generics. As 
evidences showed, other important indicators that should be considered when we 
evaluate the quality of these drugs. The combined interpretation of QC results with data 
from clinical trials and feedback about therapeutic outcomes, for any drug, become highly 
important. This is particularly significant in order to include or exclude any potential risk 
factors that contribute to treatment failure or poor clinical outcomes ;t,K͕ϭϵϵϴͿ. 
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Microbiological sensitivity testing of Amoxicillin 
 
Sample characteristics 
 
The total samples collected for this study ǁĞƌĞϭϬϮ ƐƉĞĐŝŵĞŶƐĨƌŽŵϭϬϬƉĂƟĞŶƚƐǁŝƚŚ
ŵĞĚŝĂŶĂŐĞŽĨϯϰǇĞĂƌƐ;ŵŝŶŝŵƵŵof ϲǇĞĂƌƐĂŶĚŵĂǆŝŵƵŵŽĨϲϱǇĞĂƌƐͿ͘ 
% of patients % (± SD) Notes 
% of patients using Amoxicillin as first 
treatment for the current symptoms  
ϲϰ͘ϯй;цϮ͘ϲͿ 
- 
% of patients used 
other drug before 
Amoxicillin 
used other beta-
lactam antibiotics  
ϰϰ͘ϱй;цϯ͘ϮͿ ϯϲƉĂƟĞŶƚƐƵƐĞĚŽƚŚĞƌ
drug before the 
Amoxicillin 
Used other antibiotics ϱϲ͘ϭй;цϯ͘ϬͿ 
 
KĨƚŚĞϭϬϮ cases the following table showed the distribution of the cases according to the 
reason behind using the Amoxicillin: 
Category of Patients % (± SD) 
Patients took Amoxicillin based on doctor’s prescription ϭϴ.ϳ ;цϮ͘ϭͿ 
Patients take Amoxicillin based on recommendation of the pharmacist ϯϮ͘Ϯ ;цϭ͘ϵͿ 
Amoxicillin taken as requested by the patients themselves ϰϵ͘ϭ ;цϭ͘ϴͿ 
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Figure ϭϯ: Classification of patients using Amoxicillin products 
 
Follow-up of the patients 
 
ϱĚĂǇƐĂŌĞƌĞĂĐŚƉĂƟĞŶƚƌĞĐĞŝǀĞĚŚŝƐ/her medication (appropriate Amoxicillin dosage 
forms including capsules or suspension with different concentrations), the study team 
called back all of the patients those gave their contact numbers in the pharmacies. The 
purpose of these phone calls was to ask the patients about the following: 
· Completion of the treatment fully as prescribed; 
· Feeling about the relief of the symptoms  
Patients’ indicator Results 
Total number of patients with contact ϴϲƉĂƟĞŶƚƐ 
No. Patients responded ϳϵ;ϵϭ͘ϵйͿ 
No. Patients reported completion of the treatment  ϱϴ;ϵϯ͘ϰйͿ 
% of patients feeling about 
the relief of the symptoms  
Complete relief ϮϮ͘ϳй;цϮ͘ϭͿ 
Partial relief ϰϲ͘ϵй;цϮ͘ϲͿ 
No relief ϯϬ͘ϰй;цϭ͘ϴͿ 
 
Based on 
prescription
ϭϵ%
Pharmacist 
recommend 
the drug
ϯϮ%
Patients 
themselves 
request the 
drug
ϰϵ%
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Microbiological sensitivity 
 
For the purpose of this study, no typology identification was carried out for the isolates 
under testing. Rather the study team reported the presence or absence of microorganism 
growth before adding the Amoxicillin disks. In addition to that, the number of isolates 
with clear growth inhibition after the insertion of antibiotic disk was also reported. This 
data was linked to the demographic data above. 
Isolates % Notes 
% of isolates with clear growth on agar 
media before adding Amoxicillin disk 
ϳϴ.ϰ% 
;цϮ͘ϭͿ 
KŶϮϮƉůĂƚĞƐŶŽŐƌŽǁƚŚǁĂƐ
detected 
% of isolates with clear growth inhibition 
after adding the disk 
ϰϴ͘ϵй 
;цϮ͘ϭͿ 
KŶϰϲƉůĂƚĞƐŶŽĐůĞĂƌŐƌŽǁƚŚ
inhibition was seen 
 
Patients category Total 
Isolates 
Clear Growth 
(%) 
Growth Inhibited 
(%) 
Total patient isolates ϵϰ ϰϴ;ϱϭ͘ϭйͿ ϰϲ;ϰϴ͘ϵйͿ 
Patients using Amoxicillin as first 
treatment 
ϲϰ Ϯϱ;ϯϵ͘ϭйͿ ϯϵ;ϲϬ͘ϵйͿ 
Amoxicillin taken without 
professional advice 
ϰϵ Ϯϲ;ϱϯ͘ϭйͿ Ϯϯ;ϰϲ͘ϵйͿ 
Patients feel complete or partial 
relief 
ϱϱ 
ϯϭ;ϱϲ͘ϰйͿ Ϯϰ;ϰϯ͘ϲйͿ 
Patients feel no relief Ϯϰ Ϯ;ϴ͘ϯйͿ ϮϮ;ϵϭ͘ϳйͿ 
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Figure ϭϰ: Summery of growth inhibition after using Amoxicillin discs 
  
ϰϴ
Ϯϲ
ϯϭ
Ϯϱ
Ϯ
ϰϲ
Ϯϯ
Ϯϰ
ϯϵ
ϮϮ
Total patients' isolates
Amoxicillin taken without professional advice
Patients feel complete or partial relief
Patients using Amoxicillin as first treatment
Patients feel no relief
Chart Title
Isolates with Growth Inhibition (%) Isolates without Growth Inhibition (%)
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Summery discussion 
 
Amoxicillin in Sudan has unique characteristics which make any study about its use and its 
quality is of considerable importance. These characteristics include the following: 
ϭ. ƵƌƌĞŶƚůǇƚŚĞƌĞĂƌĞϳϳƉƌŽĚƵĐƚƐƌĞŐŝƐƚĞƌĞĚŝŶ^ƵĚĂŶďĞƚǁĞĞŶĚŝīĞƌĞŶƚĚŽƐĂŐĞ
forms and concentrations (NMPB, National Medicines and Poisons Board, 
ϮϬϭϬͿ; 
Ϯ. It is the forth generic in terms of quantity (collectively exported and 
manufactured in the country) ĚƵƌŝŶŐƚŚĞƉĞƌŝŽĚϮϬϬϲͬϮϬϬϳ ;&DK,͕ϮϬϬϴͿ; 
ϯ. It was among highly consumed products in the market, especially without 
prescription, which reflects the wide use of this drug in the community (FMOH, 
ϮϬϬϴͿ; 
ϰ. It is a “symbol of antibiotic” in the community and it is culturally considered as 
one of the best accessible anti-infective drugs; 
ϱ. ĂƐĞĚŽŶƚŚĞƌĞƐƵůƚƐŽďƚĂŝŶĞĚĨƌŽŵƉĂƌƚϭ of this research; it was the second 
generic that health professionals widely complain its effectiveness; 
ϲ. ĂƐĞĚŽŶƚŚĞƌĞƐƵůƚƐŽďƚĂŝŶĞĚĨƌŽŵƉĂƌƚϭ of this research; it was the top 
generic that health professionals shift the patient from it to other antibiotics 
On the contrary for the last two points, all assayed products were complying with 
standard specifications in its chemical contents. Based on the findings revealed from the 
primary investigation and analysis of targeted pharmaceutical products (among which 
“three” ŵŽǆŝĐŝůŝŶϱϬϬŵŐĐĂƉƐƵůĞƉƌŽĚƵĐƚƐǁĞƌĞƚĞƐƚĞĚͿ͖ƚŚĞƌĞƐƵůƚƐdidn’t respond to 
concerns reported about Amoxicillin products circulated in the market. Although the 
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products have been tested were chemically sounds but still they were clinically not 
effective (based on feedback of health professionals’ survey). There are valid questions 
regarding the possibility of developing microbial resistance to this generic in Sudan. 
Taking into considerations the microbial resistance in such case is not an exclusive reason 
for therapeutic failure, as bioavailability problems and lack of appropriate 
use/administration may contribute also to these reported failures ;dĂǇůŽƌΘŽƚŚĞƌƐ͕ϭϵϵϱͿ. 
Looking closely to the trend of Amoxicillin use both inside and outside the health system 
in Sudan (prescription based versus OTC treatment), it indicate the extent to which 
Amoxicillin is widely misused. Studies in Europe showed clear association between higher 
consumption of antibiotics and the rate of microbial resistance to it (Stephanie & others, 
ϮϬϬϭͿ. This was especially noticed among the highly consumed antibiotics in the 
community similar to Amoxicillin in case of Sudan ;t,K͕ϮϬϬϵͿ. In Sudan it is generally 
noticed that Amoxicillin is commonly, and mainly, used in both pediatric and adult 
patients for the treatment of upper and lower respiratory tract infections (U/LRTI), this 
usually besides other indications. Many studies confirmed the increasing prevalence of 
Streptococcus pneumoniae among patients with U/LRTI (beside other kinds of 
microorganisms) ;>ĞĞƐŝŬΘŽƚŚĞƌƐ͕ϮϬϬϲͿ. These facts critically raise the question about 
whether Amoxicillin is still an appropriate treatment of these kinds of infections. The 
implications of answering this question have great impact both at macro and micro levels 
in policy making process and at community level as well ;ĞƌĚĞŶΘŽƚŚĞƌƐ͕ϮϬϬϱͿ. 
Currently there is no specific study in Sudan that “linked the usage of Amoxicillin with its 
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quality of effectiveness”; considering the large amount of Amoxicillin products consumed 
over the country. 
In general, scientists agreed that the resistance of bacteria to certain antibiotic(s) is a 
matter of response from the bacteria towards the environmental changes due to the 
existence of the antibiotic “resistance as biological response”. This is valid regardless 
whether or not the antibiotic(s) were effective against the bacteria ;DƵƌƌĂǇ͕ϮϬϬϳͿ. This 
point supports the hypothesis about the possible contribution of microbial resistance 
against Amoxicillin. Upon the wide and extensive use of Amoxicillin in the community, 
there is considerable possibility of emerging resistance to this drug among 
microorganisms that were previously sensitive to it ;ĂůΘŽƚŚĞƌƐ͕ϮϬϬϮͿ. Resistance for 
beta lactam antibiotics (Amoxicillin one of this group) were traditionally being associated 
with the bacteria that producing beta lactamase enzyme, as this leads to deactivation of 
the drug by breaking the beta lactam ring in its structure “the active part of the structure” 
;<ĂƚǌƵŶŐ͕ϮϬϬϭͿ.  Although the introduction of combination product, that include 
Clavulonic Acid beside Amoxicillin, lead to dramatic change in overcoming this problem, 
but still there is a wide use of Amoxicillin alone for treatment of some conditions. In 
comparison, it is clear that the combination mentioned before is more effective than the 
usage of Amoxicillin alone. However, due to some factors including the economic aspects 
and the shape of the market in Sudan still we can observe the wide use of Amoxicillin in 
different kinds of infections (especially in U/LRTI). 
World Health Assembly Resolution in ϭϵϵϴƵƌŐĞĚDĞŵďĞƌ^ƚĂƚĞƐƚŽĚĞǀĞůŽƉŵĞĂƐƵƌĞƐŝŶ
to compact the development of microbial resistance for antimicrobials ;t,K͕ϮϬϬϵͿ. 
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Countries were also encouraged to develop sustainable systems to detect resistant 
pathogens, to monitor volumes and patterns of use of antimicrobials and the impact of 
control measures. For further details, World Health Assembly Resolution in ϮϬϬϱƵƌŐĞĚ
Member States to “ensure the development of a coherent, comprehensive and 
integrated national approach to implementing the strategy for containment of 
antimicrobial resistance” and to “monitor regularly the use of antimicrobial agents and 
the level of antimicrobial resistance in all relevant sectors” ;t,K͕ϮϬϬϵͿ. 
The above data gave clear indicators about the factors that may possibly influence the 
development of bacterial resistance for Amoxicillin products. That is unnecessary be 
linked to antibiotic use for viral respiratory infections as considered among the health 
professionals. In fact misdiagnosis the conditions and its symptoms lead to empirical and 
blind treatment of the case (in case of respiratory infections both viral and bacterial 
agents can cause similar clinical symptoms). Among other factors the extensive use of 
Amoxicillin and other similar products due to many reasons (e.g. patients’ pressure on 
health professional to obtain rapid treatment for their disease) also played important 
role. This was seen clearly in the results obtained from this study. 
Based on the results generated from this study it becomes very obvious the needs to 
develop structured protocol to assess the quality of Amoxicillin and other similar products 
using microbiological assay approach. The step of this assay should be the starting point 
for in-depth analysis that aims to identify the possible causes for the treatment failure in 
patients using Amoxicillin and other similar products.  
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The products 
 
dŚƌĞĞƉƌŽĚƵĐƚƐŽĨĞŌƌŝĂǆŽŶĞƐŽĚŝƵŵ;ϭŐŵƉŽǁĚĞƌĨŽƌŝŶũĞĐƟŽŶͿǁĞƌĞŝŶĐůƵĚĞĚ in this 
study. One of these is the originator’s product which is “Rocephin”, manufactured by Roche - 
Switzerland, and for the purposes of this study it was selected as reference product. The 
other two products were chosen basically in the first part of this research and were 
continued to be the same subject in this part. The details of the products were 
demonstrated in the table. 
Trade Company 
Country of 
origin 
Origin classification 
'ϬϯϮϬdϬϭ ϮϬ Switzerland High income 
'ϬϯϭϬdϬϮ ϭϬ India Low income 
'ϬϯϭϰdϬϯ ϭϰ Jordan Lower-middle-income 
 
Statistical analysis 
 
The range of concentrations of each product was statistically satisfactory to produce wide 
range of plotting points sufficient for producing clear statistical data. The concentrations 
prepared and used in this assay include Ϭ͘ϭϮϱ͕Ϭ͘ϱ͕ϭ͘Ϭ͕ϰ͘Ϭ͕ϭϲ͘ϬĂŶĚϯϮ͘Ϭmg/ml (according 
to MIC of targeted bacteria, please see below). The assay was repeated using three 
concentrations of each antibiotic by triplicates for each microorganism. 
Organism MICϵϬmg/ml 
Streptococcus pneumoniae Ϭ͘ϬϲϬ 
Klebsiella pneumoniae Ϭ͘ϭϮϱ 
Staphylococcus aureus ϰ͘ϬϬϬ 
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For the purpose of this analysis, the linearity and precision of the method used were all 
determined. This was done by plotting the log-transformed concentrations of each product 
against inhibition zone in mm. The data followed the linear statistical model which was 
confirmed by the values of intercept and slope of the best straight line when applied in the 
equation (y = b + mx, b is the y-intercept and m is the slope). The x-ŝŶƚĞƌĐĞƉƚ;ůŽŐϭϬŵŐͬ>Ϳ
ĂŶĚƐůŽƉĞŽĨƚŚĞƌĞŐƌĞƐƐŝŽŶůŝŶĞǁŝƚŚϵϱйĐŽŶĮĚĞŶĐĞŝŶƚĞƌǀĂůƐ;ϵϱй/ͿǁĞƌĞďŽƚŚĐĂůĐƵůĂƚĞĚ
and used for regression approach to analysis of to determine the statistical significance of 
these variables.  
The equivalencies of products under this experiment were concluded by comparing the 
slope and intersect of each product using a symmetrical parallel-line assay. In this analysis, 
and in accordance to the purpose of the study, potency was defined as the slope of the 
linear regression and concentration. In this case and if we assume that the test products and 
the innovator are equivalent, then the products must show a trend of parallel and overlaid 
curve with the cure of the innovator. At the same time, when there are parallel curves but it 
have different intercepts this may indicate the existence of same active ingredient but at 
different concentration above or below that of the innovator product. The relative potency 
for each product to the potency of the innovator was calculated using the distance between 
the innovator line and that of the test product. 
The response values (diameter of inhibition zones) were calculated using the standard 
deviation and slope method and these were stated in term of means +/- the standard 
deviations and with the calculated coefficients of variation. To test the accuracy of the test; 
i.e. its ability to detect the differences in concentration significantly, standard curve was 
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obtained by using different concentrations of Ceftriaxone working standard solution with 
ƉŽƚĞŶĐǇŽĨϵϴ͘ϲйͬ>Ϳ͘dŚŝƐĐƵƌǀĞǁĂƐĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞĐƵƌǀĞŽĨĂůƉƌŽĚƵĐƚƐƵŶĚĞƌĂƐƐĂǇ͘ 
 
Results 
 
The table below shows the potency estimates and other parameters derived from linear 
regression with their statistical comparison of test product versus innovator by Curve Fitting 
Analysis 
Product ƌϮ Intercept ± SD P-value Slope ± SD P-value Potency estimate (%) 
Organism: Staphylococcus aureus 
'ϬϯϮϬdϬϭ Ϭ͘ϵϳ Ϯ͘ϰϬϭ ± Ϭ͘ϮϬϱ Ϭ͘ϬϬϬ Ϭ͘ϬϮϳ Ϭ͘ϬϬϬ ϭϬϬ͘Ϭй 
'ϬϯϭϬdϬϮ Ϭ͘ϵϭ Ϯ͘ϮϮϯ ± Ϭ͘ϭϴϳ Ϭ͘ϬϬϬ Ϭ͘ϬϮϲ Ϭ͘ϬϬϬ ϴϰ͘ϯй 
'ϬϯϭϰdϬϯ Ϭ͘ϳϴ Ϯ͘ϭϳϮ ± Ϭ͘ϭϲϰ Ϭ͘ϬϬϬ Ϭ͘ϬϮϳ Ϭ͘ϬϬϬ ϳϬ͘й 
Organism: Klebsiella pneumoniae  
'ϬϯϮϬdϬϭ Ϭ͘ϵϳ Ϯ͘ϭϵϴ ± Ϭ͘ϭϳϮ Ϭ͘ϬϬϬ Ϭ͘ϬϮϯ Ϭ͘ϬϬϬ ϭϬϬ͘Ϭй 
'ϬϯϭϬdϬϮ Ϭ͘ϵϭ Ϯ͘ϬϮϯ ± Ϭ͘ϭϮϰ Ϭ͘ϬϬϬ Ϭ͘ϬϮϱ Ϭ͘ϬϬϬ ϴϵ͘ϰй 
'ϬϯϭϰdϬϯ Ϭ͘ϳϴ Ϯ͘Ϭϴϵ ± Ϭ͘ϭϲϲ Ϭ͘ϬϬϬ Ϭ͘ϬϮϯ Ϭ͘ϬϬϬ ϳϰ͘ϭй 
Organism: Streptococcus pneumoniae 
'ϬϯϮϬdϬϭ Ϭ͘ϰϭ Ϯ͘ϯϱϭ ± Ϭ͘ϯϭϭ Ϭ͘ϬϬϬ Ϭ͘ϬϮϮ Ϭ͘ϬϬϬ ϭϬϬ͘Ϭй 
'ϬϯϭϬdϬϮ Ϭ͘ϱϮ Ϯ͘ϯϮϱ ± Ϭ͘ϯϮϰ Ϭ͘ϬϬϬ Ϭ͘ϬϮϰ Ϭ͘ϬϬϬ ϱϭ͘ϰй 
'ϬϯϭϰdϬϯ Ϭ͘ϰϴ Ϯ͘ϯϬϱ ± Ϭ͘ϰϱϮ Ϭ͘ϬϬϬ Ϭ͘ϬϮϰ Ϭ͘ϬϬϬ ϰϳ͘ϭй 
Table ϭϭ: Summery of relative potencies and other parameters of Ceftriaxone products 
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Figure ϭϱ: Single dose-response curves for Ceftriaxone products against targeted organisms 
 
Figure ϭϲ: Combined dose-response curves for Ceftriaxone products against targeted organisms 
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Figure ϭϱ and ϭϲ above shows the log concentration-response relationship and the best 
straight line obtained from data from the microbiological assay of the innovator. The cases 
for Klebsiella pneumoniae and Staphylococcus aureus showed a linear relationship between 
ƚŚĞůŽŐĂƌŝƚŚŵŽĨƚŚĞĐŽŶĐĞŶƚƌĂƟŽŶ;ůŽŐϭϬŵŐͬ>ͿĂŶĚƚŚĞĚŝĂŵĞƚĞƌ;ŵŵͿŽĨŝŶŚŝďŝƟŽŶǌŽŶĞƐ
with relatively high coefficients of determination ;ƌϮranging from Ϭ͘ϵϳƚŽϬ͘ϳϴ) and 
statistically ƐŝŐŶŝĮĐĂŶƚŝŶƚĞƌĐĞƉƚĂŶĚƐůŽƉĞ;WфϬ͘ϬϬϭďǇEKsͿ͘On the other hand the 
results for Streptococcus pneumoniae showed different trends. The main observation from 
the row data showed that the response of the organism (growth inhibition) was only 
ĂƉƉĞĂƌĞĚĂƚŚŝŐŚĞƌĐŽŶĐĞŶƚƌĂƟŽŶ͘dŚĂƚǁĂƐĂƉƉĞĂƌĞĚĂƚĂĐŽŶĐĞŶƚƌĂƟŽŶϯϮƟŵĞƐƚŚĞD/ϵϬ
for this organism, i.e. ϮŵŐͬŵů, and this observed for all products tested. This was significant 
findings by its own under the fact that growth inhibition was expected to be at lower 
concentrations than that. 
Excluding the data of Streptococcus pneumoniae and considering the data from other 
organisms, all of the products exhibited a different intercept (P фϬ͘ϬϬϱ), the log 
concentration-response relationship for one of the generics ('ϬϯϮϬdϬϮͿǁĂƐ parallel and 
overlaid to innovator linear curve without significant difference (WфϬ͘ϬϬϱ), while other 
ŐĞŶĞƌŝĐ;'ϬϯϮϬdϬϯͿǁĂƐƉĂƌĂůĞůďƵƚŶŽƚoverlaid to innovator linear curve. These findings 
signifying the facts that generic 'ϬϯϮϬdϬϮĂŶĚŐĞŶĞƌŝĐ'ϬϯϮϬdϬϯhad the same biologic 
activity (potency). On the other hand generic 'ϬϯϮϬdϬϮand generic 'ϬϯϮϬdϬϯshowed 
reůĂƟǀĞĞƐƟŵĂƚĞĚƉŽƚĞŶĐǇŽĨϴϲ͘ϵйĂŶĚϳϮ͘ϯйŽĨthe originator product respectively. All 
these data indicate that generic 'ϬϯϮϬdϬϮŝƐpharmaceutically equivalent to the originator 
product while generic 'ϬϯϮϬdϬϯĚŝĚŶ͛ƚƉƌŽǀĞƚŚĞƐĂŵĞƌĞůĂƟŽŶ.  
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  Pageͳͺ ͵
Summery discussion 
 
The results obtained from the chemical analysis tests, in part two of this study, weren’t 
somewhat enough to answer the complaints from health professionals regarding the quality 
issues around Ceftriaxone powder for injection (especially certain products). Although these 
products complied with reference standard specifications in term of its chemical content 
limits. But considerably there are major concerns about its quality and even the clinical 
outcomes of these products. Ceftriaxone was the most generic in which the patients 
experienced shifting decisions by their doctors, either to shift them to other trade products 
or shift them to other different generics. 
In this regard we have to consider the following facts: 
ϭ. All assayed products complied with reference standard specifications in its 
chemical contents; 
Ϯ. The products are in an injectable form, so we can assume its bioequivalence 
because it isn’t expected to experienced bioavailability problems especially as 
intravenous solution from 
This will urge many questions regarding the reasons lead to these complaints and about that 
specific product. No single reason before this study could be considered as evidence for the 
primary cause of this observation. 
As example, among the circulated Ceftriaxone products available in the market; there was 
specific trade product represent one of the major concerns received during the first part of 
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the study. This product was the main source of complaints and based on the results in this 
part it is clear that it is not equivalent to the other products. 
Equivalency of pharmaceutical products becomes essential and basic criteria for proving the 
quality of any product ;t,K͕ϭϵϵϴͿ. In general there are different methods could be used by 
the regulatory authorities to evaluate this characteristic. This may include the in-vitro/in-vivo 
bioavailability studies and other methods like bioassay. Using bioassay method is not new in 
different pharmaceutical sciences; however, it was used limitedly, and mainly, for 
pharmacokinetic studies ;^ŝŵŽŶΘzŝŶ͕ϭϵϳϬͿ͘>ĂƚĞŝŶϭϵϴϬƐƚŚĞďŝoassay method has drew 
the attention as possible tool for establishing scientific judgment about pharmaceutical 
equivalence of certain categories of products like anti-infectives and vitamins (Humphrey & 
>ŝŐŚƚďŽǁŶ͕ϭϵϵϮͿ. The method could help significantly in obtaining more conclusions about 
the similarity and the differences between products that supposed to contain similar and 
equivalent active ingredient. This is especially true when we consider the fact that any 
pharmaceutical formulation usually contains the active ingredient in addition to other 
substances (e.g. preservatives, impurities, etc). In most of the cases these materials were not 
considered in the assessment of the quality or the equivalency of generic products (Layloff, 
ϭϵϵϳͿ. 
Considering the critical importance of anti-infectives (especially Ceftriaxone) to public health 
in Sudan, it is now become very essential to investigate the assumption about the 
differences in therapeutic equivalent between the products available in the market. The 
equivalence and potency of intravenous/parenteral generic products of Ceftriaxone, away 
from clinical studies, can’t be evaluated by using the conventional physical and chemical 
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methods only. It was proved that, after carrying out this study, using a well designed 
microbiological bioassay this should help the authorities to do such kind of re-evaluations. 
The statistical method adopted here was used for similar study done on other anti-infective 
intravenous preparations ;ƵůƵĂŐĂΘŽƚŚĞƌƐ͕ϮϬϬϵͿ. Previously it was believed that agar-
diffusion assay is less reliable that other chemical methods (e.g. HPLC) because it implies on 
wide sourcing of biological errors. Still this method is statistically suitable to be used in such 
kind of studies (equivalence and potency evaluation studies). The logic behind the statistics 
used in this study (and similar studies in general) was based on the assumption that: if two 
Ceftriaxone products were equivalent to each other, so by obtaining two symmetrical and 
straight parallel lines (plotting of the mean zone size against the logarithmic concentration), 
then the relative potency of test product to the reference product could be derived by 
calculating the distance between the two lines ;ƵůƵĂŐĂΘŽƚŚĞƌƐ͕ϮϬϬϵͿ. In the same time 
these curves in their bioassay should not differ significantly from each other. 
In conclusion, this simple method of analysis is very important for any regulatory authority 
to be considered as routine process. The method showed many advantages as it allows 
rapid, cost-saving, precise, and accurate determination of pharmaceutical equivalence of 
drugs in pharmaceutical dosage-form. This in fact is one of the considerable innovations for 
any quality monitoring system in the country related to injectable products.  
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Rapid observational study about the reconstitution practice of Ceftriaxone 
powder for injection 
 
Effectiveness of Ceftriaxone 
 
The participants see the drug and potent one and still effective as anti-infective. It is now the 
drug of choice for many conditions and doctors start with it in many cases. Part of the 
participants reported their observation about the efficacy of this drug, based on their 
experience early at its introduction phase it was very effective compared to other generics. 
But nowadays its efficacy started to decrease compared to that period. Some patients use 
Ceftriaxone and it they were not getting better so doctors shift them to other drugs. This 
shifting usually affects the psychological acceptance of the patients to their disease and they 
see that as difficult to cure infection. The drug is highly available in the hospital and more 
ƚŚĂŶϳƉƌŽĚƵĐƚƐƵƐƵĂůǇƵƐĞĚǁŝƚŚŝŶƚŚĞŚŽƐƉŝƚĂůĨƌŽŵĚŝīĞƌĞŶƚŽƌŝŐŝŶƐ͘ 
Dissolution practices 
 
There was common agreement between the nurses on how Ceftriaxone been reconstituted. 
All of the nurses only use water for injection or sometimes they use normal saline IV fluids. 
This point was agreed among all of the nurses participated in this session. 
Concurrent administration with Calcium incorporated products 
 
Despite the fact that the group came from different disciplines and with different years of 
experience in both the public and the private sector, the information about the cautions in 
mixing Ceftriaxone with Calcium (and other trivalent cations) is new to the entire group. One 
of the participants report one incident of prescribing both items for one patient, but she 
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couldn’t judge the therapeutic outcomes in this case and whether this affect the patients 
cure or not. Another participant pointed the situations related to renal dysfunction patients 
as they usually need anti-infectives and they also need Calcium Chloride. But this was not a 
concurrent administration in one IV line, rather it is usually separate.  
Effect of origin on practice 
 
Nursing community has preferences regarding which products to use over the other. Certain 
origins were used more frequently than others and this due to repeated experience with 
patients taking that specific products compared with other patient those administering the 
other products. Alternatives to preferred products usually give less therapeutic outcomes in 
the patients. There was other dimension raised during the discussion about the economic 
implications of using different products available in the market. The observation pointed out 
the fact that, the most likely used products is that with medium price compared with other 
ƉƌŽĚƵĐƚƐ͘ϲƉĂƌƟĐŝƉĂŶƚƐƌĞƉŽƌƚƚŚĞŝƌďĞůŝĞĨƐĂďŽƵƚƚŚĞůŝŶŬĂŐĞďĞƚǁĞĞŶƚŚĞƐŽƵƌĐĞƐŽĨŽƌŝŐŝŶ
and the quality of medicines. They stated that they don’t advice the patients to take any 
drugs come for certain countries of origin. 
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Summary about this chapter 
 
In the following chapter an overall discussion about the findings obtained different parts will 
be combined in a way that informed the improvement of quality monitoring systems of 
pharmaceuticals. This becomes essential in management science in which the use of 
evidence in building any interventions becomes the important feature of successful 
organizations. Moving from one strategy to another in any area usually needs supporting 
and scientific justifications for that step. In this specific context the proposed strategy is 
basically focus on how to move from testing a number of products blindly, towards more 
informed testing schemes based on available data. 
In this chapter we will examine the practical approach of this proposed strategy to use a risk 
based post marketing surveillance system of medicines in Sudan. The strategy should inform 
the way by which the authorities should select medicines for regular and regular checks. To 
build such kind of systems this usually demands various kinds of information and data from 
different sources. The diversity of the data is useful under such kind of operational 
researches and its outcomes usually bring practical solutions. The data generated under this 
research indicates useful information and outlines about how to select effective strategy to 
improve the capacity of medicines regulatory authority to detect medicines of low quality. 
With the diversity of data generated from this research, and even though the routine data 
from the system, this should be a very helpful mean to enrich the decision taken at any level.  
We will discuss in more details the shape and dynamics of the pharmaceuticals market in 
Sudan with some description about the current system of Post-marketing surveillance in the 
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country. Based on the findings obtained from this research a practical scheme will be 
proposed to expand the PMS system. The applications of risk assessment/management 
techniques in the areas relevant to quality management of pharmaceuticals will be discussed 
in brief. This will provide the base for building the model for expanding the PMS system in 
Sudan. The usefulness and expected applications of this model will be discussed later in this 
chapter. 
Since the focus of this study was on the system in Sudan, the following details applied on the 
situation in Sudan. However, still the concept is valid to be applied in different settings.  
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ϭ- Pharmaceuticals market in Sudan 
National Medicines and Poisons Board in Sudan is the responsible body for granting market 
authorization of pharmaceuticals as a requirement for all medicines distributed in public and 
private sector in Sudan. BaseĚŽŶƌĞĐĞŶƚƐƚĂƟƐƟĐƐ͕ĞŶĚŽĨϮϬϭϬ͕ there are about ϯϳϬϵ 
registered products in term of trade names that has been authorized [of which ϭϭй were 
locally produces]. Based on the regulations, the registration renewal is required for the 
registered medicines ĞǀĞƌǇϱǇĞĂƌƐ ;EDW͕EĂƟŽŶĂůDĞĚŝĐŝŶĞƐĂŶĚWŽŝƐŽŶƐŽĂƌĚ͕ϮϬϭϬͿ. 
The table below indicates the major indicators of pharmaceutical market in Sudan at the 
macro level ;&DK,͕ϮϬϬϳͿ. 
Table ϭϮ:  The major market indicators 
Indicator  ϮϬϬϳ ϮϬϬϲ ϮϬϬϱ 
All values are in millions US$ 
Total Sudan market value (all sectors) Ϯϴϱ Ϯϯϰ ϮϮϮ 
Total market growth Ϯϭй ϱй ϳй 
Total medicines supply value (paid)  Ϯϭϯ ϭϲϰ ϭϱϮ 
Public sector medicines supply value ϰϵ ϯϵ ϰϭ 
Private sector medicines supply value ϭϲϰ ϭϱϯ ϭϭϭ 
Local production share in paid market Ϯϰ͘ϵй Ϯϯ͘ϴй NA 
CMS share in paid market ϮϮ͘ϲй ϭϵ͘ϯй ϭϳ͘ϲй 
 
The growth rate of the market in Sudan, especially after pace agreement, was very clear and 
many of pharmaceuticals companies expanded (or plan to expand) its establishment into the 
market not only in pharmaceuticals but also in other medical products. 
The market in Sudan is favorable environment for generic pharmaceutical companies that 
based mainly in low income countries (especially: India, China, Egypt, Jordan, Syria) that 
represents significant figures in the market (see table below) ;&DK,͕ϮϬϬϳͿ. 
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Table ϭϯ: Major countries contributing to Sudan market 
Country Share % Region 
Egypt ϳ͘ϴ Arab 
India ϲ͘ϭ Asia 
United Kingdom ϱ͘Ϭ Europe 
Switzerland ϯ͘Ϯ Europe 
Jordan ϯ͘Ϭ Arab 
Germany Ϯ͘ϴ Europe 
China Ϯ͘Ϭ Asia 
 
Importers (agents) and local producers are the major players in private sector in Sudan in 
addition to the direct (special) importation which represents only small part of the market in 
this sector. dŚĞƚŽƚĂůŝŵƉŽƌƚĂƟŽŶŝŶϮϬϬϳ ǁĂƐĂďŽƵƚϭϬϰŵŝůŝŽŶh^Ψ;ŶŽŶŽƟĐĞĂďůĞŐƌŽǁƚŚ
ĨƌŽŵϮϬϬϱͿďǇϳϳĂŐĞŶĐŝĞƐĨƌŽŵϮϬϬĚŝīĞƌĞŶƚ companies and manufacturers. Sudan 
pharmaceuticals market could be described generally as generic market, in which the 
ŐĞŶĞƌŝĐƚƌĂĚĞƐƌĞƉƌĞƐĞŶƚƐĂďŽƵƚϵϬ-ϵϱйŽĨƚŚĞŵĂƌŬĞƚŝŶƚĞƌŵƐŽĨŝƚĞŵƐ͘DŽƌĞƚŚĂŶϳϬйŽĨ
the total export value is from Arab and Asian countries and accordingly the total value of the 
market is consider not large compare to the volume in term of quantities. As mentioned 
before the lŽĐĂůƉƌŽĚƵĐƚƐƌĞƉƌĞƐĞŶƚĂďŽƵƚϭϭ% of the total registered items ;&DK,͕ϮϬϬϴͿ. 
When we consider all of this it will become clearly obvious that most of the products 
available in the market were imported from developing countries or countries with 
economies in transition. It will be very important to the “NMPB” to increase its capacity to 
detect and depict the existence of substandard medicines at different levels in the supply 
chain especially before it reach the end users (patients) to ensure safe and effective use of 
these medicines ;ZĂƚĂŶĂǁŝũŝƚƌĂƐŝŶΘtŽŶĚĞŵĂŐĞŐŶĞŚƵ͕ϮϬϬϮͿ. 
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Statistics showed that ĂŵŽŶŐƚŚĞƚŽƉϭϱŵĞĚŝĐŝŶĞƐ͕ƚŚĂƚĞŶƚĞƌed ƚŚĞŵĂƌŬĞƚŝŶ^ƵĚĂŶϮϬϬϳ, 
all items were in the national essential list of medicines in terms of generic names. But at the 
same time and aŵŽŶŐƚŚĞƚŽƉϱϬŵĞĚŝĐŝŶĞƐϮϬй;ϭϬŝƚĞŵƐͿwere not essential medicines 
and their major source in general is CMS. ďŽƵƚϮϭйŽĨƚŚĞŵĞĚŝĐŝŶĞƐsupplied through the 
public sector are locaůǇƉƌŽĚƵĐĞĚ;ĐŽŵƉĂƌĞƚŽϴйŽŶůǇthe year before) ;&DK,͕ϮϬϬϴͿ.  
 
Table ϭϰ͗dŽƉϭϱmedicines in the mĂƌŬĞƚϮϬϬϲ 
Medicines % of Share/Source 
Generic Name Strength Dosage Form Agents CMS Local 
ϭ. Paracetamol ϱϬϬŵŐ Tablet ϳ ϰ ϴϵ 
Ϯ. Metronidazole ϮϱϬD' Tablet Ϯ ϭϬ ϴϴ 
ϯ. Acetylsalicylic Acid ϯϬϬŵŐ Tablet ϭ Ϯϳ ϳϮ 
ϰ. Amoxicillin ϮϱϬD' Capsule ϵ ϱϳ ϯϰ 
ϱ. Diclofenac Sodium ϮϱŵŐ Tablet ϭϱ ϭϰ ϳϭ 
ϲ. Ampicillin + Cloxacillin ϱϬϬD' Capsule ϭϭ Ϯϱ ϲϰ 
ϳ. Chlorphenarmine Maleate ϰD' Tablet ϰ ϭϱ ϴϭ 
ϴ. Chloroquine  ϮϬϬŵŐ Tablet Ϭ Ϭ ϭϬϬ 
ϵ. Multivitamins & Minerals - Capsule ϭϬϬ Ϭ Ϭ 
ϭϬ. Folic Acid ϱD' Tablet ϴϲ Ϭ ϭϰ 
ϭϭ. Amoxicillin ϱϬϬŵŐ Capsule ϭϱ ϮϬ ϲϱ 
ϭϮ. Glibenclamide ϱD' Tablet ϰϴ ϰ ϰϴ 
ϭϯ. Mebendazole ϭϬϬŵŐ Tablet ϰ ϰ ϵϮ 
ϭϰ. Water for Injection - Injection Ϭ ϭϬϬ Ϭ 
ϭϱ. Ferrus salt ϲϬ-ϳϬŵŐ Tablet Ϭ ϭϬϬ Ϭ 
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Medicines registration outcomes in Sudan: 
NMPB is the responsible body for issuing MA of different pharmaceutical products (beside 
poisons) and it is supported by standing committee that delegated from to approve the 
registration of human medicines (there is another committee for veterinary medicines). This 
committee consists of many experts in different sectors in health and pharmacy that 
approve or reject the submission request to register the pharmaceutical products. This is 
based adopted and published requirements and measures which were available in the 
department offices and on the federal pharmacy directorate web site. Up to this report 
there are about ϯϳϬϵ registered medicines in term of trade names (register by trade name 
using INN system). The following table summarized the registered items disaggregated by 
therapeutic groups versus the dosage forms: 
Pharmacological groups 
Solid 
oral 
Parenteral 
Liquid 
oral 
other large 
liquid 
Topical Other Total % 
Gastro-intestinal system ϮϭϮ Ϯϭ ϯϴ ϭϴ ϴ ϯ ϯϬϬ Ϭϴ͘ϭ 
Cardiovascular system ϯϲϬ ϭϰ Ϭ ϵ Ϭ Ϭ ϯϴϯ ϭϬ͘ϯ 
Respiratory system ϯϯ ϯ ϯϰ ϱ ϮϬ Ϭ ϵϱ ϬϮ͘ϲ 
Central nervous system ϯϰϳ ϰϮ ϰϳ ϭϭ ϯ Ϭ ϰϱϬ ϭϮ͘ϭ 
Infections ϱϭϴ Ϯϯϲ ϮϮϱ ϰϲ ϵϮ Ϭ ϭϭϭϳ ϯϬ͘ϭ 
Endocrine system ϭϱϰ ϯϲ ϭϬ ϱ ϭϰ Ϭ Ϯϭϵ ϱ͘ϵ 
Obstetrics, gynaecology, & 
urinary-tract disorders 
Ϯϱ ϭϰ ϭ ϰ ϰ ϯ ϱϭ Ϭϭ͘ϰ 
Nutrition and blood ϭϯϱ ϱϬ ϯϳ ϴϱ Ϭ Ϭ ϯϬϳ Ϭϴ͘ϯ 
Musculoskeletal and joint 
diseases 
ϭϵϵ Ϯϴ ϭϵ ϭϴ ϯϮ Ϭ Ϯϵϲ Ϭϴ.Ϭ 
Skin ϳ ϯ ϲ Ϯϱ ϭϭϵ Ϭ ϭϲϬ Ϭϰ͘ϯ 
Other ϲϳ ϵϴ ϰϬ ϵϳ Ϯϴ ϭ ϯϯϭ Ϭϴ͘ϵ 
 Total ϮϬϱϳ ϱϰϱ ϰϱϳ ϯϮϯ ϯϮϬ ϳ 
ϯϳϬϵ 
 % ϱϱ͘ϱ ϭϰ͘ϳ ϭϮ͘ϯ Ϭϴ͘ϳ Ϭϴ͘ϲ ϬϬ͘Ϯ 
dĂďůĞϭϵ͗^ƵŵŵĞƌǇƚĂďůĞŽĨƌĞŐŝƐƚĞƌĞĚƉƌŽĚƵĐƚƐŝŶ^ƵĚĂŶ 
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Ϯ- Current system of Post-marketing surveillance “PMS” in Sudan 
The PMS system in Sudan is generally similar to many other systems in developing countries. 
Its main component, and may be the only one, is the routine sampling and testing of the 
authorized products distributed at different components of the supply chain. The following 
described briefly the outlines of the system. 
Ϯ-ϭSelection of medicines 
Medicines selected for analysis and testing under the current system usually determined 
based on the following process: 
ϭ. Every month one pharmacological/therapeutic group normally targeted for testing 
based on the classification of BNF; 
Ϯ. ϰϬйŽĨƌĞŐŝƐƚĞƌĞĚƉƌŽĚƵĐƚƐwithin each group were randomly selected to be the 
ŵĂũŽƌƚĂƌŐĞƚĨŽƌƐĂŵƉůĞĐŽůĞĐƟŽŶĂŶĚƚŚĞĂŶĂůǇƐŝƐ͘dŚŝƐƵƐƵĂůǇƌĞƉƌĞƐĞŶƚƐϵϬйup 
ƚŽϵϱйof monthly analysis plan of PMS; 
ϯ. The remaining share of the products subjected to testing usually represents the 
items reported in the routine complaints receiving system. Normally assigned 
committee is responsible for the determination of products to be tested under this 
scheme out of all complaints received. 
Ϯ-ϮComplaint system 
This sysƚĞŵǁĂƐĞƐƚĂďůŝƐŚĞĚĚƵƌŝŶŐϮϬϬϲĂŶĚŝƚƵƐĞĚĚŝīĞƌĞŶƚĐŽŵŵƵŶŝĐĂƟŽŶƚŽŽůƐŝŶĐůƵĚŝŶŐ
a hotline phone number (free of charge) in addition to direct acceptance of reports. These 
reports could arrive from different categories of the community including health 
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professionals and the public as well. Certain forms used to describe details about the 
product and reported problem(s). Since ...... a total of ....... reports have been received and 
discussed in the committee, (with average of ...... reports received annually). From these 
reports a total of..... products subjected for quality checks ;EDW͕ϮϬϬϴͿ. 
 
Ϯ-ϯQuality evaluation 
The National Quality Control Laboratory “NQCL” is the responsible body for quality 
evaluation under this system. Certain communication plan usually applied between the PMS 
unit and the laboratory for follow-up and coordination. Quality evaluation checks under this 
system are basic physiochemical tests to evaluate the products under testing. The chemical 
analysis represents the main source of information to build the regulatory decisions 
(whether to recall, to revoke or any other decision). Studies indicated the weakness in NQCL 
mainly related to the capacity of the laboratory in different terms including human resources 
and the technical capacity ;t,K͕ϮϬϭϬͿ. The capacity of the national laboratory to test 
medicines was a major component of plans during the last few ǇĞĂƌƐ͘/ŶϮϬϬϵ the total 
number of pharmaceutical products that have been tested (most of it were cosmetic 
products) was ϮϴϴϰƐĂŵƉůĞƐŽƵƚŽĨϮϵϮϴƐĂŵƉůĞƐ collected. According to results obtained 
ϮϵϲŽĨŝƚĞŵƐƚĞƐƚĞĚĚŽĞƐŶ͛ƚƉĂƐƐƚŚĞƋƵĂůŝƚǇƐƉĞĐŝĮĐĂƟŽŶƐƚĞƐƚƐ. 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  Pageͳͻ͹ 
 
 
 
 
 
 
 
 
 
Figure ϭϳ: conceptual model of current PMS in Sudan 
 
 
Looking at this system we can realize its passive nature, i.e. it depends basically on passive 
approach in selecting medicines/products for testing. There are no active measures in its 
components that adopt dynamic information to feedback the selection process of medicines 
and/or the regulatory decisions. 
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Ϯ-ϰDetection rate & outcomes of the system 
On average, through the last ϱǇĞĂƌƐ, ϵй of the tested items under this system were found 
not complying with reference specifications and this was varies from one year to another. 
The non-compliance problems vary in its nature ranging from small physical problems up to 
critical chemical contents problems. 
The following table indicates the summery of failed items per year: 
Year Number tested % of non comply Notes 
    
    
    
    
 
The following table summarizes the details of medicines recalled from the markets during 
the last three years ;EDW͕ϮϬϭϬͿ: 
Pharmacological groups 
Solid 
oral 
Parenteral 
Liquid 
oral 
other large 
liquid 
Topical Other Total % 
Gastro-intestinal system ϯ Ϭ ϭ Ϭ Ϭ Ϭ ϰ Ϭϵ͘ϴ 
Cardiovascular system: ϰ Ϯ Ϭ Ϭ Ϭ Ϭ ϲ ϭϰ͘ϲ 
Respiratory system Ϭ Ϭ Ϯ Ϭ Ϭ Ϭ Ϯ Ϭϰ͘ϵ 
Central nervous system Ϭ ϭ Ϭ Ϭ Ϭ Ϭ ϭ ϬϮ͘ϰ 
Infections ϲ ϭ ϯ ϱ Ϭ Ϭ ϭϱ ϯϲ͘ϲ 
Endocrine system ϰ Ϭ Ϭ Ϭ Ϭ Ϭ ϰ Ϭϵ͘ϴ 
Obstetrics, gynaecology, & 
urinary-tract disorders 
Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ ϬϬ͘ϬϬ 
Nutrition and blood Ϯ Ϭ Ϭ Ϭ Ϭ Ϭ Ϯ Ϭϰ͘ϵ 
Musculoskeletal and joint 
diseases 
ϯ ϭ ϭ Ϭ Ϭ Ϯ ϳ ϭϳ͘ϭ 
Skin Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ ϬϬ͘ϬϬ 
Other Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ ϬϬ͘ϬϬ 
 Total ϮϮ ϱ ϳ ϱ Ϭ Ϯ 
ϰϭ 
 % ϱϯ͘ϳ ϭϮ͘Ϯ ϭϳ͘ϭ ϭϮ͘Ϯ ϬϬ͘ϬϬ Ϭϰ͘ϵ 
dĂďůĞϮϬ͗^ƵŵŵĞƌǇƚĂďůĞŽĨƌĞĐĞŶƚůǇrecalled products 
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The following table summarizes the details of medicines revoked from the markets during 
the last three years ;EDW͕ϮϬϭϬͿ: 
Pharmacological groups 
Solid 
oral 
Parenteral 
Liquid 
oral 
other large 
liquid 
Topical Other Total % 
Gastro-intestinal system ϳ Ϭ Ϭ Ϭ Ϭ Ϭ ϳ ϭϭ͘ϳ 
Cardiovascular system ϳ Ϭ Ϭ Ϭ Ϭ Ϭ ϳ ϭϭ͘ϳ 
Respiratory system ϯ Ϭ Ϭ Ϭ Ϭ Ϭ ϯ Ϭϱ͘ϬϬ 
Central nervous system ϭ Ϭ Ϭ Ϭ Ϭ Ϭ ϭ Ϭϭ͘ϳ 
Infections ϭϬ ϭ Ϭ Ϯ Ϭ Ϭ ϭϯ Ϯϭ͘ϳ 
Endocrine system ϭϮ Ϭ Ϭ Ϭ Ϭ Ϭ ϭϮ ϮϬ͘ϬϬ 
Obstetrics, gynaecology, & 
urinary-tract disorders 
ϭ Ϭ Ϭ Ϭ Ϭ Ϭ ϭ Ϭϭ͘ϳ 
Nutrition and blood Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ͘ϬϬ 
Musculoskeletal and joint 
diseases 
ϱ Ϭ Ϭ Ϭ ϭ Ϭ ϲ ϭϬ͘ϬϬ 
Skin Ϭ ϭ Ϭ Ϭ ϯ Ϭ ϰ Ϭϲ͘ϳ 
Other ϰ Ϭ Ϭ Ϭ Ϭ Ϯ ϲ ϭϬ͘ϬϬ 
 Total ϱϬ Ϯ Ϭ Ϯ ϰ Ϯ 
ϲϬ 
 % ϴϯ͘ϯ Ϭϯ͘ϯ Ϭ͘ϬϬ Ϭϯ͘ϯ Ϭϲ͘ϳ Ϭϯ͘ϯ 
dĂďůĞϮϭ͗^ƵŵŵĞƌǇƚĂďůĞŽĨƌĞĐĞŶƚůǇƌĞǀŽŬĞĚƉƌŽĚƵĐƚƐ 
Note: the products in table ϮϬ& Ϯϭ were not necessarily similar to each other. 
Ϯ-ϱAwareness about the system 
Getting back to the results obtained from health professionals’ survey we found that only 
ϰϮйŽĨƚŚe pharmacists aware about this system. This relatively equal among different 
ŐĞŽŐƌĂƉŚŝĐĂůĂƌĞĂƐƐƵƌǀĞǇĞĚ͕ďƵƚŝƚĨĂůƐƵƉƚŽϭϰйŝŶƚŚĞƉĞƌŝƉŚĞƌĂůĂƌĞĂƐŝŶƚŚĞĐŝƚǇ͘
ŽŶƐŝĚĞƌŝŶŐƚŚĞĞǆƉĞƌŝĞŶĐĞŽĨƉŚĂƌŵĂĐŝƐƚƐƌĞƐƉŽŶĚĞĚ͕ƚŚŽƐĞǁŝƚŚĞǆƉĞƌŝĞŶĐĞŵŽƌĞƚŚĂŶϱ
years have more knowledge about the system better than other groups (especially those 
ǁŝƚŚϯ-ϱǇĞĂƌƐŽĨĞǆƉĞƌŝĞŶĐĞͿ͘ 
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Category Yes No 
ůƉŚĂƌŵĂĐŝƐƚƐ;ĐŽůĞĐƟǀĞͿŶсϴϮ ϰϮ͘ϴ ϱϳ͘Ϭ 
ϭǇĞĂƌ– ϮǇĞĂƌƐ;ŶсϮϲͿ ϰϰ͘Ϭ ϱϲ͘Ϭ 
ϯǇĞĂƌƐ– ϱǇĞĂƌƐ;ŶсϮϱͿ ϯϯ͘ϯ ϲϮ͘ϱ 
More thaŶϱǇĞĂƌƐ;ŶсϯϭͿ ϲϰ͘ϳ ϱϯ͘ϯ 
 
ŵŽŶŐĂůŽĨƚŚĞƐĞƉŚĂƌŵĂĐŝƐƚƐϯϴйŚĂǀĞƌĞƐĞƌǀĂƟŽŶƐĂďŽƵƚƚŚŝƐƐǇƐƚĞŵĂŶĚŝƚƐŽƵƚĐŽŵĞƐŝŶ
detecting the low quality medicines and how it responds to the challenges in the field. 
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ϯ- Expansion of the PMS system 
Considering many facts that affect the value of current PMS system (such as the broad area 
in Sudan, capacity of NQCL and the limited financial resources) it become obvious that the 
current system need to be improved in an innovative way. The following graphical model 
indicates the suggested improvements of the system (compared to figure ϭϳ of current 
model) by introducing more methods and approaches to get better outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ϭϴ: conceptual model of proposed expansion PMS in Sudan 
or both 
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According to the results obtained from previous study that investigated intensely the main 
causes of substandard medicines problem, the results pointed out different forms of 
problems with possibly different causes behind the detected cases. This started at the raw 
materials selection, through the manufacturing process, distribution and up to the storage 
;EŝĐŚŽůƐŽŶ͕ϮϬϬϱͿ. Accordingly, the way in which PMS system is designed should aim to 
reduce the manufacturing and trading of substandard. This form of such kind of vigilance 
should consider the process that checks the drug’s identity, chemical integrity, physical 
stability, and biological activity, and exclude the possible damaging effects of inappropriate 
handling, packaging, and storage (Ndomondo-SigoŶĚĂΘŽƚŚĞƌƐ͕ϮϬϬϬͿ. On the other hand 
the combined interpretation of quality control results with the clinical data or therapeutic 
outcomes of any product under this proposed scheme will support the regulatory decisions 
taken. This is particularly important in order to take overview picture for causes and effects 
of any problem and to include or exclude any potential factors that contribute to observed 
incident of substandard product.  
Any strong PMS system should rely and based on strong drug monitoring information 
systems ;&ŽƌǌůĞǇ͕ϮϬϬϲͿ. This information system should be able to track the problems up to 
patients’ level including the feedback from healthcare providers at different levels. For 
example, the system should consider and monitor regularly the information about the 
shifting practices of treatments. This indicates important information about the efficacy part 
of any product under observation. With regard to the generics that usually included in the 
process of shifting are generally similar to those tested under this research which indicates 
the importance and significance of this source of information. The proposed survey should 
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also be able to bring such kind of information. In other aspect, the information system 
should differentiate between the complaints regarding the therapeutic process, that related 
to adverse reactions/events and that related to use of generics or any other sort of 
problems. By applying different reporting mechanisms the authorities will develop strong 
accumulated knowledge about the products, its manufactures and its distributors; what we 
can call “Product Profile”. This should become a routine part of quality management system 
of pharmaceuticals products. Beside all of these, there are other potential sources of 
information need to be collected and considered in taking the regularity decisions (not only 
the results of PMS). This includes the following: 
ϭ. Pre-marketing surveillance test results; 
Ϯ. Acceptability of the remaining shelf-life at time of receipt; 
ϯ. The history of the drug and its agent at NQCL before distribution; 
ϰ. The quality status at time of collection in accordance to Pharmacopeia; 
ϱ. The quality at the end of the shelf-life; 
ϲ. Drugs most frequently failed the tests; 
ϳ. The lost of potency among the time; 
In this system the authorities should emphasize more on building the relations with health 
ƉƌŽĨĞƐƐŝŽŶĂůƐĨŽƌŵĚŝīĞƌĞŶƚĐĂƚĞŐŽƌŝĞƐ͘dŚĞƌĞƐƵůƚƐƐŚŽǁƐƚŚĂƚŽŶůǇϭϱйĂŶĚϭϬйŽĨ
pharmacists and doctors respectively have ever notified the authorities by any information 
related to medicines they deal with. Even those who ever notified the authorities, most of 
them never received a feedback on their reports or notice any kind of action done as 
response to their reports (at least up to their knowledge). The role of pharmacy or health 
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regularity bodies is very important and vital in the linkage between the professional 
practitioners and the products they use during their work. The feedback of the practitioners 
about the products efficacy, safety and quality should be communicated effectively between 
the two sides. Conducting the proposed survey “described in the above model” under the 
umbrella of the “NMPB” (and the dissemination of annual reports based on this survey) 
should help in building the trust of professional practitioners towards the authorities and it 
will encourage them to report more frequently. This will have direct impact on improving 
the detection rate of low quality products circulated in the market. The system in this part 
should specify clearly the decision making mechanism related to the reported cases. This 
should help the reporters to know exactly how their reports will be treated and they will 
acknowledge the process the authorities take under this reporting mechanism. 
Considering the critical importance of anti-infectives to public health in Sudan ;&DK,͕ϮϬϬϲͿ, 
it is now become very essential to investigate the problem around this therapeutic group as 
special part of the PMS system “specialized surveillance”. All of the indicators from this 
research pointed out the volume of problems around products under this group. It is not 
only the resistance problems part but also its equivalence and other aspects. This proposed 
system appreciates the importance of establishing a monitoring system of “antimicrobials 
use” in the country including data about resistance ;ůŽŵďĞƌŐ͕ϮϬϬϳͿ. This system should 
ensure the development of strong mechanism that aim to monitor regularly the use of 
antimicrobial agents and the level of antimicrobial resistance in all relevant sectors. 
The reasons behind the recommendation to introduce the mini-labs strategy in this system 
was principally due to the fact that it could provide an inexpensive, low technology, non-
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laboratory-based testing option. It helps to assess product identity, disintegration, and drug 
content, which is of value in resource-limited settings like Sudan. When it is used by skilled 
persons, it provides an opportunity to identify substandard drugs in relatively inexpensive 
and quick process which is combined with other methods (WonĚĞŵĂŐĞŐŶĞŚƵ͕ϭϵϵϵͿ. 
The approach by which this system designed and proposed is strong because it responds to 
problems that have been identified in most of PMS systems. In this regard the system will 
help the authorities because it is characterized by the following: 
ϭ. It is an effective quality monitoring system that use effectively the available 
resources; 
Ϯ. It helps to increase the detection rate of substandard medicines; 
ϯ. It was based on improving the availability/sharing of information about the 
substandard medicines, the detected cases and the explanations behind that; 
ϰ. It provide advance and in-depth analysis of the detected cases; 
ϱ. It applies continuous improvement process (through research and development). 
It is important to notice that handling of medicines quality judgments need to be combined 
with clinical outcomes analysis and ADRs surveillance and reporting. This should be a 
significant measure in order to avoid any subjectivity in the reported cases which need to be 
based on highly supported professionalism ;ƌĞǁĞƌΘŽůĚŝƚǌ͕ϭϵϵϵͿ. 
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ϰ- Applications of risk assessment/management techniques 
ϰ͘ϭTheoretical background 
When considering different risk analysis processes in any industry or services the risk 
definition is important step in order to manage the risk under analysis. In general it is know 
that risk defined as “combination of the probability of occurrence of harm and the severity of 
that harm” ;/,͕ϮϬϬϱͿ. This definition found to be valid for all field or areas and it cover 
wide range of risk categories including pharmaceuticals. In the context of medicines quality 
when considering the sampling and testing schemes the event in this case is any non-
satisfactory testing outcome and the risk is sample selection that does not maximize the 
possibility of identifying this an outcome. So by identifying the best way to discover this 
“risk” the process will ensure the maximum detection rate of low quality products. 
As discussed earlier we can find that many regulatory authorities started to apply the 
concepts of risk management in its regulatory decisions. ICH member states started to apply 
this concept few years ago and there are different guidelines about the application of this 
technique in the area of medicines quality control and quality assurance. Its applications in 
inspection and assessment activities had shown significant contribution in improving the 
management systems that applied this approach. However, its use in post marketing phase 
of products lifetime still limited and  countries under process to develop and improve this 
application. 
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The following summarizes the experience of European Union countries about the usefulness 
of this approach ;D͕ϮϬϭϭͿ: 
· Risk management assisted in resources allocation among different activities including 
inspection planning, inspection intensity and in assessment intensity; 
· It was useful in evaluating the significance of quality defects detected, evaluating the 
possibilities for potential recalls and significance of inspectional findings of 
manufacturing sites; 
· It helps the authorities to determine the appropriateness and type of post-inspection 
regulatory follow-up; 
In general, any quality risk management should be based on two fundamental principles. 
First; scientific knowledge should be applied when evaluating the risk and this should be 
linked to patient protection. Second; when decisions were taken to respond to identified 
risk(s) the efforts in this management process should be proportionate with the level of risk 
;ĂƌŽŶĞ͕ϮϬϬϴͿ. The application of these principles in this research was considered as part of 
an analytical approach used to arrive to the conclusions made. 
It is a common proactive practice to use both formal and informal risk assessment tools; 
both proven to be effective. The formal tools use well known techniques with more formal 
and structured process. This may includes Preliminary Hazard Analysis technique, Risk 
Ranking and Filtering technique and other techniques. The informal tools on the other hand 
may use more routine data in building models that help the organization to identify the 
potential risks in its systems. Whatever the tool used to evaluate the risk this should include 
clear identification of the vulnerability of outcomes under evaluation. In this process key set 
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of information need to be identified in any analysis. This includes information about the 
vulnerability of different aspects in the system (go wrong) and the possibilities for a getting 
that. In addition to this, the likelihood (probability) it will go wrong and the severity of that 
;&͕ϭϵϵϵͿ. Under the area of medicines quality, the triggering factors that might put the 
product under suspicious as substandard need to be identified. This process may include 
qualitative and/or quantitative methods of relating the probability of occurrence and 
severity of the risk if it happened. In other theories the use of “relative risk measure” to 
combine multiple levels of severity and probability into an overall estimate of relative risk is 
also acceptable ;/͕ϮϬϬϲͿ. In this study the later technique was used to generate the model 
for selecting and detecting more low quality medicines among the authorized products in 
the system. The aim of any medicines authority, related to quality assurance, is to reduce 
the risk to public health if low quality medicines find its way to the markets. Accordingly, the 
purpose behind using this technique is to support the regularity authority in Sudan to make 
best use of the routine sampling and testing plans to increase the detection rate of these 
low quality medicines. The outcome of this process will help in selecting the products to be 
tested each year using a risk ranking approach that takes account of the available 
information to rank all categories of registered products. 
ϰ͘ϮApplications in quality monitoring 
In EU countries the assessment of products to be included in post marketing evaluation for 
quality monitoring adopts the same technique. The selection of products usually based on 
the evaluation of a range of criteria that included, among others, therapeutic categories, 
market availability, stability and manufacturing process, experience with products. The 
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decision also combined these factors with some inputs from authorized staff in the regularly 
authorities and the GMP inspectorates ;D͕ϮϬϬϴ). This ranking process made by 
considering the risk factors and its weight, then the selection of products for inclusion in any 
analysis plans will be based on the assigned risk level. After the completion of the 
assessment about the potential risk factors appeared in the analysis, these risk factors were 
critically evaluated considering the probability of achieving unsatisfactory testing results and 
the possible consequences of this outcome based on the profile of products under 
evaluation. Then the products (or its categories) were ranked against these factors, and the 
list of products to be tested every year should take account of this ranking. The important 
part of this system is its simplicity as it use the already existing information from different 
sources i.e. triangulation of available data (see model building section below for more 
details). 
Management decisions in monitoring the quality and efficacy of pharmaceutical products in 
post marketing phase are usually difficult and complicated. The approach of using risk based 
management of quality monitoring, as described above, is one of the possible tools that can 
facilitate and support strong decision making process. Recently there was remarkable 
growing use of descriptive and analytical models for decision making in health services 
;^ĂŶĚĞƌƐŽŶΘ'ƌƵĞŶ͕ϮϬϬϵͿ. The models usually use the routine data and information 
generated from within the systems in order to increase the efficiency and to support quality 
improvement process. Different types of models could be used in this area depends on the 
objectives of the process and the available data. Considering the context under this 
research, risk-based model will be the most suitable and feasible approach. 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  PageͳʹͲ 
Below we will discuss the possible use of risk based descriptive and analytical model to 
support the decisions related to monitoring the quality of medicines in post marketing 
phase. 
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ϱ- Logic of building the model 
ϱ͘ϭTheoretical background 
The following graphical demonstration described the logic behind building any decision 
support model (based on ;^ĂŶĚĞƌƐŽŶΘ'ƌƵĞŶ͕ϮϬϬϵͿ) 
 
 
 
 
 
Figure ϭϵ: Logic of building a general decision support model 
 
Upon the application of this concept, the proposed model to improve the post marketing 
surveillance of medicines was developed as described below. The general characteristics of 
this model include: 
· The model came out of this process is basically a descriptive model in it nature, 
however, and based on the robustness analysis of the model, this provide a very 
strong starting point for advanced analytical model may be developed further in the 
future; 
· The descriptive nature of the model is strong enough to show the relationships 
between the cause and outcomes of PMS system currently taken place in Sudan; 
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· The description generated from this model help greatly to build a hypothesis about 
the most at risk items that should be the subject of further quality evaluation or 
assessment (see details below); 
· This model includes a framework for risk management for pharmaceutical quality 
which should contribute in more consistent and science-based decision-making; 
· It will support the establishment and vision of quality related practices, guidelines, 
requirements and standards regarding the testing scheme of medicines in PMS 
system. 
ϱ͘ϮModel building process 
In all risk identification procedures the core concept is the prioritization of large number of 
risk scenarios according to their individual contributions to the overall system risk (Yacov & 
ŽƚŚĞƌƐ͕ϮϬϬϮͿ. According to that the basic assumptions in this model were developed based 
on the results generated from different components of this research. Besides that, the 
researchers utilized other data from different sources to estimate the overall risk probability. 
The following factors were considered in estimating the severity of risk of each category of 
products: 
ϭ. Therapeutic groups 
Ϯ. Dosage forms 
ϯ. Manufacturing origins 
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ϭ. Therapeutic groups: the following data was used to rank the risk associated with 
different therapeutic groups 
a) Feedback from health professionals about the probability of finding more items with 
quality/efficacy problems in these groups; (research) 
b) Feedback from health professionals about prioritization of these groups in contrast 
to other groups; (research) 
c) The statistics about physical problems have been experiences by the health 
professionals; (research) 
d) Statistics about the registered items in Sudan; (NMPB) 
e) Statistic about recalled medicines; (NMPB) 
f) Statistics about revoked medicines; (NMPB) 
g) The final selection of medicines under this research; (research) 
h) Outcomes from different tests and experiments; (research) 
Note: All of these were generated from the previous parts of this research (research); in 
addition to other sources of data from currently published reports by the “NMPB”. 
 
Ϯ. Dosage forms: the following data was used to rank the dosage forms 
- The statistics about physical problems have been experiences by the health 
professionals; (research) 
- Statistics about the registered items in Sudan; (NMPB) 
- Statistic about recalled medicines; (NMPB) 
- Statistics about revoked medicines; (NMPB) 
- The final selection of medicines under this research; (research) 
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- Outcomes from different tests and experiments; (research) 
Note: All of these were generated from the previous parts of this research (research) in 
addition to other sources of data from currently published reports by the “NMPB”. 
ϯ. Manufacturing origins: the following data was used to rank the origins of medicines 
- Feedback from health professionals about probability of finding items with 
quality/efficacy problems from certain origins; (research) 
- Feedback from health professionals about shifting practices of products cross 
different origins; (research) 
- The statistics about physical problems have been experiences by the health 
professionals; (research) 
- Statistics about the registered items in Sudan; (NMPB) 
- Statistic about recalled medicines; (NMPB) 
- Statistics about revoked medicines; (NMPB) 
- The final selection of medicines under this research; (research) 
- Outcomes from different tests and experiments; (research) 
Note: All of these were generated from the previous parts of this research (research) in 
addition to other sources of data from currently published reports by the “NMPB”. 
To generate the probabilities related ƚŽƚŚĞƐĞǀĞƌŝƚǇŽĨƌŝƐŬƐĨŽƌƚŚĞƐĞϯǀĂƌŝĂďůĞƐ͕ƚŚĞ
calculations were built on the weighting methods against the total of events reported under 
each variable considered (excel sheet for calculations in annex XXX). 
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The following are the outcome of this process: 
Therapeutic groups Probabilities  
Infections Ϭ͘ϯϳϲ 
Respiratory system Ϭ͘ϭϰϰ 
Cardiovascular system Ϭ͘ϭϭϵ 
Nutrition and blood Ϭ͘Ϭϵϭ 
Endocrine system Ϭ͘Ϭϳϳ 
Central nervous system Ϭ͘Ϭϯϱ 
Gastro-intestinal system Ϭ͘Ϭϯϱ 
Obstetrics, gynaecology, and urinary-tract disorders Ϭ͘Ϭϭϯ 
Note: since no data available for the other therapeutic groups they were excluded from this process. 
Dosage form Probabilities  
Solid oral Ϭ͘ϳϱϲ 
other large liquid Ϭ͘ϭϯϲ 
Parenteral Ϭ͘ϬϴϬ 
Liquid oral Ϭ͘Ϭϭϭ 
Topical Ϭ͘ϬϬϲ 
 
Origins Probabilities  
Local Ϭ͘ϯϳϰ 
Low&mid income countries Ϭ͘ϯϳϯ 
high income countries Ϭ͘Ϯϱϰ 
Note: results didn’t showed big differences between products produced locally or in low/middle income countries 
 
In addition to these factors, it was fundamental in this process to consider the impact of 
identified risks on the public health. Since this was difficult without a precise data, it was 
decided to consider the “consumption rate” of the products as indicator for harm that may 
result from each product. Based on this, products with high consumption rate expected to 
entail more harm than products with low consumption rate. In this regard the eighty-twenty 
ƌƵůĞ;ϴϬ͗ϮϬͿǁĂƐĂƉƉůŝĞĚ ;:ƵƌĂŶ͕ϭϵϳϬͿ͘dŚĞĐŽŶĐĞƉƚŝƐƐŝŵƉůĞ͕ϮϬйŽĨƌĞŐŝƐƚĞƌĞĚŝƚĞŵƐ
expected to hĂǀĞϴϬйŽĨƚŚĞŵĂƌŬĞƚƐŚĂƌĞĂŶĚĂĐĐŽƌĚŝŶŐůǇƚŚĞĞǆƉĞĐƚĞĚŚĂƌŵƌĞƉƌĞƐĞŶƚĞĚ
by this ration. 
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After obtaining these outcomes, the same approach was applied in large scale decision tree 
(trail) that considered the different possible categories from the combinaƟŽŶƐŽĨƚŚĞϰ
factors. The output of this process provides the primary data for the descriptive model. Then 
the Risk Ranking and Filtering technique was used to obtain the final outcomes of the model 
and this technique was found very useful to obtain the final results ;Dd͕ϮϬϭϬͿ. The 
statistical package used for this process was the Cumulative Sum Charts “ISO-ϳϴϳϭ͟ (ISO, 
ϭϵϵϳͿ. The results of this process generate the model that could be used to support the 
decision making to select specifically targeted medicines for quality checks based on the 
anticipated risks (detailed model in annex XXX). 
ϱ͘ϯMain outcomes of this model 
From the model we can notice the following: 
ϭ. dŚĞƌĞĂƌĞϯϲϬĚŝīĞƌĞŶƚƉŽƐƐŝďůĞĐĂƚĞŐŽƌŝĞƐŽĨƉƌŽĚƵĐƚƐĐŽƵůĚďĞƚĂƌŐĞƚĞĚĨŽƌĂŶǇ
quality monitoring scheme; 
Ϯ. The final selection of medicines for evaluation in this research found to be within the 
ĮƌƐƚϲϰĐĂƚĞŐŽƌŝĞƐ;ƚŚŝƐƌĞƉƌĞƐĞŶƚƐϭϳ͘ϱйŽĨƚŚĞƚŽƚĂůͿ͘ǀĞŶ more, all of the items that 
were not complied with reference standards rest within thĞĮƌƐƚϰϰĐĂƚĞŐŽƌŝĞƐ (it represents 
ϭϭ͘ϮϬйŽĨƚŚĞƚŽƚĂůͿ͖ 
ϯ. From the outcomes below, we can see the huge difference between the top five and 
ƚŚĞďŽƩŽŵĮǀĞ͘/ŶĨĂĐƚƚŚĞƉƌŽďĂďŝůŝƟĞƐŝŶƚŚĞĮƌƐƚĐĂƚĞŐŽƌǇĂƌĞϮϭ͕ϰϬϬƟŵĞƐŚŝŐŚĞƌ
than the least group; 
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ϰ. The tŽƉϱϮĐĂƚĞŐŽƌŝĞƐƌĞƉƌĞƐĞŶƚƐĂďŽƵƚϴϬйŽĨƚŚĞǁŚŽůĞƉƌŽďĂďŝůŝƟĞƐŝŶƚŚĞŵŽĚĞů
;ŝ͘Ğ͘ďǇƚĂƌŐĞƟŶŐƚŚĞƐĞĐĂƚĞŐŽƌŝĞƐŽĨŵĞĚŝĐŝŶĞƐŝƚŵĂǇŝŶĐůƵĚĞϴϬйŽĨƚŚĞƉŽƐƐŝďůǇůŽǁ
quality products); 
ϱ. The following showed the main features and outcomes of the model: 
Top five categories with highest probabilities 
Therapeutic groups Dosage form Origin Consumption Rank 
Infections solid-oral Local high consumption ϴ͘ϱϬϱ 
Infections solid-oral Low&mid income countries high consumption ϴ͘ϰϴϮ 
Infections solid-oral high income countries high consumption ϱ͘ϳϳϲ 
Respiratory system solid-oral Local high consumption ϯ͘Ϯϱϳ 
Respiratory system solid-oral Low&mid income countries high consumption ϯ͘Ϯϰϵ 
 
Least five categories with the lowest probabilities 
Therapeutic groups Dosage form Origin Consumption Rank 
Obs, gyn and UT disorders Other high income countries low consumption Ϭ͘ϬϬϭ 
Skin topical high income countries low consumption Ϭ͘ϬϬϭ 
Obs, gyn and UT disorders* topical Local low consumption Ϭ͘ϬϬϭ 
Obs, gyn and UT disorders topical Low&mid income countries low consumption Ϭ͘ϬϬϭ 
Obs, gyn and UT disorders topical high income countries low consumption Ϭ͘ϬϬϭ 
* Obstetrics, gynecology, and urinary-tract disorders 
ϱ͘ϰStatistical analysis of the outcomes 
The outcomes analysis showed considerable diversity of its main statistical tests (correlation 
and significance). The following table summarizes these relations: 
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Correlations 
  Risk Summery 
Risk Pearson Correlation 1 .360 
Sig. (2-tailed)  .001 
   
Summery Pearson Correlation .360 1 
Sig. (2-tailed) .001  
   
 
 
This summery showed moderate correlation relationship between the anticipated risk of 
medicines category and the possibility of detecting (at least one) low quality product in that 
group. The summery also showed that when the risk increased, there is proportional 
increase of detected that product. Still there are some limitations of this model (based on 
this statistics). This includes the following: 
ϭ. Data about the outcome summery are ǀĞƌǇůŝŵŝƚĞĚŝŶŶƵŵďĞƌĂƐŽŶůǇϰϬƌĞƐults 
(outcomes) were used in this model. Nevertheless it also showed positive and 
relatively significant correlation factor as indicated above. Using more data in the 
future from the routine testing process should confirm  the significance of using this 
model; 
Ϯ. The model gives same weight for all factors under analysis (therapeutic groups, 
dosages ...etc) and doesn’t consider its importance against each other (its weights). 
This is relatively an advance step in improving this model and it should be completed 
when more data is available 
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ϲ- Usefulness of this model and approach 
The model provided scientific approach in checking the quality of pharmaceuticals circulated 
in the market. The proposed scheme to expand the quality/efficacy checks of medicines 
proven to be a useful strategy to ensure the availability of effective products and of good 
quality. This is new approach and it will help the decision-makers in a resources limited 
settings, in which it is well understood the challenges to make choices, to support their 
decisions. 
By applying this approach the following factors need to be considered critically: 
ϭ. The market profiles of selected medicines is key determinant for the final 
selection; 
Ϯ. The capacity of the quality control laboratories as it is critical to inform the 
selection process and the final decisions about the number to be picked under 
each category of products; 
ϯ. The availability of adequate financial resources at different levels of the system 
will limit the way by which the model is applied 
Based on all of these points raised about this model we can see the usefulness of this 
proposed approach in the following aspects: 
ϲ͘ϭSelection decisions of medicines for quality/efficacy checks 
The selection of products to be included in each annual programme should be based on 
rigorous criteria that maximize the outcomes of the testing and evaluation process. Based on 
this model the following selection protocol was proposed to be applied by the “NMPB”: 
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ϭ. After the determination of the capacity of the authorized laboratories, the annual 
plan for testing/evaluation should consider the ranking of different categories. The 
selection of products for inclusion in any annual plans will be related to categories 
those ranked highest on the list at the time the products are selected, which is 
usually done in preceding year; 
Ϯ. The selection mechanism may be done through two possible approaches: 
- Starting to target the categories of products one by one depends on its rank; or 
- Distributing the products in each month based on the weight of its categories 
(but again based on its rank) 
ϯ. If two categories were similar in their expected risk probabilities we can use either 
outranking technique or even swap technique (known statistical methods); 
ϰ. Products eligible for this selection process should be authorized at least two years 
prior to its selection. This will ensure that the product completed the distribution 
phase of its “product life” and the feedback from the system is sufficient for its 
inclusion; 
ϱ. Consideration should be made for products that authorized more than two years ago 
but which have never been tested. This indicate its market status (was not actually 
marketed) and it should be excluded; 
ϲ. The selection of products for inclusion in the annual plan that based on the proposed 
risk ranking should at least make up to ϵϬйŽĨƚŚĞtotal targeted products. The 
remaining ϭϬйmay be allocated at random chance from the other categories outside 
the model. This will depend on the capacity of the authorized laboratories; 
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ϳ. The selection process should consider different information that gathered from 
different sources to inform the evaluation plans. This include the following: 
a) Experts’ opinion should be considered. For example the regular meeting of states 
inspectors plus the establishment of advisory group for quality monitoring that 
give its advice on the main test parameters in the product specifications; 
b) Health priorities in the country from the routine morbidity and mortality data; 
c) Bioequivalence information about the products (Midha & ŽƚŚĞƌƐ͕ϮϬϬϱͿ; 
d) Market information about the product including its distribution pattern; 
e) Health and safety information about the product that indicate its impact on 
public health; 
f) Quality problems experienced in other countries and disseminated by the 
relevant authorities; 
g) The classification of medicines whether it is essential or not (based on the 
National Essential Drug List); 
h) The status of the remaining shelf life of selected products and if that is known to 
affect the outcomes of the testing/evaluation; 
ϴ. Sampling sites should be selected based on evidences about the structure of 
distribution channel in the country as two previous studied in Sudan provided 
important data about the vulnerability of different parts of the distribution system in 
the country ('Ăŵŝů͕ϮϬϬϴͿ. This should consider the climatic conditions, the equal 
share of sampling load between states, availability of targeted product/batch, size of 
the market, the clinical use of the product , etc; 
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ϵ. As it was shown before, using questionnaire based-sampling of products this should 
provide more in-depth understanding of the samples collected and other 
related/associated factors; 
ϭϬ. Information should be sent in advanced to selected sampling sites to confirm the 
availability and the market status of targeted products and this could be done using 
any sort of data collection tool (i.e. questionnaires); 
ϭϭ. In addition to this process, the experience from other countries as we discussed 
before, may help to improve the system: 
i. In Australia complementary medicines and non-prescription drugs were 
routinely examined based on the pharmacovigilance reports obtained from 
the field 
ii. In Cyprus products containing sensitive substances, products used for serious 
diseases and generic products posing interchangeability problems were 
considered as the primary targets for the system; 
iii. In Cuba the PMS focuses on samples collected from manufacturers in 
connection with GMP inspection, rather than on samples collected directly 
from the “market based on the limited capacity of the quality control 
laboratory 
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ϲ͘ϮDetection rate  
As it was discussed before the adverse event the model tried to avoid in this case is the 
failure to identify a non-satisfactory testing outcome of the products (in other terms filature 
to detect the substandard drug). Accordingly, the other main use of this model is to 
maximize the possibility of identifying such product. As it was seen before, by apply this 
ŵŽĚĞůƉƌĂĐƟĐĂůǇƚŚĞƉŽƐƐŝďŝůŝƚǇŽĨĚĞƚĞĐƟŶŐϴϬйŽĨůŽǁƋƵĂůŝƚǇƉƌŽĚƵĐƚƐǁŝůŝŶĐƌĞĂƐĞĚŝĨƚŚĞ
progrĂŵĨŽĐƵƐĞĚŽŶƚĞƐƟŶŐƚŚĞĮƌƐĐĂƚĞŐŽƌŝĞƐŽĨƚŚĞŵŽĚĞů͘/ŶŽƚŚĞƌƚĞƌŵƐϭϭйŽĨƚŚĞ
registered products represent the main source of substandard medicines in the system. This 
is significant finding and it could help the authorities to increase the detection rate of these 
low quality products. 
In this regard, we should appreciate the role of the active surveillance in increasing the 
detection rate of these products. The proposed expansion of PMS system was built on this 
concept. By having more dynamic and active surveillance this will enable the interaction 
between different part of the system. The information system will become more able to 
indicate the potential problems and cases that may involve low quality products. The other 
advantage of this active approach is the involvement of health professionals in efforts to 
compact the problem of substandard medicines. 
With no doubt, health care professionals are the major partners with potential importance 
and roles in improving the detection of substandard medicines. Since this category is well 
oriented and educated about this problem, they should be essential part of any solution. 
This will add additional value for appreciating the detection of these medicines before it 
reaches the patients. 
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ϲ͘ϯImproving the effectiveness of the system 
The impact of substandard medicines on public health, resources utilization and its 
economic impacts all of these drives the need for such kind of interventions and innovations. 
The model provide good tool that help the development of effective plans that aim to 
compact this problem and decrease its effects on public health. This approach was 
considered effective for many reasons as it will assist in allocating the resources and in 
prioritization of the activities. Besides that, the model will help in creating optimal and cost-
effective scheme for monitoring the quality/efficacy of pharmaceutical products. 
To judge whether or not any system is effective or not, we should evaluate the system 
against its objectives and whether or not these we achieved. Although the hypothesis about 
the linkages between the model outcomes and the inputs need to be further studies, the 
model indicate the possibility to improve the PMS system as shown above regarding the 
selection process and the detection rate. 
It will be highly recommended to observe the results of applying this approach after at least 
ϱǇĞĂƌƐůŝĨĞƐƉĂŶ͕ĂƐĂĚĞƋƵĂƚĞĚĂƚĂǁŝůďĞŐĞŶĞƌĂƚĞĚƚŽĚĞǀĞůŽƉŵŽƌĞƐƚƌŽŶŐƉƌĞĚŝĐƚĂďŝůŝƚǇ
tool to detect the possibility of getting certain results. The range of results and the outcomes 
anticipated from these results could inform more how the system dynamic showed 
directions and trends of risks. When analyzing the results from the findings, and its 
associated factors, this should be very helpful for better understanding of the system. This 
includes results about products that complied with specifications, products associated with 
minor issues been identified, products found a out of specification and problems represent 
critical health risks. 
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As it was discussed above, the proposed system will help the relevant authorities to respond 
effectively to the concerns about the quality from different sources. This is important as the 
issue of low quality medicines is of interest for different parties including the consumers as it 
affects their cure and it has cost implications. The prescribers will be interested of effective 
system as low quality products affect their patient trust and their expected clinical 
outcomes. Besides that, the pharmaceutical companies will be concerned about the system 
as they are considering very much the reputation of their companies and the general trust 
on their products. Finally, the governments will highly appreciate effective stress in order to 
ensure the protection of public health and prevention of increased public expenditure for 
drugs ;h^W͕ϮϬϬϰͿ, ;ĞŶŶĞƩΘŽƚŚĞƌƐ͕ϭϵϵϵͿ. 
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Conclusion 
 
· This research ended by creating a risk-based model of Post marketing Surveillance 
System “PMS”; 
· The proposed model aimed to improve the way the quality of medicines could be 
monitored. It is useful approach as it considered the risks associated with detecting 
low quality products; 
· The model will enable the authorities to develop and apply dynamic and active 
approach in tracing the quality and efficacy problems in circulated products in the 
market; 
· The experiments and sub-studies done under this research contributed significantly 
to strength the justifications for applying this model in this area. Compared to the 
conventional model of PMS, this model is cost-effective approach need to be 
considered in a resource limited settings in the developing countries; 
· The application of this model will not be effective without the active involvement of 
health professionals form the healthcare field. This involvement will strengthen the 
outcomes of the model and at the same time it will help the implementing bodies to 
improve the model if the future; 
· This research is small scale project and due to that still there are some limitations 
identified in its development. Still the findings showed statistically significant 
outcomes for measures to improve the PMS system; 
· Further research and development efforts in this area need to be done in the future. 
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Recommendations 
 
ϭ. “NMPB” may consider the application of the proposed model for quality risk management 
in the practical field in the upcoming year to improve the post marketing system as key  
part of medicines regulation; 
Ϯ. Implementation of medicines selection protocol proposed by this study to improve the 
outcomes of PMS system and to increase the detection rate of low quality medicines; 
ϯ. Development/enforcement of routine passive and active surveillance that bring more data 
about quality from different sources; 
ϰ. “NMPB” should consider the improvement of drug monitoring information systems as 
priority step. These systems should be able to track more problems in different levels; 
ϱ. Development of national database as central component for medicines quality 
management information system to support the formulation of strategic policy and plan to 
contain the incidence of low quality medicines; 
ϲ. “NMPB” should build strong relations with health professionals and should strength the 
communication and feedback systems with them; 
ϳ. Responsible authorities should develop practical mechanism to monitor the use of 
antimicrobial agents and the level of antimicrobial resistance in all relevant sectors; 
ϴ. Re-evaluating the outcomes of this model a ϱǇĞĂƌƐĂŌĞƌŝƚƐŝŵƉůĞŵĞŶƚĂƟŽŶƚŽĂƐƐĞƐƐŝƚƐ
effectiveness and the improvement plan; 
ϵ. Expanding the PMS to check the quality and efficacy beyond the physiochemical analysis to 
include more tests including microbiological assay, bioassay, bioequivalence studies, 
minilabs, dissolution test, etc as routine tests. 
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ϭϬ. Strengthening the capacity of National Quality Control Laboratory to implement the 
proposed expansion plan of PMS by securing additional resources in terms of human 
resources, capacity building programs, financial support and adequate workplace; 
ϭϭ. Development of educational programs targeting health professionals regarding the 
management of low quality medicines including substandard and counterfeit products. 
ϭϮ. Doctors and pharmacists should report more about the medicines they deal with and they 
should become the vigilant channels for counterfeit/substandard drugs;  
ϭϯ. “NMPB” or other relevant bodies should improve information dissemination to help in 
educating the consumers to be a part of medicines quality management channels; 
ϭϰ. Conduction of in-depth studies about the use of Amoxicillin inside and outside the health 
system in Sudan; 
ϭϱ. Further research is needed to assess the capacity of medicines regulatory system to identify 
the gaps that affect the detection of substandard medicines before and after entering the 
market and to develop an action plan to address these gaps; 
ϭϲ. More operational researches needed to determine the most effective regulatory 
mechanisms to reduce the circulation of substandard drugs in order to reduce the harm 
from substandard drugs 
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ͳǣquestionnaire 
ƇƔţũƅŔƉƈţũƅŔĺŔƇŬŗ 
Questionnaire on Medicines Quality for pharmacists 
 
Date…………………………………….. City: …………….…………….……………. 
State:-…………………………….………    Province:-………………….………………. 
Area Type:-………..……………………………………………………….………………. 
Code-……………………………………………………………………….……………… 
Pharmacy name (optional):-………………………………...……………………………. 
Information provider:-      ?  Pharmacist          ?  assistant          ?  other 
Data collector:-…………………………………………………….………………….. 
 
Substandard Medicines:- 
That are medicines not comply with the specifications including the active ingredient content 
řƅŕŸſƅŔŘŧŕƈƅŔƐƏśţƈŕƎƔžŕƈŗŚŕſŰŔƏƈƆƅřƂŗŕųƈũƔŻũŗśŸśƓśƅŔřƔƏŧƛŔƓƍ 
1. Did you think that there is problem of substandard (low quality) 
medicines found in the medicines market in Sudan? 
        ?  Yes                            ?  No                       ?  No comments 
 
2. Did you think that it is major or minor problem? 
                   ?  Major                             ?  Minor 
 
3. Did you deal with patients Complaints for ineffective medicines(s)? 
                   ?  Yes                                ?  No 
 
4. If yes, did you think that the problem in the medicine itself or in the 
administration method (dosing, time, food interaction, etc)? 
?  Majority in medicine itself                    ?  Majority in Administration method 
 
5. What are the common Complaints did you receive? 
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?  Symptoms not relieved          ?  Side effects        ?  physical 
appearance 
?  Alternative medicine              ?  All of these         ?  other 
6. What are the common medicine(s) that you have experienced 
patient(s) Complaints:- 
Generic name…………………………………………………………….………….. 
Trade Name…………………………………………………….……………………. 
Company/Source……………………………………………...…………………….. 
 
7. Did you think that this company have quality problem regarding its 
remaining range of products? 
              ?  Yes                          ?  No                   ?  No comments 
 
8. Did you deal with medicine(s) have been physically changed? 
              ?  Yes                          ?  No 
 
9. If yes, what are the medicines if you experienced these? 
 
Generic Dosage Form Changes Notes Source 
    
    
    
 
 
10. Did you have experience in shifting patient(s) from one product to 
another product (for same generic) because of uncontrolled patient(s) 
symptoms or complaints? 
              ?  Yes                          ?  No 
 
 
 
 
11. If yes, in this case(s) what is the: 
Case (1):- 
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 Patient was on Alternative Your comment 
Generic name    
Trade Name   
Company   
· If the locally manufactured drug is available in the market did you 
recommend it for the patient in this case? 
              ?  Yes                          ?  No 
Case (2):- 
 Patient was on Alternative Your comment 
Generic name    
Trade Name   
Company   
· If the locally manufactured drug is available in the market did you 
recommend it for the patient in this case? 
              ?  Yes                          ?  No 
12. Did you experienced if any: (your own observations) and/or (patients 
compliance) and/or (doctors comments) and/or (other college 
pharmacists) about the quality of the following generics regardless the 
trade name:- 
                                   * choose the number(s) 
1- Your own observations      2- Patients compliance 
3- Doctors comments    4- Other college pharmacists 
Generics Yes No If yes from * 
21.  Amoxicillin susp/cap    
22.  Ampiclox inj    
23.  Artesonate    
24.  Aspirin    
25.  Atenolol tab    
26.  Carbimazole tab    
27.  Cefuroxime sodium inj    
28.  Chloramphenicol cap/tab    
29.  Chlorpheniramine    
30.  Ciprofloxacin tab    
31.  Co- trimoxazole    
32.  Digoxin inj/tab    
33.  Ethinylestradiol/levonorgestrel    
34.  Furosemide    
35.  Glibenclamide tab    
36.  Hydrocortisone    
37.  Mefenamic Acid    
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38.  Metronidazole susp/tab    
39.  Nifedipine    
40.  Paracetamol    
 
 
13. From your experience what are the pharmacological groups (name 3) 
did you think that it should be monitored continually for its quality and 
you think that there are some problems in its medicines? 
 
Groups Yes Why 
Gastro-intestinal drugs   
Cardiovascular drugs   
Respiratory drugs   
Central Nervous system drugs   
Anti-infections drugs   
Urinary tract drugs   
Dermatological preparations   
Nutrition and blood preparations   
Obstetrics & gynecological drugs   
 
14. Is the Drug Safety poster from pharmacy directorate availability? 
              ?  Yes                          ?  No 
15. Are you familiar with the post marketing surveillance system in 
directorate of pharmacy? 
        ?  Yes                            ?  No                       ?  No comments 
16. If yes, what is your comment upon the efficacy of the system to monitor 
drugs quality? 
    ?  Very effective            ?  partially effective          ?  not effective 
 
17. Did you notify or report any compliance about drugs quality to the 
directorate of pharmacy? 
        ?  Yes                            ?  No                       ?  No comments 
18. If yes, what is the response did you find in this case if any? 
…………………………………………………………………………..... 
…………………………………………………………………………….. 
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19. Did you deal with recall process done by one of the private companies 
(itself) in the market because of quality problems? 
        ?  Yes                            ?  No                       ?  No comments 
 
20. If yes in this case what is the:- 
Generic name……………………………………………………….. 
Trade Name…………………………………………………………. 
Company…………………………………………………………….. 
Batch No……………………………………………………………… 
 
21. Did this process is based on written letter from pharmacy directorate or 
just the company just recalls it by its self? 
 ?  With written letter              ?  Without written letter           ?  No comments 
22. "The cheap item considerably of less in quality than the expensive item 
for the same generic", how did you evaluate this? 
?  yes, always true          ?  yes, but not always               ?  not true 
 
23. How did you evaluate the following assuming all are available:- 
Product type Good quality 
Low 
quality 
The Innovator Brand name for generic   
Generic product from high income country for the same generic   
Generic product from low income country for the same generic   
Generic product Locally produced in Sudan for the same generic   
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ʹǣquestionnaire 
ƇƔţũƅŔƉƈţũƅŔĺŔƇŬŗ 
Questionnaire on Drugs Quality - Doctors 
 
řƔƊŧśƈƅŔřƔƏŧƛŔŚƆŴŘŧƏŠƅŔLow QualityƐŧƈƏƓžƉƔƆƈŕŸƅŔŶƔƈŠƀũŎƔĻŕŬŠŕƍƉŔŧƏŬƅŔƓžŕƍŧŠŔƏś
ƓŗųƅŔ¿ƂţƅŔƓžƉƔƆƈŕŸƅŔŉŔũŔ¿ƏţŚŕƈƏƆŸƈŶƔƈŠśƓƅŔŽŧƎƔƉŕƔŗśŬƛŔŔŨƍŉŕŗųƛŔřŰŕŦƏƓŗųƅŔ¿ƂţƅŔ
ƉƔƊžƉƔŧŷŕŬƈƏřƅŧŕƔŰŉŕŗųŔŵƏŲƏƈƅŔŔŨƍƓžũƔśŬŠŕƈƅŔřŠũŧ¿ƔƊƅřŬŔũŧƉƈŲƃƅŨƏ ƀœŕžŶƈƏ
ƉŕƔŗśŬƛŔŔŨƍƓƆŷřŗŕŠƛŔ¿ƜŦƉƈřƔŲƂƅŔƋŨƍƓžőŔũƅŕŗƃśƈƍŕŬƈƃƅũŧƂƊƇŔũśţƛŔ 
Information provider:-  ?  Specialist       ?  Registrar       ?  General Physician 
 
 
?   I am sorry I couldn’t  respond to this questionnaire 
 
1. Do you think there is a problem of low quality (substandard) 
drugs found in the drugs market in Sudan? 
        ?  Yes                            ?  No                       ?  No comments 
 
2. Do you think that it is major or minor problem? 
              ?  Major                         ?  Minor 
 
3. Do you experience therapeutic failure with some patients? 
              ?  Yes always                  ?  Not always                  ?  No 
 
4. If happened, do you think that the failure is due to the subjects’ 
variability or due to the quality of medicines? 
      ?  Majority due to subjects’ variability ?  Majority due to drugs quality 
.What is the drug in this case (as example):- 
Generic Name…………………………………………………………. 
 
 
 
 
 
5. For you substandard drugs: 
? Prolong your patients’ illness ?  Yes  ?  No 
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?  Additional cost for your patients ?  Yes  ?  No 
?  Could be contributed to drugs resistance ?  Yes  ?  No 
? Decrease your patients trust on your practice ?  Yes  ?  No 
?  Could lead to patient death ?  Yes  ?  No 
?  All of these  
?  None of these  
 
 
6. Comparably where did you think that the effect of substandard 
medicines will be worse in case of….. 
     ?  Over the Counter Drugs (OTC)       OR         ?  Prescribed Drugs (Rx) 
7. Are you sometimes insisting to prescribe certain trade names 
of drugs for the patients? 
        ?  Yes                            ?  No                       ?  No comments 
8. If yes, the reason is? 
?  Success experience with those trades            ? Price considerations 
  ?  Failure experience with other trades               ?  Other…………………….. 
9. Did you have experience in shifting patient(s) from one product 
to another product (for same generic) because of uncontrolled 
patient(s) symptoms?           ?  Yes                          ?  No 
 
 
 
 
 
10. If yes, in this case(s) what is the: 
 Patient was on Alternative Your comment 
Trade name    
 
11. Assuming that the locally produced drug is available in the 
market, did you recommend it for the patient in this case? 
              ?  Yes                          ?  No 
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12. "The cheap item considerably of less in quality than the 
expensive item for the same generic", how did you evaluate this? 
?  yes, always true          ?  yes, but not always               ?  not true 
13. Is it valid that for your patients “available low quality drug is better 
than that drug is not available at all”? 
              ?  Yes                          ?  No                 ?  Some times it is true 
14. Did you think that drugs should be recalled (withdrawal) from 
the market due to the following reasons? 
? Chemical problems (active and in-active contents problems) ?  Yes  ?  No 
? Changes in color ?  Yes  ?  No 
? Fracture of tablets or capsules ?  Yes  ?  No 
? Repeated doctors and or patients complaints ?  Yes  ?  No 
 
15. Did you some times consult pharmacists about their view on 
the quality of certain drugs you want to prescribe? 
              ?  Yes                          ?  No 
 
 
 
 
 
 
 
 
 
 
 
 
 
16. Did you have any observations and/or patients complaints 
about the quality of the following generics regardless the trade 
name:- 
 
Generics Yes No 
41.  Amoxicillin susp/cap   
42.  Ampiclox   
43.  Artesunate   
44.  Aspirin   
45.  Atenolol tab   
46.  Carbimazole tab   
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47.  Cefuroxime sodium inj   
48.  Chloramphenicol cap/tab   
49.  Chlorpheniramine   
50.  Ciprofloxacin tab   
51.  Co- trimoxazole   
52.  Digoxin inj/tab   
53.  Ethinylestradiol/levonorgestrel   
54.  Furosemide   
55.  Glibenclamide tab   
56.  Hydrocortisone   
57.  Mefenamic Acid   
58.  Metronidazole susp/tab   
59.  Nifedipine   
60.  Paracetamol   
61.     
62.     
 
 
17. How did you evaluate the following assuming all are available:- 
Product type Good quality 
Low 
quality 
Original Brand name (international Companies)   
Generic product from high income countries   
Generic product from low income countries   
Generic product Locally produced in Sudan   
 
18. Did you notify or report any compliance about drugs safety or 
quality for any regularity body? 
              ?  Yes                          ?  No 
19. If yes; what is the drug, the problem and response in this case? 
Drug Problem Response 
  
 
 
 
  
Other 
medicines 
you note its 
problem 
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͵ǣstudy results 
Substandard Medicines Study in Sudan 
Pilot Study – Outcomes summary 
 
The objectives of the Summery report:- 
ϭ. To identify the suitability of the proposed questionnaires to collect the 
needed data regarding the health workers directly deals with medicines 
(opinions in marketed medicines). 
Ϯ. To identify the most appropriate methodology of data selection and sample 
identification and presentation. 
 
· dŚĞƉŝůŽƚƐƚƵĚǇǁĂƐĚŽŶĞŝŶϭϬƉƌŝǀĂƚĞƉŚĂƌŵĂĐŝĞƐŝŶ<ŚĂƌƚŽƵŵůŽĐĂůŝƚǇĂŶĚƚŚĞ
sample was divided into the following categories: 
Category Type No of pharmacies 
Private pharmacy Housing Area ϱ 
Private pharmacy Private Hospitals Ϯ 
Private pharmacy Near Hospitals OR Doctors Clinics ϯ 
 
· There is suggestion to include the public health facilities pharmacies in the survey 
but there are some problems especially in the criteria to select and whether this 
will affect the results or not. 
Some notes from the pilot study: 
ϭ. dŚĞƌĞŝƐƐŽŵĞƋƵĞƐƟŽŶƐŶĞĞĚƚŽďĞƌĞĨŽƌŵƵůĂƚĞĚƚŽďĞĐůĞĂƌ;Yϲ͕YϳͿ 
Ϯ. There is need to introduce question about the observations of the 
pharmacists regarding the physical changes in medicines that they have been 
experienced in their work. 
ϯ. Doctor survey is seems to be difficult unless there is defined target doctors 
and the strategy to get access to them. 
ϰ. There is need to introduce the option of no comments in some answers 
ŽƉƟŽŶƐ;YϲͿ͘ 
ϱ. For deep analysis what type of data need to be concentrate on it? 
ϲ. To eliminate some of surveyed medicines and introduce another ones (e.g. 
Artesunate + Nifedipine + Some injectables). 
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Results: 
This is only simple analysis for questions response without any interpretations of 
data or deep analysis: 
Yϭ͗ The existence of substandard medicines in Sudan:- 
Yes ϵϬй 
No ϭϬй 
 
YϮ͗ To what extend:- 
Major ϮϮй 
Minor ϴϴй 
 
Yϯ͗ Patient compliance of non effective medicine:- 
Yes ϭϬϬй 
No Ϭ 
 
Yϰ͗ In his opinion the problem is in…... 
Drug itself Ϯϱй 
Administration method ϳϱй 
 
Yϱ͗ What are the medicines in this case? 
Medicines Source Type of pharmacy Times 
Amoxicillin Sudan Near Doctors Clinics Ϯ 
Amoxicillin CMS Housing Area Ϯ 
Artesunate CMS Near Hospital ϭ 
Ciprofloxacin India Housing Area ϭ 
Nifedipine Lebanon Private Hospital ϭ 
Ibuprofen India Housing Area ϭ 
Erythromycin Sudan Housing Area ϭ 
Azithromycin Jordan Housing Area ϭ 
Glibenclamide Sudan Private Hospital ϭ 
 
Yϲ͗ The comment on the company products if have another quality problem: 
Yes ϯϯй 
No ϲϳй 
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Yϳ͗ Opinion evaluation regarding sources of medicines: 
Product Type Good Quality Low Quality 
Innovator Brand ϭϬй Zero 
Generic from High Income countries ϭϬϬй Zero 
Generic from Low  Income countries ϯϬй ϳϬй 
Generic Locally produced ϱϬй ϱϬй 
 
Yϴ͗ Replacing generic from brand X to brand Y: 
Yes ϵϬй 
No ϭϬй 
 
YϵA: ĂƐĞƐƌĞƉƌĞƐĞŶƟŶŐĂŶƐǁĞƌŽĨYϴ͗- 
Generic Brand X Source Brand Y Source 
Amoxicillin GMC Sudan Amipharma Sudan 
Amoxicillin CMS - Amipharma Sudan 
Amoxicillin Amipharma Sudan Clavox KSA 
Ceftrixone CMS - Hikma Jordan 
Cephalexin Shangahi Sudan Luka India 
Simvastatin Blue Nile Sudan Pharmaline Lebanon 
Glibenclamide Elie Sudan Euglycon UK 
Erythromycin CMS - Amipharma Sudan 
Ciprofloxacin - Sudan Mepha Switzerland 
Ciprofloxacin - India Hikma Jordan 
Omeprazole Gasec UAE Losec Switzerland 
Amilodipine - India - Egypt 
 
Yϵ͗Suggesting the locally produced medicine as alternative: 
Yes ϱϴй 
No ϰϮй 
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YϭϬ͗ Experience regarding quality problems:- 
1- His own observations      2- Patients compliance 
3- Doctors comments    4- other college pharmacists 
Generics Yes Sources 
63.  Amoxicillin 80% 2 – 4 – 1 
64.  Metronidazole  70% 2 – 1 
65.  Paracetamol 70% 1 - 2 
66.  Ceftrixone sodium 60% 3 
67.  Ciprofloxacin tab 60%  
68.  Glibenclamide tab 60% 3 - 2 - 4 
69.  Carbimazole tab 40%  
70.  Aspirin 30% 2 
71.  Aminophyllin inj 10%  
72.  Ampiclox 10%  
73.  Atenolol tab 10%  
74.  Benzyl penicillin inj 10%  
75.  Digoxin inj/tab 10%  
76.  Adrenaline inj Zero  
77.  Chloramphenicol oral Zero  
78.  Chloramphenicol inj Zero  
79.  Ferrous Sulphate Zero  
80.  Gentamicin inj Zero  
81.  Hydrocortisone inj Zero  
82.  Methyl Ergometrine inj Zero  
 
Yϭϭ͗ Pharmacological groups in priorities: 
Groups Yes 
Cardiovascular drugs 80% 
Central Nervous system drugs 60% 
Anti-infections drugs 50% 
Gastro-intestinal drugs 30% 
Respiratory drugs 30% 
Nutrition and blood preparations 30% 
Urinary tract drugs 20% 
Dermatological preparations 0 
Obstetrics & gynecological drugs 0 
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YϭϮ͗ Post marketing Surveillance system awareness: 
Yes ϰϬй 
No ϲϬй 
 
Yϭϯ͗ If aware, his opinion:- 
Very effective ϰϬй 
partially effective ϱϬй 
Not effective ϭϬй 
 
Yϭϰ͗ "The cheap item considerably of less in quality than the expensive item 
for the same generic":- 
yes, always true ϭϬй 
yes, but not always ϲϬй 
not true ϯϬй 
 
Yϭϱ͗ Report or compliance to pharmacy directorate:- 
Yes ϯϬй 
No ϳϬй 
 
Yϭϲ͗ If yes, what is the medicines and what is the response:- 
Medicines Response 
Ibuprofen Not formal reporting 
Seven Seas Not formal reporting 
 
Yϭϳ͗ Dealing with company recall process: 
Yes ϳϬй 
No ϯϬй 
 
Yϭϴ͗ What is the cases:- 
Generic Trade Company 
Multivitamin Vitamax GSK 
sŝƚĂŵŝŶϲ - SPIC / Dar Eldoa 
Carbamazepine Epistron Siho 
- Botelium Mepha 
Cough Syrup Sedofan Julphar 
Promethazine - (Jordan) 
Sildenafil Agiel  
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Ͷǣinformation form 
ϭ- General  & Primary Information 
Date of collection……………….………… ……………………………. 
Area: 
?  Khartoum Hospital street pharmacies. 
?  Center of Khartoum pharmacies. 
?  East areas pharmacies. 
?  South areas pharmacies. 
?  Peripheral 
Field of samples  ?  Near Hospital        ?   Household Retail pharmacy 
Sample code…………...……………………………………………………….. 
Company code………..…………..…………….……………………………... 
Medicine trade name code…..……………………...……...….……………... 
Medicine generic name……………………………………..………………... 
Concentration…….……..……………………………………………………... 
Dosage form  ?  Tablet  ?  Capsule  ?  Injection  ?  Suspension    ?  Syrup 
Pharmacological group…………………...…………………………………... 
Batch No…………………………………………….………………………….. 
Date of receiving from the supplier……………..…………………………... 
Manufacturing date………………..…………………….……………………. 
Expiration date………………………..…………...……………..……………. 
The remaining shelf-life at time of receiving…………..…………….……... 
Quantity collected/units……………………………………………………... 
Retail price in SDG….……………………………………………………….... 
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Ϯ- Other Information 
Source of origin:-  ?   Multinational company    ?    High income country 
                                 ?    Low income country         ?   Local 
Did the manufacturer have GMP certificate                    ?  Yes          ?  EϬ 
Number of other products register for this company……………………... 
Registered Shelf life in Drug Regulatory Authority……...………………... 
Did this product subjected to shelf life expansion          ?  Yes          ?  EϬ 
Did his batch subjected to pre-marketing test                 ?  Yes          ?  EϬ 
Did The government lab satisfy before distribution      ?  Yes          ?  EϬ 
Did his batch subjected to post-marketing test               ?  Yes          ?  EϬ 
Did product available in other form/concentration ?  Yes ?  EϬ͙͙͙ ͘͘ 
Date of importation…………………………………………………………… 
Mean of importation                  ?  By Air                             ?  By Sea 
/ŵƉŽƌƚĞĚƋƵĂŶƟƚǇͬƵŶŝƚƐŝŶϮϬϬϳ͙ ͙͙ ͙͙ ͙͙ ͙͙ ͙͙ ͙͙ ͙͙ ͙͙  ͘
Product share in the market………………………………………………….. 
Did this medicine on the national essential list               ?  Yes           ?  EϬ 
Number of competitors (Foreign…………….….. Local…………………...) 
Medicine Classification                ?  OTC                     ?  Prescription 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϮϰϬ 
 
 PageͶʹͲ 
ϯ- Storage form 
Manufacturer storage condition: ……………………………………………………………………. 
…………………………………………………………………………………………….………………………… 
Brief physical/visual description before storage: 
……………………………………………………………………………….……………………………………. 
…………………………………………………………………………………………………..………………… 
Date of storing in the laboratory………………………………………..……………….………. 
Starting Date for analysis……………………………………………………………….……………. 
Storage period…………………………………………………………………………..….…………… 
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Annex ͷ: Distribution of private retail pharmacies in Khartoum state 
City Administration Unit 
Total number % of the Total 
Per Unit Per City Per Unit Per City 
Khartoum 
Khartoum – Center 
328 

41% 
Khartoum – East  
El Shohada – Soba  
El Azhari  
El Nasser  
El Kalaklat  
Khartoum Bahri 
Bahri 
179 

23% Bahri North  
Eastern Nile  
Omdurman 
Omdurman 
282 

36% 
Sothern City site   
El Bokaa  
El Ameer  
El Thora  
Karari  17 
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Annex ͸: Trade products selection process 
Generic:    Acetylsalicylic Acid                                             ŽŶĐĞŶƚƌĂƟŽŶ͗ϯϬϬŵŐdablet 
 Trade Company 
Country 
of Origin 
Origin 
Classification 
Available in other 
form PMS 
1.  Aspicima Abd El Munim Sudan Local Yes Yes/+ 
2.  Citypirin Adult City Pharma Sudan Local No Yes/+ 
3.  Asprimax Climax Sudan Local No No 
4.  Eliprin Elie Sudan Local No No 
5.  Cafalgin Adult Humavite Sudan Local No No 
6.  Marwaprin Marwa Sudan Local No No 
7.  Samfpirin Salah Sudan Local Yes Yes/+ 
8.  Asadin Chemical Sudan Local No No 
9.  Aspruna - Sudan Local No Yes/+ 
10. Aspro Bodrian Kenya Low income No No 
11. Aspicot kerkisawi Lebanon Low income No Yes/- 
12. Aspirin Development Germany High income Yes No 
 
Mostly used 
Mostly used 
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Generic:    Amoxicillin Trihydrate                                             Concentration: ϱϬϬ mg Capsule 
 
Trade Company 
Country 
of Origin 
Origin Classification Available in other form PMS 
1.  Cimoxil Abd Al Momin Sudan Local Yes No 
2.  Amixillin Amipharma Sudan Local Yes Yes/+ 
3.  Epoxil Elie Sudan Local Yes No 
4.  Tauxil Sigma-Tau Sudan Local Yes No 
5.  Wafraxil Wafra Sudan Local Yes No 
6.  Amoxonil Shifa Sudan Local Yes No 
7.  G.M Amoxicillin GMC Sudan Local Yes No 
8.  Hipen Salmawit India Low income Yes Yes/+ 
9.  Aramoxyl Samhar Syria Low income Yes No 
10. Lamoxy Badr India Low income Yes No 
11. Amoxydar Forte Kambal Jordan Lower-middle-income No No 
12. Amoxicap - Malaysia Upper-middle-income Yes No 
13. Moxen Hiba Cyprus High income Yes No 
14. Amoxapen Siho Cyprus High income Yes No 
Mostly used 
Mostly used 
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Generic: Ceftriaxone sodium                                             Concentration: Ϭ͘ϱŐŵWŽǁĚĞƌĨŽƌŝŶũĞĐƟŽŶ 
 
 
Trade Company 
Country of 
Origin 
Origin Classification Available in other form PMS 
ϭ.  
Rozifine Mahadi Syria Low income 
Yes No 
Ϯ.  
Rociflex El Hussein Syria Low income 
Yes No 
ϯ.  
Onecef Rahma India Low income 
No No 
ϰ.  
Samixon Pharma exier Jordan Lower-middle-income 
Yes No 
ϱ.  
Triaxone Kambal UAE High income 
Yes No 
ϲ.  
Rocephin Dal Switzerland High income 
Yes No 
ϳ.  
Mesporin Nabil Switzerland High income 
Yes No 
 
 
 
 
Mostly used 
Mostly used 
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Generic: Chlorphenarmine Maleate                                             Concentration: ϰ mg Tablet 
 
 
Trade Company 
Country of 
Origin 
Origin Classification Available in other form PMS 
1.  Cimalurg Abd El Munim Sudan Local No No 
2.  Amihistin Amipharma Sudan Local Yes No 
3.  Citramin City Pharma Sudan Local No No 
4.  Epohist Elie Sudan Local No No 
5.  Marwastine Marwa Sudan Local No No 
6.  Wafrastin Wafra Sudan Local No No 
7.  Allerfin Pharma Jordan Lower-middle-income Yes No 
8.  Istamex El atlanti Greece High income Yes No 
9.  Chlorohistol Kambal UAE High income No No 
 
 
Most used 
Most used 
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Generic: Ciprofloxacin                                             Concentration: ϱϬϬ mg Tablet 
 
Trade Company 
Country of 
Origin 
Origin Classification Available in other form PMS 
1.  Amiciprox Amipharma Sudan Local NO Yes/+ 
2.  G.M Proxal GMC Sudan Local Yes NO 
3.  Ciproflex El Hussien Syria Low income NO NO 
4.  Roxin Dar Dawa Pakistan Low income Yes NO 
5.  Microflox Fast India Low income Yes NO 
6.  Ciprobid Salmawit India Low income Yes NO 
7.  Ciproquin Omdurman India Low income NO NO 
8.  Ciprolet Pharma care India Low income NO Yes/+ 
9.  Ciplox Marwaco India Low income Yes NO 
10. Ciprodar Kambal Jordan Lower-middle-income Yes NO 
11. Ciprolon Pharma Exier Jordan Lower-middle-income Yes Yes/+ 
Most used 
Most used 
Most used 
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12. Ciproflox Pharma Jordan Lower-middle-income NO NO 
13. Siprobel Comprehensive Turkey Upper-middle-income NO NO 
14. Bactiflox Nabil Switzerland High income Yes Yes/+ 
15. Ciprinol EPICO Slovenia High income Yes NO 
16. Ladinin M&M Greece High income Yes NO 
 
 
 
 
 
 
 
 
 
Most used 
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Generic: Diclofenac Sodium                                             Concentration: Ϯϱ mg Tablet 
 
 
Trade Company 
Country 
of Origin 
Origin Classification Available in other form PMS 
1.  
Amifenac Amipharma Sudan 
Local NO NO 
2.  
Epofenac Elie 
Sudan Local NO NO 
3.  
G.M Diclofenac GMC 
Sudan Local NO NO 
4.  
Yesenac Shangahi 
Sudan Local NO NO 
5.  
Votrex Pharma Exier Jordan Lower-middle-income 
Yes NO 
6.  
Diclogesic Kambal Jordan Lower-middle-income 
Yes NO 
ϳ.  
Olfen - 25 Nabil Switzerland High income 
Yes NO 
8.  
Voltaren Siusoba Italy High income 
Yes NO 
9.  
Taks Mabara Cyprus High income 
NO NO 
10. 
Remethan 25 Siho Cyprus High income 
Yes NO 
Mostly used 
Mostly used 
Most used 
Mostly used 
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Generic: Glibenclamide                                             Concentration: ϱ mg Tablet 
 
Trade Company 
Country of 
Origin 
Origin Classification Available in other form PMS 
1.  Cimanil Abd Munim Sudan Local NO NO 
2.  Epoclamide Elie Sudan Local NO NO 
3.  Wafranil Wafra Sudan Local NO NO 
4.  Glicon Dar Dawa Pakistan Low income NO NO 
5.  Glibamid Kerkisawi Lebanon Low income NO NO 
6.  Betanase Salmawit India Low income NO NO 
7.  Glibil Pharma exier Jordan Lower-middle-income NO NO 
8.  Glibesyn Kambal Cyprus High income NO NO 
9.  Gliban Mabara Cyprus High income NO NO 
10. Glitisol 5 Siho Cyprus High income NO NO 
11. Euglucon Dal Italy High income NO NO 
12. Glibenclamide Dal England High income NO NO 
Mostly used 
Mostly used 
Mostly used 
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Generic: Mefenamic Acid                                             Concentration: ϱϬϬ mg Tablet 
 
 
Trade Company 
Country of 
Origin 
Origin Classification Available in other form PMS 
1.  G.M Menapon GMC Sudan Local Yes Yes/+ 
2.  Elifan Elie Sudan Local Yes NO 
ϯ.  Mefnac DS Dar Dawa Pakistan Low income Yes Yes/+ 
4.  Pangesic Forte kanar Jordan Lower-middle-income Yes Yes/+ 
5.  Fendol D.S Fast Jordan Lower-middle-income Yes Yes/+ 
6.  Mafepain Dal KSA High income Yes NO 
 
 
 
 
 
Mostly used 
Mostly used 
Mostly used 
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Generic: Metronidazole                                             Concentration: ϮϱϬ mg Tablet 
 
 
Trade Company 
Country 
of Origin 
Origin Classification Available in other form PMS 
1.  Aminidazole Amipharma Sudan Local Yes Yes/+ 
2.  Epindazole Elie Sudan Local Yes NO 
3.  G.M Metrozal GMC Sudan Local Yes NO 
4.  Marwazole Marwa Sudan Local No NO 
5.  Yesazol Shangahi Sudan Local No NO 
6.  Wafrazole Wafra Sudan Local No NO 
7.  Metrozole Development Jordan Lower-middle-income Yes NO 
8.  Nidazole Fast Jordan Lower-middle-income Yes NO 
9.  Supplin Arabi Astoria High income No NO 
 
Mostly used 
Mostly used 
Most used 
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Generic: Paracetamol                                             Concentration: ϱϬϬ mg Tablet 
 Trade Company Country Classification Available in other  PMS 
1.  Amidol Amipharma Sudan Local Yes No 
2.  Clmamol Climax Sudan Local No No 
3.  Elidol Elie Sudan Local No No 
4.  Citymol City Pharma Sudan Local No No 
5.  G.M Paracetamol GMC Sudan Local No No 
6.  Humadol Humavite Sudan Local No No 
7.  Marwadol Marwa Sudan Local Yes No 
8.  Wafradol Wafra Sudan Local Yes No 
9.  Regamol Africa India Low income No No 
10.  Zerin Dar Dawa Bangladesh Low income No No 
11.  Dolomol Fast Jordan Lower-middle-income No No 
12.  Ultramol Rahma Syria Low income Yes No 
13.  Panadol Bodrian Ireland High income Yes No 
14.  Adol Kambal UAE High income Yes No 
Mostly used 
Mostly used 
Mostly used 
Mostly used 
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Annex ͹: Plan for medicines sample collection 
Package A 
 Generics Product A - High Product B - Low Product C - Local 
1. Amoxicillin 
   
   
   
   
2. Paracetamol 
   
   
   
   
3. Metronidazole 
   
   
   
   
4. Glibenclamide 
   
   
   
   
5. Diclofenac 
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Package B 
 Generics Product A - High Product B - Low Product C - Local 
1. Ciprofloxacin 
   
   
   
   
2. Mefenamic Acid 
   
   
   
   
3. Chlorphenarmine Maleate 
   
   
   
   
4. Aspirin 
   
   
   
   
5. Ceftriaxone 
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Annex :ͺ Samples analysis form 
Lab wok revision 
Physical 
Test Limits Results Comments 
Unit dose per container   
?  The sample pass. 
?  The sample fails. 
Description   
?  The sample pass 
?  The sample fails. 
Color and Uniformity of 
Color   
?  The sample pass 
?  The sample fails. 
Odor   
?  The sample pass 
?  The sample fails. 
Melting behavior   
?  The sample pass 
?  The sample fails. 
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Water solubility   
?  The sample pass 
?  The sample fails. 
Chloroform solubility   
?  The sample pass 
?  The sample fails. 
Dissolution test   
?  The sample pass 
?  The sample fails. 
Disintegration test   
?  The sample pass 
?  The sample fails. 
Weight   
?  The sample pass 
?  The sample fails. 
Hardness   
?  The sample pass 
?  The sample fails. 
pH test   
?  The sample pass 
?  The sample fails. 
Optical rotation   
?  The sample pass 
?  The sample fails. 
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Uniformity of       dosage 
units   
?  The sample pass 
?  The sample fails. 
Dosage form status 
(Damage)   
?  The sample pass 
?  The sample fails. 
Packaging material 
status   
?  The sample pass 
?  The sample fails. 
Label   
?  The sample pass 
?  The sample fails. 
Presence of 
contamination   
?  The sample pass 
?  The sample fails. 
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Chemical Tests 
Test Limits Results  
Identity test   
?  The sample pass 
?  The sample fails. 
%of stated 
concentration   
?  The sample pass 
?  The sample fails. 
Degradation   
?  The sample pass 
?  The sample fails. 
IR   
?  The sample pass 
?  The sample fails. 
TLC    
?  The sample pass 
?  The sample fails. 
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Annex ͻ: Amoxicillin Sensitivity Study 
Sample collection form 
 
Dear colleague, 
Please note that, this form and the sample as well are targeting the patients those will take 
Amoxicillin only as the main drug indicated for upper respiratory infections. 
 
A am  
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Annex XXX Ranking outcome 
Therapeutic 
groups  
Risk 
probability 
Dosage 
form 
Risk 
probability Origin 
Risk 
probability 
Consumption 
rate 
Risk 
probability Overall risk Rank 
Anti Ϭ͘ϯϳϲ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϴϱϬϱ ϴ͘ϱϬϱ 
Anti Ϭ͘ϯϳϲ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϴϰϴϮ ϴ͘ϰϴϮ 
Anti Ϭ͘ϯϳϲ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘Ϭϱϳϳϲ ϱ͘ϳϳϲ 
RT Ϭ͘ϭϰϰ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϯϮϱϳ ϯ͘Ϯϱϳ 
RT Ϭ͘ϭϰϰ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϯϮϰϵ ϯ͘Ϯϰϵ 
CVS Ϭ͘ϭϭϵ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϮϲϵϮ Ϯ͘ϲϵϮ 
CVS Ϭ͘ϭϭϵ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϮϲϴϱ Ϯ͘ϲϴϱ 
RT Ϭ͘ϭϰϰ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϮϮϭϮ Ϯ͘ϮϭϮ 
Anti Ϭ͘ϯϳϲ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϮϭϮϲ Ϯ͘ϭϮϲ 
Anti Ϭ͘ϯϳϲ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϮϭϮϭ Ϯ͘ϭϮϭ 
NUT Ϭ͘Ϭϵϭ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϮϬϱϴ Ϯ͘Ϭϱϴ 
NUT Ϭ͘Ϭϵϭ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϮϬϱϯ Ϯ͘Ϭϱϯ 
MUS Ϭ͘Ϭϴϴ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘Ϭϭϵϵϭ ϭ͘ϵϵϭ 
MUS Ϭ͘Ϭϴϴ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘Ϭϭϵϴϱ ϭ͘ϵϴϱ 
CVS Ϭ͘ϭϭϵ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϭϴϮϴ ϭ͘ϴϮϴ 
END Ϭ͘Ϭϳϳ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϭϳϰϮ ϭ͘ϳϰϮ 
END Ϭ͘Ϭϳϳ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘Ϭϭϳϯϳ ϭ͘ϳϯϳ 
Anti Ϭ͘ϯϳϲ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϭϱϯϬ ϭ͘ϱϯϬ 
Anti Ϭ͘ϯϳϲ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϭϱϮϲ ϭ͘ϱϮϲ 
Anti Ϭ͘ϯϳϲ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘Ϭϭϰϰϰ ϭ͘ϰϰϰ 
NUT Ϭ͘Ϭϵϭ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘Ϭϭϯϵϴ ϭ͘ϯϵϴ 
MUS Ϭ͘Ϭϴϴ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϭϯϱϮ ϭ͘ϯϱϮ 
END Ϭ͘Ϭϳϳ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘Ϭϭϭϴϯ ϭ͘ϭϴϯ 
Anti Ϭ͘ϯϳϲ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϭϬϯϵ ϭ͘Ϭϯϵ 
Anti Ϭ͘ϯϳϲ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϵϬϬ Ϭ͘ϵϬϬ 
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Anti Ϭ͘ϯϳϲ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϴϵϴ Ϭ͘ϴϵϴ 
RT Ϭ͘ϭϰϰ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϴϭϰ Ϭ͘ϴϭϰ 
RT Ϭ͘ϭϰϰ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϴϭϮ Ϭ͘ϴϭϮ 
GIT Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϳϵϮ Ϭ͘ϳϵϮ 
CNS Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϳϵϮ Ϭ͘ϳϵϮ 
GIT Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϳϵϬ Ϭ͘ϳϵϬ 
CNS Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϳϵϬ Ϭ͘ϳϵϬ 
CVS Ϭ͘ϭϭϵ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϲϳϯ Ϭ͘ϲϳϯ 
CVS Ϭ͘ϭϭϵ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϲϳϭ Ϭ͘ϲϳϭ 
Anti Ϭ͘ϯϳϲ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϲϭϭ Ϭ͘ϲϭϭ 
RT Ϭ͘ϭϰϰ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϱϴϲ Ϭ͘ϱϴϲ 
RT Ϭ͘ϭϰϰ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϱϴϰ Ϭ͘ϱϴϰ 
RT Ϭ͘ϭϰϰ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϱϱϯ Ϭ͘ϱϱϯ 
GIT Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϱϯϴ Ϭ͘ϱϯϴ 
CNS Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϱϯϴ Ϭ͘ϱϯϴ 
NUT Ϭ͘Ϭϵϭ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϱϭϱ Ϭ͘ϱϭϱ 
NUT Ϭ͘Ϭϵϭ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϱϭϯ Ϭ͘ϱϭϯ 
MUS Ϭ͘Ϭϴϴ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϰϵϴ Ϭ͘ϰϵϴ 
MUS Ϭ͘Ϭϴϴ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϰϵϲ Ϭ͘ϰϵϲ 
CVS Ϭ͘ϭϭϵ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϰϴϰ Ϭ͘ϰϴϰ 
CVS Ϭ͘ϭϭϵ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϰϴϯ Ϭ͘ϰϴϯ 
SKN Ϭ͘ϬϮϭ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϰϳϱ Ϭ͘ϰϳϱ 
SKN Ϭ͘ϬϮϭ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϰϳϰ Ϭ͘ϰϳϰ 
CVS Ϭ͘ϭϭϵ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϰϱϳ Ϭ͘ϰϱϳ 
END Ϭ͘Ϭϳϳ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϰϯϱ Ϭ͘ϰϯϱ 
END Ϭ͘Ϭϳϳ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϰϯϰ Ϭ͘ϰϯϰ 
RT Ϭ͘ϭϰϰ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϵϴ Ϭ͘ϯϵϴ 
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Anti Ϭ͘ϯϳϲ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϯϴϮ Ϭ͘ϯϴϮ 
Anti Ϭ͘ϯϳϲ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϯϴϭ Ϭ͘ϯϴϭ 
NUT Ϭ͘Ϭϵϭ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϳϬ Ϭ͘ϯϳϬ 
NUT Ϭ͘Ϭϵϭ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϲϵ Ϭ͘ϯϲϵ 
MUS Ϭ͘Ϭϴϴ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϱϴ Ϭ͘ϯϱϴ 
MUS Ϭ͘Ϭϴϴ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϱϳ Ϭ͘ϯϱϳ 
NUT Ϭ͘Ϭϵϭ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϯϰϵ Ϭ͘ϯϰϵ 
RT Ϭ͘ϭϰϰ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϰϱ Ϭ͘ϯϰϱ 
RT Ϭ͘ϭϰϰ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϰϰ Ϭ͘ϯϰϰ 
MUS Ϭ͘Ϭϴϴ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϯϯϴ Ϭ͘ϯϯϴ 
CVS Ϭ͘ϭϭϵ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϮϵ Ϭ͘ϯϮϵ 
SKN Ϭ͘ϬϮϭ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϮϯ Ϭ͘ϯϮϯ 
END Ϭ͘Ϭϳϳ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϭϯ Ϭ͘ϯϭϯ 
END Ϭ͘Ϭϳϳ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϯϭϮ Ϭ͘ϯϭϮ 
END Ϭ͘Ϭϳϳ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϮϵϲ Ϭ͘Ϯϵϲ 
OBS Ϭ͘Ϭϭϯ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϵϰ Ϭ͘Ϯϵϰ 
OBS Ϭ͘Ϭϭϯ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϵϯ Ϭ͘Ϯϵϯ 
CVS Ϭ͘ϭϭϵ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϴϱ Ϭ͘Ϯϴϱ 
CVS Ϭ͘ϭϭϵ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϴϰ Ϭ͘Ϯϴϰ 
Anti Ϭ͘ϯϳϲ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϮϲϬ Ϭ͘ϮϲϬ 
NUT Ϭ͘Ϭϵϭ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϱϭ Ϭ͘Ϯϱϭ 
MUS Ϭ͘Ϭϴϴ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϰϯ Ϭ͘Ϯϰϯ 
RT Ϭ͘ϭϰϰ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϯϰ Ϭ͘Ϯϯϰ 
Anti Ϭ͘ϯϳϲ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϮϮϱ Ϭ͘ϮϮϱ 
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Anti Ϭ͘ϯϳϲ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϮϮϰ Ϭ͘ϮϮϰ 
NUT Ϭ͘Ϭϵϭ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϭϴ Ϭ͘Ϯϭϴ 
NUT Ϭ͘Ϭϵϭ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϭϳ Ϭ͘Ϯϭϳ 
END Ϭ͘Ϭϳϳ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϭϯ Ϭ͘Ϯϭϯ 
MUS Ϭ͘Ϭϴϴ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϭϭ Ϭ͘Ϯϭϭ 
MUS Ϭ͘Ϭϴϴ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϭϬ Ϭ͘ϮϭϬ 
OBS Ϭ͘Ϭϭϯ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϮϬϬ Ϭ͘ϮϬϬ 
GIT Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϵϴ Ϭ͘ϭϵϴ 
CNS Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϵϴ Ϭ͘ϭϵϴ 
GIT Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϵϳ Ϭ͘ϭϵϳ 
CNS Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϵϳ Ϭ͘ϭϵϳ 
CVS Ϭ͘ϭϭϵ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϵϯ Ϭ͘ϭϵϯ 
END Ϭ͘Ϭϳϳ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϴϰ Ϭ͘ϭϴϰ 
END Ϭ͘Ϭϳϳ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϴϰ Ϭ͘ϭϴϰ 
Anti Ϭ͘ϯϳϲ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϱϯ Ϭ͘ϭϱϯ 
NUT Ϭ͘Ϭϵϭ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϰϴ Ϭ͘ϭϰϴ 
RT Ϭ͘ϭϰϰ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϰϲ Ϭ͘ϭϰϲ 
RT Ϭ͘ϭϰϰ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϰϲ Ϭ͘ϭϰϲ 
MUS Ϭ͘Ϭϴϴ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϰϯ Ϭ͘ϭϰϯ 
GIT Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϰϮ Ϭ͘ϭϰϮ 
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CNS Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϰϮ Ϭ͘ϭϰϮ 
GIT Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϰϮ Ϭ͘ϭϰϮ 
CNS Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϰϮ Ϭ͘ϭϰϮ 
GIT Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϯϰ Ϭ͘ϭϯϰ 
CNS Ϭ͘Ϭϯϱ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϯϰ Ϭ͘ϭϯϰ 
END Ϭ͘Ϭϳϳ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϮϱ Ϭ͘ϭϮϱ 
Anti Ϭ͘ϯϳϲ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϮϰ Ϭ͘ϭϮϰ 
Anti Ϭ͘ϯϳϲ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϮϰ Ϭ͘ϭϮϰ 
Anti Ϭ͘ϯϳϲ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϮϯ Ϭ͘ϭϮϯ 
Anti Ϭ͘ϯϳϲ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϭϮϯ Ϭ͘ϭϮϯ 
CVS Ϭ͘ϭϭϵ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϮϭ Ϭ͘ϭϮϭ 
CVS Ϭ͘ϭϭϵ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϮϭ Ϭ͘ϭϮϭ 
SKN Ϭ͘ϬϮϭ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϭϵ Ϭ͘ϭϭϵ 
SKN Ϭ͘ϬϮϭ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϭϭϴ Ϭ͘ϭϭϴ 
RT Ϭ͘ϭϰϰ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϵϵ Ϭ͘Ϭϵϵ 
GIT Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϵϳ Ϭ͘Ϭϵϳ 
CNS Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϵϳ Ϭ͘Ϭϵϳ 
NUT Ϭ͘Ϭϵϭ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϵϯ Ϭ͘Ϭϵϯ 
NUT Ϭ͘Ϭϵϭ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϵϮ Ϭ͘ϬϵϮ 
MUS Ϭ͘Ϭϴϴ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϵϬ Ϭ͘ϬϵϬ 
MUS Ϭ͘Ϭϴϴ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϴϵ Ϭ͘Ϭϴϵ 
RT Ϭ͘ϭϰϰ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϴϲ Ϭ͘Ϭϴϲ 
RT Ϭ͘ϭϰϰ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϴϲ Ϭ͘Ϭϴϲ 
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SKN Ϭ͘ϬϮϭ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϴϱ Ϭ͘Ϭϴϱ 
SKN Ϭ͘ϬϮϭ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϴϱ Ϭ͘Ϭϴϱ 
Anti Ϭ͘ϯϳϲ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϴϰ Ϭ͘Ϭϴϰ 
Anti Ϭ͘ϯϳϲ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϴϰ Ϭ͘Ϭϴϰ 
GIT Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϴϰ Ϭ͘Ϭϴϰ 
CNS Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϴϰ Ϭ͘Ϭϴϰ 
GIT Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϴϰ Ϭ͘Ϭϴϰ 
CNS Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϴϰ Ϭ͘Ϭϴϰ 
CVS Ϭ͘ϭϭϵ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϴϮ Ϭ͘ϬϴϮ 
SKN Ϭ͘ϬϮϭ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϴϭ Ϭ͘Ϭϴϭ 
END Ϭ͘Ϭϳϳ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϳϴ Ϭ͘Ϭϳϴ 
END Ϭ͘Ϭϳϳ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϳϴ Ϭ͘Ϭϳϴ 
OBS Ϭ͘Ϭϭϯ solid-oral Ϭ͘ϳϱϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϳϰ Ϭ͘Ϭϳϰ 
OBS Ϭ͘Ϭϭϯ solid-oral Ϭ͘ϳϱϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϳϯ Ϭ͘Ϭϳϯ 
CVS Ϭ͘ϭϭϵ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϳϭ Ϭ͘Ϭϳϭ 
CVS Ϭ͘ϭϭϵ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϳϭ Ϭ͘Ϭϳϭ 
Anti Ϭ͘ϯϳϲ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϲϳ Ϭ͘Ϭϲϳ 
Anti Ϭ͘ϯϳϲ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϲϳ Ϭ͘Ϭϲϳ 
NUT Ϭ͘Ϭϵϭ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϲϯ Ϭ͘Ϭϲϯ 
MUS Ϭ͘Ϭϴϴ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϲϭ Ϭ͘Ϭϲϭ 
RT Ϭ͘ϭϰϰ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϱϵ Ϭ͘Ϭϱϵ 
SKN Ϭ͘ϬϮϭ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϱϴ Ϭ͘Ϭϱϴ 
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GIT Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϱϳ Ϭ͘Ϭϱϳ 
CNS Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϱϳ Ϭ͘Ϭϱϳ 
NUT Ϭ͘Ϭϵϭ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϱϰ Ϭ͘Ϭϱϰ 
NUT Ϭ͘Ϭϵϭ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϱϰ Ϭ͘Ϭϱϰ 
END Ϭ͘Ϭϳϳ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϱϯ Ϭ͘Ϭϱϯ 
OBS Ϭ͘Ϭϭϯ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϱϯ Ϭ͘Ϭϱϯ 
OBS Ϭ͘Ϭϭϯ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϱϯ Ϭ͘Ϭϱϯ 
MUS Ϭ͘Ϭϴϴ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϱϯ Ϭ͘Ϭϱϯ 
MUS Ϭ͘Ϭϴϴ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϱϯ Ϭ͘Ϭϱϯ 
SKN Ϭ͘ϬϮϭ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϱϬ Ϭ͘ϬϱϬ 
SKN Ϭ͘ϬϮϭ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϱϬ Ϭ͘ϬϱϬ 
OBS Ϭ͘Ϭϭϯ solid-oral Ϭ͘ϳϱϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϱϬ Ϭ͘ϬϱϬ 
CVS Ϭ͘ϭϭϵ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϰϴ Ϭ͘Ϭϰϴ 
RT Ϭ͘ϭϰϰ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϰϳ Ϭ͘Ϭϰϳ 
RT Ϭ͘ϭϰϰ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϰϳ Ϭ͘Ϭϰϳ 
RT Ϭ͘ϭϰϰ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϰϳ Ϭ͘Ϭϰϳ 
RT Ϭ͘ϭϰϰ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϰϳ Ϭ͘Ϭϰϳ 
END Ϭ͘Ϭϳϳ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϰϲ Ϭ͘Ϭϰϲ 
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END Ϭ͘Ϭϳϳ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϰϲ Ϭ͘Ϭϰϲ 
Anti Ϭ͘ϯϳϲ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϰϲ Ϭ͘Ϭϰϲ 
CVS Ϭ͘ϭϭϵ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϵ Ϭ͘Ϭϯϵ 
CVS Ϭ͘ϭϭϵ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϵ Ϭ͘Ϭϯϵ 
CVS Ϭ͘ϭϭϵ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϵ Ϭ͘Ϭϯϵ 
CVS Ϭ͘ϭϭϵ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϵ Ϭ͘Ϭϯϵ 
NUT Ϭ͘Ϭϵϭ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϳ Ϭ͘Ϭϯϳ 
OBS Ϭ͘Ϭϭϯ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϲ Ϭ͘Ϭϯϲ 
MUS Ϭ͘Ϭϴϴ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϲ Ϭ͘Ϭϯϲ 
GIT Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϲ Ϭ͘Ϭϯϲ 
CNS Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϲ Ϭ͘Ϭϯϲ 
GIT Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϲ Ϭ͘Ϭϯϲ 
CNS Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϲ Ϭ͘Ϭϯϲ 
SKN Ϭ͘ϬϮϭ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϰ Ϭ͘Ϭϯϰ 
RT Ϭ͘ϭϰϰ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϮ Ϭ͘ϬϯϮ 
RT Ϭ͘ϭϰϰ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϮ Ϭ͘ϬϯϮ 
END Ϭ͘Ϭϳϳ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϭ Ϭ͘Ϭϯϭ 
OBS Ϭ͘Ϭϭϯ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϭ Ϭ͘Ϭϯϭ 
OBS Ϭ͘Ϭϭϯ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϭ Ϭ͘Ϭϯϭ 
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Anti Ϭ͘ϯϳϲ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϭ Ϭ͘Ϭϯϭ 
Anti Ϭ͘ϯϳϲ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϭ Ϭ͘Ϭϯϭ 
Anti Ϭ͘ϯϳϲ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϭ Ϭ͘Ϭϯϭ 
Anti Ϭ͘ϯϳϲ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϯϭ Ϭ͘Ϭϯϭ 
NUT Ϭ͘Ϭϵϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϬ Ϭ͘ϬϯϬ 
NUT Ϭ͘Ϭϵϭ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϬ Ϭ͘ϬϯϬ 
NUT Ϭ͘Ϭϵϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϬ Ϭ͘ϬϯϬ 
NUT Ϭ͘Ϭϵϭ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϯϬ Ϭ͘ϬϯϬ 
MUS Ϭ͘Ϭϴϴ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϵ Ϭ͘ϬϮϵ 
MUS Ϭ͘Ϭϴϴ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϵ Ϭ͘ϬϮϵ 
MUS Ϭ͘Ϭϴϴ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϵ Ϭ͘ϬϮϵ 
MUS Ϭ͘Ϭϴϴ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϵ Ϭ͘ϬϮϵ 
CVS Ϭ͘ϭϭϵ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϳ Ϭ͘ϬϮϳ 
CVS Ϭ͘ϭϭϵ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϳ Ϭ͘ϬϮϳ 
RT Ϭ͘ϭϰϰ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϲ Ϭ͘ϬϮϲ 
RT Ϭ͘ϭϰϰ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϲ Ϭ͘ϬϮϲ 
END Ϭ͘Ϭϳϳ 
other 
large- Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϱ Ϭ͘ϬϮϱ 
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liquid 
END Ϭ͘Ϭϳϳ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϱ Ϭ͘ϬϮϱ 
END Ϭ͘Ϭϳϳ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϱ Ϭ͘ϬϮϱ 
END Ϭ͘Ϭϳϳ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϱ Ϭ͘ϬϮϱ 
GIT Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϰ Ϭ͘ϬϮϰ 
CNS Ϭ͘Ϭϯϱ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϰ Ϭ͘ϬϮϰ 
CVS Ϭ͘ϭϭϵ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
SKN Ϭ͘ϬϮϭ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
SKN Ϭ͘ϬϮϭ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
CVS Ϭ͘ϭϭϵ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
OBS Ϭ͘Ϭϭϯ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
Anti Ϭ͘ϯϳϲ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
Anti Ϭ͘ϯϳϲ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
GIT Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
CNS Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
GIT Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
CNS Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϮϭ Ϭ͘ϬϮϭ 
NUT Ϭ͘Ϭϵϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϬ Ϭ͘ϬϮϬ 
NUT Ϭ͘Ϭϵϭ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϬ Ϭ͘ϬϮϬ 
MUS Ϭ͘Ϭϴϴ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϬ Ϭ͘ϬϮϬ 
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large-
liquid 
MUS Ϭ͘Ϭϴϴ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϮϬ Ϭ͘ϬϮϬ 
RT Ϭ͘ϭϰϰ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϴ Ϭ͘Ϭϭϴ 
END Ϭ͘Ϭϳϳ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϳ Ϭ͘Ϭϭϳ 
END Ϭ͘Ϭϳϳ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϳ Ϭ͘Ϭϭϳ 
Anti Ϭ͘ϯϳϲ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϳ Ϭ͘Ϭϭϳ 
Anti Ϭ͘ϯϳϲ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϳ Ϭ͘Ϭϭϳ 
NUT Ϭ͘Ϭϵϭ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϲ Ϭ͘Ϭϭϲ 
NUT Ϭ͘Ϭϵϭ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϲ Ϭ͘Ϭϭϲ 
MUS Ϭ͘Ϭϴϴ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϲ Ϭ͘Ϭϭϲ 
MUS Ϭ͘Ϭϴϴ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϲ Ϭ͘Ϭϭϲ 
SKN Ϭ͘ϬϮϭ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϱ Ϭ͘Ϭϭϱ 
CVS Ϭ͘ϭϭϵ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϱ Ϭ͘Ϭϭϱ 
GIT Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϰ Ϭ͘Ϭϭϰ 
CNS Ϭ͘Ϭϯϱ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϰ Ϭ͘Ϭϭϰ 
END Ϭ͘Ϭϳϳ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϰ Ϭ͘Ϭϭϰ 
END Ϭ͘Ϭϳϳ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϰ Ϭ͘Ϭϭϰ 
OBS Ϭ͘Ϭϭϯ liquid-oral Ϭ͘ϭϯϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϯ Ϭ͘Ϭϭϯ 
OBS Ϭ͘Ϭϭϯ liquid-oral Ϭ͘ϭϯϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϯ Ϭ͘Ϭϭϯ 
SKN Ϭ͘ϬϮϭ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϯ Ϭ͘Ϭϭϯ 
SKN Ϭ͘ϬϮϭ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϯ Ϭ͘Ϭϭϯ 
RT Ϭ͘ϭϰϰ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϮ Ϭ͘ϬϭϮ 
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RT Ϭ͘ϭϰϰ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϮ Ϭ͘ϬϭϮ 
RT Ϭ͘ϭϰϰ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϮ Ϭ͘ϬϭϮ 
RT Ϭ͘ϭϰϰ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϮ Ϭ͘ϬϭϮ 
GIT Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϮ Ϭ͘ϬϭϮ 
GIT Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϮ Ϭ͘ϬϭϮ 
CNS Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϮ Ϭ͘ϬϭϮ 
CNS Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϮ Ϭ͘ϬϭϮ 
GIT Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϭ Ϭ͘Ϭϭϭ 
GIT Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϭ Ϭ͘Ϭϭϭ 
CNS Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϭ Ϭ͘Ϭϭϭ 
CNS Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϭ Ϭ͘Ϭϭϭ 
Anti Ϭ͘ϯϳϲ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϭ Ϭ͘Ϭϭϭ 
NUT Ϭ͘Ϭϵϭ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϭ Ϭ͘Ϭϭϭ 
MUS Ϭ͘Ϭϴϴ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϭϭ Ϭ͘Ϭϭϭ 
CVS Ϭ͘ϭϭϵ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϬ Ϭ͘ϬϭϬ 
CVS Ϭ͘ϭϭϵ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϬ Ϭ͘ϬϭϬ 
CVS Ϭ͘ϭϭϵ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϬ Ϭ͘ϬϭϬ 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϮϳϮ 
 
CVS Ϭ͘ϭϭϵ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϭϬ Ϭ͘ϬϭϬ 
END Ϭ͘Ϭϳϳ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϵ Ϭ͘ϬϬϵ 
OBS Ϭ͘Ϭϭϯ liquid-oral Ϭ͘ϭϯϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϵ Ϭ͘ϬϬϵ 
SKN Ϭ͘ϬϮϭ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϵ Ϭ͘ϬϬϵ 
RT Ϭ͘ϭϰϰ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϴ Ϭ͘ϬϬϴ 
RT Ϭ͘ϭϰϰ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϴ Ϭ͘ϬϬϴ 
GIT Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϴ Ϭ͘ϬϬϴ 
GIT Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϴ Ϭ͘ϬϬϴ 
CNS Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϴ Ϭ͘ϬϬϴ 
CNS Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϴ Ϭ͘ϬϬϴ 
OBS Ϭ͘Ϭϭϯ 
small-
parenteral Ϭ͘Ϭϴ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϴ Ϭ͘ϬϬϴ 
OBS Ϭ͘Ϭϭϯ 
small-
parenteral Ϭ͘Ϭϴ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϴ Ϭ͘ϬϬϴ 
NUT Ϭ͘Ϭϵϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
NUT Ϭ͘Ϭϵϭ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
NUT Ϭ͘Ϭϵϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
NUT Ϭ͘Ϭϵϭ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
MUS Ϭ͘Ϭϴϴ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
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MUS Ϭ͘Ϭϴϴ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
MUS Ϭ͘Ϭϴϴ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
MUS Ϭ͘Ϭϴϴ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
SKN Ϭ͘ϬϮϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
SKN Ϭ͘ϬϮϭ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
SKN Ϭ͘ϬϮϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
SKN Ϭ͘ϬϮϭ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
CVS Ϭ͘ϭϭϵ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
CVS Ϭ͘ϭϭϵ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϳ Ϭ͘ϬϬϳ 
RT Ϭ͘ϭϰϰ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
RT Ϭ͘ϭϰϰ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
END Ϭ͘Ϭϳϳ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
END Ϭ͘Ϭϳϳ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
END Ϭ͘Ϭϳϳ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
END Ϭ͘Ϭϳϳ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
GIT Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
CNS Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
GIT Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
CNS Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϲ Ϭ͘ϬϬϲ 
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CVS Ϭ͘ϭϭϵ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
CVS Ϭ͘ϭϭϵ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
OBS Ϭ͘Ϭϭϯ 
small-
parenteral Ϭ͘Ϭϴ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
NUT Ϭ͘Ϭϵϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
NUT Ϭ͘Ϭϵϭ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
MUS Ϭ͘Ϭϴϴ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
MUS Ϭ͘Ϭϴϴ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
SKN Ϭ͘ϬϮϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
SKN Ϭ͘ϬϮϭ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϱ Ϭ͘ϬϬϱ 
RT Ϭ͘ϭϰϰ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
END Ϭ͘Ϭϳϳ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
END Ϭ͘Ϭϳϳ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
OBS Ϭ͘Ϭϭϯ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
OBS Ϭ͘Ϭϭϯ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
GIT Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
CNS Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
OBS Ϭ͘Ϭϭϯ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
OBS Ϭ͘Ϭϭϯ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
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NUT Ϭ͘Ϭϵϭ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
NUT Ϭ͘Ϭϵϭ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
MUS Ϭ͘Ϭϴϴ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
MUS Ϭ͘Ϭϴϴ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
SKN Ϭ͘ϬϮϭ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
SKN Ϭ͘ϬϮϭ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
CVS Ϭ͘ϭϭϵ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϰ Ϭ͘ϬϬϰ 
END Ϭ͘Ϭϳϳ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
END Ϭ͘Ϭϳϳ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
OBS Ϭ͘Ϭϭϯ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
OBS Ϭ͘Ϭϭϯ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
GIT Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
GIT Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
CNS Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
CNS Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
GIT Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
GIT Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
CNS Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
CNS Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
NUT Ϭ͘Ϭϵϭ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
MUS Ϭ͘Ϭϴϴ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
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SKN Ϭ͘ϬϮϭ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϯ Ϭ͘ϬϬϯ 
END Ϭ͘Ϭϳϳ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
OBS Ϭ͘Ϭϭϯ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
OBS Ϭ͘Ϭϭϯ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
GIT Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
GIT Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
CNS Ϭ͘Ϭϯϱ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
CNS Ϭ͘Ϭϯϱ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
SKN Ϭ͘ϬϮϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
SKN Ϭ͘ϬϮϭ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
SKN Ϭ͘ϬϮϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
SKN Ϭ͘ϬϮϭ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
OBS Ϭ͘Ϭϭϯ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ high consumption Ϭ͘ϴ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
GIT Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
CNS Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
GIT Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
CNS Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϮ Ϭ͘ϬϬϮ 
SKN Ϭ͘ϬϮϭ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
SKN Ϭ͘ϬϮϭ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
OBS Ϭ͘Ϭϭϯ 
other 
large- Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
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liquid 
OBS Ϭ͘Ϭϭϯ other Ϭ͘Ϭϭϭ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
GIT Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
CNS Ϭ͘Ϭϯϱ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
OBS Ϭ͘Ϭϭϯ 
other 
large-
liquid Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
OBS Ϭ͘Ϭϭϯ other Ϭ͘Ϭϭϭ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
SKN Ϭ͘ϬϮϭ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
SKN Ϭ͘ϬϮϭ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
OBS Ϭ͘Ϭϭϯ 
other 
large-
liquid Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
OBS Ϭ͘Ϭϭϯ other Ϭ͘Ϭϭϭ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
SKN Ϭ͘ϬϮϭ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
OBS Ϭ͘Ϭϭϯ topical Ϭ͘ϬϬϲ Local Ϭ͘ϯϳϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
OBS Ϭ͘Ϭϭϯ topical Ϭ͘ϬϬϲ Low&mid income countries Ϭ͘ϯϳϯ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϭ Ϭ͘ϬϬϭ 
OBS Ϭ͘Ϭϭϯ topical Ϭ͘ϬϬϲ high income countries Ϭ͘Ϯϱϰ low consumption Ϭ͘Ϯ Ϭ͘ϬϬϬϬϬ Ϭ͘ϬϬϬ 
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Glossary 
 
Some of the terms used within this repot were defined below based on the reference 
definition for all terms. 
1. Active Pharmaceutical Ingredient (API): 
A substance or compound intended to be used in the manufacture of a 
pharmaceutical product as a pharmacologically active compound (ingredient). 
2. Adverse Drug Reactions (ADRs): 
Any unwanted effect(s) produced by a drug that is harmful to the patient. Onset 
may be sudden or develop over time. 
3. Assay: 
The monograph standard test, with associated method of analysis, which is 
designed to determine the strength of a drug product 
4. Basic Tests: 
Simplified analytical tests that do not require complex methodologies and 
equipment. Basic tests may be used to verify the identity of a drug or to ascertain 
the absence of gross degradations or contamination. 
5. Batch: 
A defined quantity of starting material, packaging material, or product processed in 
a single process or series of processes so that the product could be expected to be 
homogeneous. In the case of continuous manufacture, the batch must correspond 
to a de.ned fraction of the production, characterized by its intended homogeneity. A 
batch may need to be divided into smaller batches, which are later combined to 
form final homogeneous batch. 
 
6. Batch Certificate: 
A document containing information that is usually issued for each batch by the 
manufacturer, or validated or issued by the competent authority of the exporting 
country, particularly for vaccines, sera, and other biological products. The batch 
certificate accompanies every major consignment. 
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7. Batch Number: 
A distinctive combination of numbers, letters, or both that specifically identifies a 
batch on the labels, the batch records, and the certificate of analysis, etc. 
8. Bioavailability: 
The rate and extent of availability of an active ingredient from a dosage form as 
measured by its concentration/time curve in the systemic circulation or its excretion 
in the urine. 
9. Bioequivalence: 
Two pharmaceutical products are bioequivalent if they are pharmaceutically 
equivalent, and their bioavailability, after administration in the same molar dose, is 
similar to such a degree that their effects can be expected to be essentially the 
same. 
10. Certificate of Analysis: 
Report of the analytical test results obtained, including the analysis conclusion of 
the examination of a sample issued by the manufacturer, repackager or trader. 
11. Counterfeit Drug: 
A pharmaceutical product that is deliberately and fraudulently mislabeled with 
respect to identity or source. Both branded and generic products can be 
counterfeited. Counterfeit drugs can include products with the correct ingredients, 
with the wrong ingredients, without active ingredients, with insufficient quantity of 
active ingredients, or with fake packaging. A counterfeit drug can be a deliberate 
imitation or a copy of a genuine product. 
12. Disintegration: 
The breaking up of a tablet or a capsule into granules or aggregates in an aqueous 
fluid. 
13. Dissolution: 
The process by which a solid substance is separated into molecules or ions that 
homogeneously disperses in an aqueous fluid to form a solution. The rate of 
dissolution is determined by the interaction between the substance and the 
medium. 
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14. Dosage Form: 
The form - tablet, capsule, injection - of a completed pharmaceutical preparation. 
15. Dosage (or strength):  
The content of the active ingredient per dosage unit is determined by the assay of 
the specific monograph and expressed, generally, in milligrams or units per dosage 
unit. 
16. Drug: 
 Any substance or pharmaceutical product for human or veterinary use that is 
intended to modify or explore physiological systems or pathological states for the 
benefit of the recipient. 
17. Drug Product: 
A Finished dosage form (e.g., tablet, capsule, or solution) that contains a drug 
substance generally, but not necessarily, in association with one or more other 
ingredients. 
18. Efficacy (of a Medicine or Treatment): 
The maximum ability of a medicine or treatment to produce a result regardless of 
dosage. A medicine passes efficacy trials if it is effective at the dose tested and 
against the illness for which it is prescribed. 
19. Essential Medicines: 
Medicines that satisfy the priority health care needs of a population. Essential 
medicines are selected with due regard for public health relevance, evidence of 
efficacy and safety, and comparative cost-effectiveness. Essential medicines are 
intended to be available within the context of functioning health systems at all times 
in adequate amounts, in appropriate dosage forms, with assured quality and 
adequate information, and at a price that individuals and communities can afford. 
20. Expiry (or Expiration) Date: 
The date up to which a product is expected to remain within specifications, if stored 
correctly. Expiry date is established by the manufacturer for each batch by adding 
the shelf-life period to the date of manufacture. 
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21. Generic Drug: 
A generic drug is the same as a brand name drug is dosage, safety, strength, how 
it is taken, quality, performance, and intended use. Before a generic drug is 
approved, an MRA should require many rigorous tests and procedures to assure 
the generic drug can be substituted for a brand name drug. 
22. Generic Name: 
The approved or International Nonproprietary Name of a drug given by the World 
Health Organization. 
23. Generic Products: 
A pharmaceutical product - usually intended to be interchangeable with the 
innovator product - is usually manufactured without a license from the innovator 
company and marketed after expiry of the patent or other exclusivity rights. The 
term should not be confused with generic names for APIs. 
24. Good Manufacturing Practices (GMP): 
The part of quality assurance that ensures that pharmaceutical products are 
consistently produced and controlled by the quality standards appropriate to their 
intended use and as required by the marketing authorization. These standards 
include criteria for personnel, facilities, equipment, materials, manufacturing 
operations, labeling, packaging, quality control, and in most cases, stability testing. 
25. Identity: 
The correct chemical substance and formula of an active ingredient in a drug 
product. 
26. Identity Test: 
The selected test in the monograph to verify that the API is correct for that drug 
product. 
27. International Nonproprietary Names: 
International nonproprietary names facilitate the identification of pharmaceutical 
substances or active pharmaceutical ingredients. Each INN is a unique name that 
is globally recognized and is public property. A nonproprietary name is also known 
as a generic name. Proposals for recommended international nonproprietary 
names are submitted to the World Health Organization on a form provided by WHO 
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by the purpose. The name used by the person discovering or first developing and 
marketing a pharmaceutical substance shall be accepted, unless there are 
compelling reasons to the contrary. 
28. Label: 
All finished drug products should be identified by labeling, as required by national 
legislation, bearing at least the following information: 
a) The name of the drug product. 
b) A list of the active ingredients (if applicable, with the International Nonproprietary 
Names), showing the amount of each active ingredient present, and a statement of 
the net contents (number of dosage units, mass, or volume). 
c) The batch number assigned by the manufacturer. 
d) The expiry date and manufacturing date in un coded form. 
e) Special storage conditions or handling precautions that may be necessary. 
f) Directions for use, and any warnings or precautions that may be necessary. 
g) The name and address of the manufacturer or the company or person responsible 
for placing the product on the market. 
29. Marketing Authorization: 
An official document issued by a competent medicines regulatory authority for the 
purpose of marketing or free distribution of a product after evaluation for safety, 
efficacy and quality. The certificate must set out, among other things, the name of 
the product, the pharmaceutical dosage form, the quantitative formula (including 
excipients) per unit dose (using INN or national generic names where they exist), 
the shelf-life and storage conditions, and packaging characteristics. The document 
speci.es the information on which authorization is based. The license also contains 
the product information approved for health professionals and the public, the sales 
category, the name and address of the holder of the authorization, and the period 
of validity of the authorization. 
30. Medicines Regulatory Authority (MRA): 
A national body that administers the full spectrum of regulatory activities associated 
with pharmaceuticals, including at least all of the following functions: marketing 
authorization of new products and variation of existing products; quality controlled 
laboratory testing (although in some countries, the laboratory may not be part of the 
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MRA); adverse drug reaction monitoring; provision of medicine information and 
promotion of rational medicine use; good manufacturing practice inspections and 
licensing of manufacturers, wholesalers, and distribution channels; enforcement of 
operations; and monitoring of drug utilization. 
31. Method Validation: 
A demonstration of the suitability of the analytical procedure for its intended use. 
The characteristics of the analytical procedures to be considered in method 
validation are accuracy, precision, robustness, linearity and range, selectivity, limit 
of detection, and limit of quantization. 
32. Monograph: 
A set of properly selected standardized tests with associated methods of analysis 
that can be used to assess the integrity of drugs (including dosage forms) and 
starting materials. These standards, when met, assure the quality of the drug with 
respect to identity, purity, strength, packaging, storage, and labeling. Monographs 
are published in pharmacopeia. 
33. Over-the-Counter (OTC) Medicine: 
Medicines that can be sold from licensed retail pharmacies or outlets without 
professional supervision and without a physician’s prescription. OTC medicines are 
considered safe and effective for use by the general public. OTC medicines are 
suitable for self-medication for minor diseases and symptoms. 
34. Pharmacopeia: 
A book containing an official list of monographs and internationally acceptable 
standards for the potency, purity, quality, packaging, and labeling of 
pharmaceutical products. The major pharmacopeias in the world are the 
International Pharmacopeia, the United States Pharmacopeia, the British 
Pharmacopoeia, the Japanese Pharmacopeia and the European Pharmacopoeia. 
Other countries have their own pharmacopeias. 
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35. Pharmacovigilance: 
All science and activities relating to the detection, assessment, understanding, and 
prevention of adverse effects or other drug-related problems. In general, 
Pharmacovigilance aims to reevaluate the safety and efficacy of pharmaceutical 
product in the market. This encompasses spontaneous adverse drug reactions, 
drug information reporting, promotion of rational use of drugs, risk management, 
and crisis preparedness. 
36. Post marketing Surveillance: 
Monitoring the quality of drugs by inspection and laboratory testing to assure that 
the storage is correct and that drugs are stable within their labeled shelf-life. 
37. Potency: 
The extent to which a drug contains the specified amount of the active ingredient. 
38. Premarketing Surveillance: 
Monitoring the quality of medicines by inspection and laboratory testing to assure 
that medicines conform to the quality standards and specifications before their 
marketing authorization. 
39. Product Certificate: 
A document containing the information set out in Form 5.1. The certificate is 
validated and issued for a specific product by the competent authority of the 
exporting country and intended for use by the competent authority in the importing 
country, or, in the absence of such an authority, by the drug procurement authority. 
40. Product Recall: 
A process for withdrawing or removing a pharmaceutical product from the 
distribution chain because of defects in the product or complaints of serious 
adverse reactions to the product. A recall may be initiated by an MRA, a 
manufacturer, or by an importer/distributor or a responsible agency. 
41. Quality: 
All characteristics—purity, strength, packaging, labeling—that allow the drug 
product to deliver its intended treatment. 
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42. Quality Assurance (QA): 
All matters that individually or collectively influence the quality of a product. The 
objective of QA is to ensure that pharmaceutical starting materials and 
pharmaceutical products meet quality standards. 
43. Quality Control (QC): 
All measures taken—including setting specifications, sampling, testing, and 
analytical clearance—to ensure that raw materials, intermediates, packaging 
materials, and finished pharmaceutical products conform to established 
specifications for identity, strength, purity, and other characteristics. 
44. Recall: 
The process of withdrawing a medicine from the market because of a quality, 
safety, or efficacy problem. 
45. Safety: 
Not causing harm or injury, having a low incidence of adverse reactions and 
significant side effects when adequate instructions for use are given, and having a 
low potential for harm under conditions of widespread availability. 
46. Sample: 
A portion of material collected according to a de.ned sampling procedure. The size 
of any sample should be sufficient to carry out all anticipated test procedures, 
including all repetitions. 
47. Sampling Procedure: 
A detailed and complete sampling operation to be applied to a de.ned material for a 
specific purpose. A detailed, written description of the sampling procedure is 
provided as sampling protocol. 
48. Shelf-Life: 
The period of time during which a drug product, if stored correctly, is expected to 
comply with the specification as determined by stability studies on a number of 
batches of the product. The shelf-life establishes the expiry date of each batch. 
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49. Specification: 
A detailed document describing the requirements with which the pharmaceutical 
products used or obtained during manufacture have to conform. Specifications 
serve as a basis for quality evaluation. 
50. Stability: 
The ability of a pharmaceutical product to retain its chemical, physical, 
microbiological, and biopharmaceutical properties within specified limits throughout 
its shelf-life. 
51. Standard: 
A technical specification that addresses a business requirement, is implemented in 
viable commercial products, and to the extent practical, complies with recognized 
standards organizations such as (ISO). 
52. Starting Material: 
Any substance of de.ned quality used in the production of a pharmaceutical 
product, excluding packaging material. 
53. Substandard Drug: 
A legal branded or generic drug that does not meet national or international 
standards for quality, purity, strength, or packaging. 
54. Validated Method: 
A method of analytical performance demonstrated by experimental data that has 
proven its suitability as analytical support of a specification proposed for particular 
drug. The nature of the method and the type of drug test determine the 
characteristics that should be considered to validate the method. 
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